**November 2019**

**CURRICULUM VITAE**

**Dan Mark Roden, M.D.C.M.**

**Office Address:** Vanderbilt University School of Medicine

1285B Medical Research Building-IV

2215B Garland Avenue

Nashville, TN 37232-0575

Phone: 615-322-0067

FAX: 615-343-4522

Email: dan.roden@vumc.org

**Home Address:** 694 Timber Lane

Nashville, TN 37215

615-385-4189

**Date and Place of Birth:** April 15, 1950 - Montreal, Canada

**Marital Status:** Married, 3 children

**Languages Spoken:** English, French and Czech

**Citizenship:**  U.S.

## Education

1966 High School: Selwyn House School, Montreal

Governor-General's Medal for Academic Excellence

1966-1970 McGill University, Montreal

McGill Daily staff 1966-69 (Managing Editor, 1968-69)

BSc, Major: Mathematics

University Scholar 1966-67

1967-68

1968-69

1970-1974 McGill University, Montreal

MDCM, Major: Medicine

University Scholar 1971-72

## Professional Experience

July 1974-June 1975 Internship, Internal Medicine

Royal Victoria Hospital, Montreal

July 1975-June 1976 Resident, Department of Medicine

Royal Victoria Hospital, Montreal

July 1976-June 1977 Private Practice, Montreal

July 1977-June 1978 Resident, Department of Medicine

Royal Victoria Hospital, Montreal

July 1978-June 1981 Research Fellow

Division of Clinical Pharmacology

Vanderbilt University School of Medicine

July 1980-June 1981 Fellow

Division of Cardiology

Vanderbilt University School of Medicine

1981-1985 Assistant Professor

Depts. of Medicine and Pharmacology (Clinical Pharmacology)

Vanderbilt University School of Medicine

March-August 1983 Visiting Research Associate

Department of Pharmacology

Columbia University

New York, New York

1985-1989 Associate Professor

Depts. of Medicine (Clinical Pharmacology) and Pharmacology

Vanderbilt University School of Medicine

1988-1992, 1996-2002 Director, Vanderbilt Arrhythmia Unit

1989-present Professor

Depts. of Medicine (Clinical Pharmacology and Cardiovascular

Medicine) and Pharmacology

Vanderbilt University School of Medicine

1992-2004 Director, Division of Clinical Pharmacology

Vanderbilt University School of Medicine

1992-2017 William Stokes Professor of Experimental Therapeutics

Vanderbilt University School of Medicine

2017- Sam L. Clark, M.D., Ph.D. Endowed Chair

Vanderbilt University School of Medicine

2004-present Director, John Oates Institute for Experimental Therapeutics

Vanderbilt University School of Medicine

2006-2016 Assistant Vice-Chancellor for Personalized Medicine Vanderbilt University School of Medicine

2015-present Professor of Biomedical Informatics

Vanderbilt University School of Medicine

2016-present Senior Vice-President for Personalized Medicine

Vanderbilt University Medical Center

## Certification

Medical Council of Canada, Certification No. 38009, July, 1975

National Board of Medical Examiners, Certification No. 145601, July, 1975

American Board of Internal Medicine, Certification No. 65326

Internal Medicine, September, 1978

Cardiovascular Disease, November, 1981

Clinical Cardiac Electrophysiology, November, 1992

American Board of Clinical Pharmacology, Certification No. 93116, September 1993

## Licensure

Province of Quebec, License No. 75-208

State of Tennessee, License No. MD-11357

## Professional Societies

American College of Physicians (Fellow) (ACP#:37080)

American College of Cardiology (Fellow)

American Heart Association (Fellow)

The Royal College of Physicians of Canada (Fellow)

American Federation for Clinical Research

American Society for Clinical Pharmacology and Therapeutics

North American Society for Pacing and Electrophysiology/Heart Rhythm Society (Fellow)

Cardiac Electrophysiology Society

The Biophysical Society

American Society for Pharmacology and Experimental Therapeutics

Southern Society for Clinical Investigation

American Society for Clinical Investigation (elected)

Association of American Physicians (elected)

American Association for the Advancement of Science (elected to fellowship)

## Service

### Intramural

1985- Member, Medical Scientist Training Program (MD-PhD Committee), Vanderbilt University

1986-1997 Coordinator, American Heart Association Medical Student Research Fellowship program at Vanderbilt; Responsible Investigator 1991-

1988-92, 1996-2002 Director, Vanderbilt Arrhythmia Service

1989-1992 Member, Vanderbilt Clinical Research Center Advisory Committee; Chairman 1991-92

1991-1994 Member, Vanderbilt Institutional Review Board (Health Sciences); Chairman 1993-94

1992-2004 Director, Division of Clinical Pharmacology

1992-1995 Member, Vanderbilt University, Department of Medicine, Faculty Appointments and Promotions Advisory Committee

1997- 1998 Member, Vanderbilt University, Department of Medicine, Senior Fellowship Committee

2000-2002 Member, Vanderbilt University, Department of Medicine, Awards Committee

2004- Principal Investigator, Vanderbilt DNA databank (BioVU)

2004- Director, John Oates Institute for Experimental Therapeutics

2006-2016 Assistant Vice-Chancellor for Personalized Medicine

2016- Senior Vice-President for Personalized Medicine

### Extramural

1985 Delegate, 4th US-USSR Symposium on Sudden Death, Birmingham, Alabama

1990-2000 United States Pharmacopeial Convention, Advisory Panel on Cardiovascular and Renal Drugs; Chair (1995-2000)

1992 External Advisory Committee, Pharmacological Sciences Training Grant, Columbia University

1992-1993 Member, Annual Scientific Session Program Committee, American College of Cardiology

1992-1998 Member, Clinical Cardiac Electrophysiology (CCEP) Test Writing Committee, American Board of Internal Medicine

1994-1997 Member, Board of Directors, American Society for Clinical Pharmacology and Therapeutics

1995-1998 Chair, Cardiovascular and Pulmonary Section, American Society for Clinical Pharmacology and Therapeutics

1996- Member, American Board of Clinical Pharmacology

1996-2002 Member, Scientific Advisory Board, Cardiac Arrhythmias Research and Education Foundation, Inc. (CARE)

1996-1999 Member, Program Committee, Annual Scientific Sessions, North American Pacing Society for Pacing and Electrophysiology (NASPE)

1997-2001 Cardiac Electrophysiology Society: Secretary-treasurer, 1997-99; President, 1999-2001

1997-1998 Vice-President, American Society for Clinical Pharmacology and Therapeutics

2000-2001 Member, Board of Governors, American Society for Clinical Pharmacology and Therapeutics

* 1. Chair, Clinical Pharmacology Section, American Society for Pharmacology and Experimental Therapeutics

2003-2005 Member, Test-writing Committee, Self-evaluation module, Clinical Cardiac Electrophysiology; American Board of Internal Medicine

2003-2006 Member, Joint AHA/ACC/ESC/NASPE guideline writing committee: Sudden Death

2006-2009 Member, ACCSAP Question Writing Committee

2012-2014 Heart Rhythm Society, Research Committee, Vice-chair

2012 Heart Rhythm Society, Search Committee for Editor-in-chief, *Heart Rhythm*

2013-2016 Burroughs Wellcome Fund, Innovation in Regulatory Science Award Advisory Committee

2013-2015 Advisory Board, Indiana Institute for Personalized Medicine

2013-2017 Chair, Research Oversight Committee, Genome Canada/Québec project: “Personalized medicine strategies for molecular diagnostics and targeted therapeutics of cardiovascular diseases”, JC Tardif and MP Dubé

2013- Member, Biobank UK International Scientific Advisory Committee

2013-2019 Member, Scientific Advisory Board, Fondation Leducq

2014-2017 Member, inaugural International Advisory Board, UK Farr Institute of Health Informatics Research

2014-2020 Member, Science and Industry Advisory Committee, Genome Canada

2014-2016 Member, Scientific Advisory Board, The Surveillance and Pharmacogenomics Initiative for Adverse Drug Reactions (SAPhIRE) program, Singapore

2016- Member, Scientific Advisory Board, Ubiquitous Pharmacogenomics EU Initiaitve/PREPARE study

2017- Member, International Advisory Board (IAB) of the Swiss Personalized Health Network (SPHN) Initiative

#### American Heart Association

1982-1983; 1987 Member, Peer Review Research Committee, Tennessee Affiliate AHA

1984-1986 Chairman, Research Committee, Middle Tennessee Chapter, American Heart Association; Member (ex officio), Peer Review Research Committee, Tennessee Affiliate, American Heart Association

1990 European Society of Cardiology - AHA (Basic Science Council) Task Force on Antiarrhythmic Drug Classification

1995-1998 Member, Katz Prize Committee, Basic Science Council, American Heart Association

1995-1999 Member, Executive Committee, Basic Science Council, American Heart Association

* 1. Member, Long Range Planning/Budget Committee, Basic Science Council, American Heart Association

2000-2005 Member, National Research Committee and Basic Cardiovascular Sciences Executive Council

2004 Elected Fellow of the American Heart Association (FAHA)

2006-2009 Member, Functional Genomics Working Group

2014- Distinguished Scientist Selection Committee

2017- Chair, Distinguished Scientist Committee

2019- Member At Large on the Leadership Committee of the Council on Genomic and Precision Medicine

#### US Federal Government

1986-1989 Member, National Veteran’s Administration (VA) Merit Review Committee for Cardiovascular Disease; Chairman 1988-1989

1987 Ad Hoc Reviewer, Pharmacology Study Section, National Institutes of Health (NIH)

1990,1991 Ad Hoc Reviewer, Cardiovascular and Pulmonary Study Section, NIH

1991-1994 Member, Cardiovascular and Pulmonary Study Section, NIH

1994-1996 Chair, Cardiovascular and Pulmonary Study Section, NIH

1996- 2000 Member, Cardiovascular and Renal Drugs Advisory Committee, Food and Drug Administration (FDA)

1998 Member, National Heart Lung and Blood Institute (NHLBI) Special Emphasis Review, Pediatric Cardiology SCORs

1999 Ad Hoc Reviewer, Clinical Trials Review Committee, NHLBI

1999 NHLBI Delegate, US-Russia Arrhythmia Symposium, National Cardiology Research Center, Moscow.

* 1. Member, Panel on Scientific Boundaries, Cardiovascular Sciences IRG; Consultant, CSR Council

2001 Consultant, FDA Joint Nonprescription Drugs Advisory Committee and

Pulmonary-Allergy Drugs Advisory Committee

2005-2006 NHLBI Strategic Planning Committees; Phase I and II

2006-2010 NHLBI Resequencing and Genotyping Resource – oversight committee

2007-2010 Pharmacogenetics Research Network, vice-chair, Steering Committee

2009-2013 Member, Cardiovascular and Sleep Epidemiology (CASE) Study Section

2010-2012 Pharmacogenetics Research Network, Chair, Steering Committee

2011- Member, NHGRI Advisory Committee for Genomic Medicine

2012-2016 Member, Science Board to the Food and Drug Administration

2014-2017 Member, External Advisory Panel, NHGRI/NCI Clinical Sequencing Exploratory Research (CSER) program

2014-2018 Member, National Advisory Council for Human Genome Research of the National Institutes of Health

2015- Department of Veterans Affairs Genomic Medicine Program Advisory Committee (Chair: 2018 - )

2018- Member, Science Committee, All of Us Research Program

#### Editorial boards

*Past*

1996 Editorial Board, *Journal of Cardiovascular Pharmacology*

1996-2001 Editorial Board, NASPE*TAPES*

1996 Chief, Pharmacology Section, Cardiac Electrophysiology Reviews

1990-2004 Editorial Board, *Journal of Cardiovascular Electrophysiology*

1997-2016 Section Editor, Contemporary Use of Cardiovascular Drugs in Clinical Cardiovascular Medicine, *Circulation*

1997 Editorial Board, *Cardiology Today: Current News in Cardiovascular Disease*

1997-2008 Editorial Board, *American Journal of Medicine*

2002-2009 Editorial Board, *Pharmacogenetics*

2011 Editorial Board, *Frontiers in Cardiac Electrophysiology*

1996-2016 Editorial Board, *Circulation*

*Current*

1991- Advisory Board, *The Medical Letter*

2003- Editorial Board, *Heart Rhythm*

2005- Editorial Board, *Clinical Pharmacology and Therapeutics*

2006- Editorial Board, *The Pharmacogenomics Journal*

2014- Editorial Board, *Cold Spring Harbor Molecular Case Studies*

2017- Editorial Committee, *Annual Review of Pharmacology and Toxicology*

## Thesis Committees

#### Primary mentor

Jeffrey Balser (MSTP/MD-PhD program) PhD, Pharmacology, 1990

Todd Wisialowski MS, Biomedical Engineering, 1990

Lawrence Selby MS, Pharmacology, 1998

Kai Liu PhD, Pharmacology, 2005

Sameer Chopra (MSTP/MD-PhD program) PhD, Pharmacology, 2007

Prince Kannankeril, MD MSCI, 2007

Andrea Havens Ramirez, MD MSCI, 2011

Kristie Young Borgman, MD MSCI, 2011

Quinn Wells, MD MSCI, 2013

Jeffrey Bennett (MSTP/MD-PhD program) PhD, Human Genetics, 2013

Kevin Bersell (MSTP/MD-PhD program) PhD, Pharmacology, 2016

Ayesha Muhammed (MSTP/MD-PhD program) (current; Human Genetics)

#### Member, thesis committee

Wayne Glasgow PhD, Pharmacology, 1988

Wai Lau PhD, Pharmacology, 1991

Steven Roberds PhD, Pharmacology, 1992

Karen Knoth PhD, Pharmacology, 1993

J. P. Johnson PhD, Pharmacology, 1997

Kevin Parker PhD, Physics, 1998

Tammy Wingo PhD, Pharmacology, 2001

Franklin Mullins (MSTP/MD-PhD program) PhD, Pharmacology, 2002

Andrew Lundquist (MSTP/MD-PhD program) PhD, Pharmacology, 2003

Leomar Ballester PhD, Pharmacology, 2007

William Thiel PhD, Pharmacology, 2009

Brett English PhD, Pharmacology, 2009

Janina Jeff PhD, Human Genetics, 2012

Courtney Campbell (MSTP/MD-PhD program) PhD, Pharmacology, 2013

Jude McElroy (MSTP/MD-PhD program) PhD, Human Genetics, 2013

Carrie Buchanan (MSTP/MD-PhD program) PhD, Human genetics, 2013

Lisa Murphy PhD, Pharmacology, 2014

Thomas Beckermann PhD, Pharmacology, 2014

Scott McCall (MSTP/MD-PhD program) PhD, Pharmacology, 2015

Pedro Texeira (MSTP/MD-PhD program) PhD, Biomedical Informatics, 2015

T.K. Feaster PhD, Pharmacology, 2015

Laura Wiley PhD, Human Genetics, 2016

Joshua Smith PhD, Biomedical Informatics, 2016

Megan Shuey PhD, Pharmacology, 2017

Shan Parikh (MSTP/MD-PhD program) PhD, Pharmacology, 2017

Katherine Konvinse (MSTP/MD-PhD program) PhD, Pathology, Microbiology and Immunology, 2019

*Current*

Andrew Hale (MSTP/MD-PhD program; Biochemistry)

Matt Wleklinski (MSTP/MD-PhD program; Pharmacology)

Jay Kang (MSTP/MD-PhD program; Human Genetics)

## Honors, distinctions, named/keynote lectures

*Honors, distinctions*

1966   Governor-General's Medal for Academic Excellence

1966-68, 1971 McGill University Scholar

1981-1986 Clinician-Scientist Award, American Heart Association

1991 Elected to the American Society for Clinical Investigation

1992 Leon I. Goldberg Young Investigator Award, American Society for Clinical Pharmacology and Therapeutics

1994-2018 Best Doctors in America

1996 Elected to the Association of American Physicians

2000-2005 Unrestricted grant in Cardiovascular Medicine (Bristol Myers Research Institute)

2003 Grant W. Liddle Prize for Translational Research (Vanderbilt Medical Center-wide)

2003 Vanderbilt Division of Cardiology Faculty Teaching Award

2005 Heart Rhythm Society: Distinguished Scientist Award

2008 Rawls Palmer Award for Progress in Medicine, American Society for Clinical Pharmacology and Therapeutics

2012 Distinguished Scientist, American Heart Association

2012 Elected to Fellowship, American Association for the Advancement of Science

2013 Functional Genomics and Translational Biology Inaugural Medal of Honor, American Heart Association

2017 McGill University School of Medicine, Alumnus Lifetime Achievement Award

2018 Louis and Artur Lucian Award for Research in Circulatory Diseases, McGill University

2019 Jay and Jeanie Schottenstein Prize in Cardiovascular Sciences, The Ohio State University Wexner Medical Center’s Heart and Vascular Center

2020 Oscar B. Hunter Career Award in Therapeutics, American Society for Clinical Pharmacology and Therapeutics

*Named/keynote lectures*

1994 Sterling Visiting Professor; Department of Pharmacology, Columbia University

1998 6th annual Leonard Horowitz memorial lecture; Allegheny University for the Health Sciences

1999 Gordon K. Moe Visiting Professor, Masonic Medical Laboratories, Utica, NY

1999 33rd Malaysia-Singapore Congress of Medicine, Plenary lecture

2001 Leon Goldberg Visiting Professor, University of Chicago

2002 New York EP Society annual meeting Keynote speaker

2004 Hoffman-Laroche Visiting Professor, University of Alberta

2006 Plenary speaker: Evolution from pharmacogenetics to pharmacogenomics, American Heart Association

2007 Charles Gruber lecturer; Thomas Jefferson University

2010 Margaret & Theodore Marr Family Visiting Lecturer, University of Ottawa Heart Institute

2010 Bernard and Joan Marshall Inaugural lecturer, St. Thomas’ Hospital, London

2010 Jon Rodman Visiting Professor, St. Jude Children’s Hospital, Memphis

2011 Michael Sole Visiting Professor and Lecturer, University of Toronto

2011 Michel Mirowski lecture, Johns Hopkins University

2012 78th Annual Conference of the German Society for Experimental and Clinical Pharmacology and Toxicology, Plenary speaker

2012 Douglas P. Zipes Distinguished Lecturer, Heart Rhythm Society

2012 Joan and Douglas Zipes lecturer in Cardiovascular Medicine, Indiana University

2012 Martin Breitman Lecturer, University of Toronto

2012 E. M. Papper Lecturer, Department of Anesthesiology, Columbia University

2012 University of North Carolina Institute for Pharmacogenomics and Individualized Therapy Award for Public Service

2013 Pacific Symposium on Biocomputing, keynote speaker

2013 Sir Richard Doll Lecturer, University of Oxford

2013 Denis Escande Biennial International Arrhythmia Symposium, keynote speaker

2014 Louis Rakita Lecturer, Cleveland Metro Hospital

2014 17th World Congress of Basic and Clinical Pharmacology, keynote speaker

2014 Mayo Clinic Individualizing Medicine Conference, keynote speaker

2015 Massachusetts General Hospital and the Broad Institute, visiting lecturer

2015 University of Wisconsin Department of Medicine, visiting professor

2015 University of South Alabama Student Research Day, keynote speaker

2015 ILSI Health and Environmental Sciences Institute (HESI) Cardiac Committee Meeting, keynote speaker

2016 American Society of Clinical Pharmacology and Therapeutics annual meeting, featured speaker.

2016 Keynote speaker, *Nature Genetics* conference on Genome Variation in Precision Medicine. Shenzhen, China

2016 Gordon Research Conference on Cardiac Regulatory Mechanisms. Invited speaker.

2016 Keynote speaker, Annual Meeting and Scientific Symposium of Taiwan Precision Medicine Society

2016 Keynote speaker, Canadian Society of Pharmacology and Therapeutics

2016 Sir Henry Dale lecture, Clinical Pharmacology, Johns Hopkins Hospital

2016 33rd Annual Laurence H. Green Memorial Lecturer, Brigham and Women’s Hospital

2016 Plenary speaker, American Heart Association annual Scientific Sessions

2017 Keynote Speaker, Gordon Conference on Cardiac Arrhythmia Mechanisms

2017 Robert J. Myerburg Endowed lecturership, Univerity of Miami

2017 James T. Willerson lecturer, Texas Heart Institute, Houston

2017 Andrew F. Holmes Dean of Medicine Distinction lecturer, McGill University

2017 Keynote speaker, Genomic Medicine Working Group meeting on Pharmacogenomics.

2019 McGill University Department of Medicine Research Day Keynote speaker (Lucian Award)

2019 Keynote speaker, 19th annual Gene Forum, Tartu, Estonia

## Previous Research Support

1978-1981 Training Grants GM07569 (PI: John A. Oates) and HL07411 (PI: G.C. Friesinger); Clinical Pharmacology Center Grant GM15431 (PI: John A. Oates)

1981-1986 Clinician-Scientist Award (81-423), American Heart Association, "Pharmacologic activity of antiarrhythmic drug metabolites" (Salary support $30,000/yr plus fringe benefits)

1982-1986 Cardiac Arrhythmia Pilot Study N-01-HV-2-8014, $433,594 (PI: R.L. Woosley)

1983-1986 Grant-in-Aid, American Heart Association (83-1276), "Pharmacology of antiarrhythmic drug combinations," $104,214 (PI: Dan M. Roden)

1984-1993 R01 HL32694, "Role of prolonged repolarization in cardiac arrhythmias," 1984-87: $218,725; 1988-93: $414,344 (PI: Dan M. Roden)

1986-1991 R01 HL36724, "*In vivo* actions of antiarrhythmic drugs," $1,050,593 (PI: Dan M. Roden)

1986-1992 Cardiac Arrhythmia Suppression Trial: NHLBI contract N-01-HC-65065 $1,237,684 (PI: Raymond L. Woosley 1986-88; Dan M. Roden 1988-1992)

1982-2002 Program Project GM31304, "Determinants of individual responsiveness to drugs" Program Director: Grant R. Wilkinson, Ph.D.) (1997-02: $4,268,916)

1977- GM07569, "Clinical Pharmacology Training Program," (PI 1992-2004: Dan M. Roden)(1997-2002: $1,687,205)

1992-2007 Program Project HL46681, "Biology of Arrhythmia Susceptibility” (former titles: Heterogeneity of Cardiac K+ Channels” (1997-2002); “Mechanisms of antiarrhythmic drug action" (1992-1997)) $4,739,243 (Program Director: Dan M. Roden)

2004-2011 R01 LM007995, “Tools for Inpatient Monitoring Using Evidence (TIME) for Safe and Appropriate Testing”, direct costs $1 million, (PI: Randolph Miller)

2008 S10 RR025141 “Automated Storage and Retrieval of Biological Samples”, (High-End Instrumentation Grant Program), direct costs $988,000 (PI: Dan M. Roden)

2010 S10 RR027764 “Automated DNA Extraction for Small Volume Samples Enabling Pediatric Biobanking” (Shared Instrumentation Grant Program), direct costs $154,567 (PI: Dan M. Roden)

2005-2011 Leducq Foundation Trans-Atlantic Network of Excellence: “Preventing Sudden Death”, total costs: $6,000,000. (US PI: Dan M. Roden).

2009-2011 RC2 GM092618 (Grand Opportunity stimulus grant), “VESPA: Vanderbilt Electronic Systems for Pharmacogenomic Assessment”, direct costs $4.13 million (co-PIs: Daniel R. Masys and Dan M. Roden)

2007-2011 National Marfan Foundation, “An Ancillary Study to Create a DNA repository and to Define Pharmacogenetic Predictors of Efficacy and Adverse Reaction during a Trial of Beta Blocker therapy (Atenolol) vs. Angiotensin Receptor Blockade (Losartan)” (PI: Dan M. Roden)

2009-2014 5R01 HL092217-04 (Darbar), “Positional Cloning and Candidate Gene Approach to Familial Atrial Fibrillation.”

2013-2014 5U19HL069757-13 (Krauss), “Pharmacogenetics and Risk of Cardiovascular Disease (PARC III)”

2001-2015 U01/U19 HL65962, “Pharmacogenomics of arrhythmia therapy” Vanderbilt site in the Pharmacogenetics/genomics Research Network (PI: Dan M. Roden).

2011-2016 R01 HL108173-01, (PI: Prince J. Kannankeril) “Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia”

1994-2016 R01 HL49989, "Modulation of cardiac repolarization," direct costs current cycle: $1,100,000 (PI: Dan M. Roden).

2013-2017 R01 HL118952, “*SCN5A* mutations and dilated cardiomyopathy”. direct costs: $900,000 (PI: Dan M. Roden).

2013-2017 1U01HL122904-01 (Peterson), “Rational Integration of Genomic Healthcare Testing (RIGHT)”

## Current Research Support

#### As Principal Investigator:

2015-2020 P50 GM115305 “Improving Prediction of Drug Action,” Vanderbilt site in the Pharmacogenetics/genomics Research Network. Total direct costs: $9,017,572 (co PIs: Josh C. Denny, Elizabeth J. Phillips, Dan M. Roden)

2007-2020 Electronic Medical Records and Genomics (eMERGE) network; “VGER: Vanderbilt Genome-Electronic Records Project”. 2007-2011: U01 HG004603, direct costs $4,290,117. 2011-2015: U01 HG006378, direct costs $2,000,000 (PI: Dan M. Roden). 2015-2020: U01HG008672, direct costs: $2,600,000 (PI: Dan M. Roden, Josh Denny). (2020-2025 renewal score: 21)

2007-2017 National Marfan Foundation (Roden) (NCE)

An Ancillary Study to Define Pharmacogenetic Predictors of Efficacy and Adverse Reaction during a Trial of Beta Blocker therapy (Atenolol) vs. Angiotensin Receptor Blockade (Losartan)

2018-2022 Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Award: Accelerating the Transition from Discovery to Clinical Implementation in Precision Medicine. Direct costs: $1,000,000 (PI: Dan M. Roden)

2018-2022 American Heart Association Strategically Focussed Network (Atrial Fibrillation)

18SFRN34110369: A novel molecular target in atrial fibrillation

Total Costs: $3,709,200 (PI: Dan M. Roden)

2020-2023 R01HL149826 “Functional Genomics of Cardiac Sodium Channel Variants” Total costs: $2,929,895 (PI: Dan M. Roden)

#### As Co-Investigator:

2015-2020 U2COD023196 (PI: Joshua C. Denny), “Data and Research Center, Precision Medicine Initiative”

2012-2022 5UL1TR000445-07 (Bernard), “NIH/NCATS: The Vanderbilt Institute for Clinical and Translational Research (VICTR)”

2014-2023 “Integrated, Individualized, Intelligent Prescribing (I3P)” NHGRI IGNITE network: 1U01HG007253-01A1 (Denny/Levy; 2014-2018); 1U01HG010232 (Peterson, 2018-2023)

2016-2020 1RM1HG009034-01 (Clayton), “Genetic Privacy and Identity in Community Settings – GetPreCiSe”

2016-2020 R01HG008605 (Wolf, Clayton), “LawSeq™: Building a Sound Legal Foundation for Translating Genomics into Clinical Application.”

2016-2021 R01HD084461 (Kannankeril), “Pharmacogenetics and Personalized Medicine after Cardiac Surgery in Children”

2016-2020 1U01HL131911-01 (Kannankeril), “Role of Genetic Variants in Sudden Death in the Young”

2019-2023 19SFRN34830019 (Knollmann), “Targeting intracellular calcium leak for ventricular arrhythmia prevention in structural heart disease”

## Manuscript Reviews

American Heart Journal

American Journal of Cardiology

American Journal of Human Genetics

American Journal of Medicine

Annals of Internal Medicine

Archives of Internal Medicine

British Journal of Pharmacology

British Journal of Clinical Pharmacology

BMC Medical Genetics

Cardiovascular Research

Chest

Circulation

Circulation: Arrhythmia and Electrophysiology

Circulation Research

Clinical Pharmacology and Therapeutics

European Heart Journal

Heart

Heart Rhythm

Journal of the American College of Cardiology

Journal of the American Medical Association

Journal of Biological Chemistry

Journal of Cardiovascular Electrophysiology

Journal of Cardiovascular Pharmacology

Journal of Clinical Investigation

Journal of General Physiology

Journal of Internal Medicine

Journal of Molecular and Cellular Cardiology

Journal of Pharmacokinetics and Biopharmaceutics

Journal of Pharmacology and Experimental Therapeutics

Molecular Pharmacology

Nature

Nature Medicine

New England Journal of Medicine

Pharmacogenetics and Pharmacogenomics

PLoS ONE

Proceedings of the National Academy of Sciences

Science

Science Translational Medicine

Systems Biology

The Lancet

The Medical Letter

# PATENTS

George AL Jr, **Roden DM**: U.S. Letters Patent No. 6,458,542, issued October 1, 2002, Method of Screening for Susceptibility to Drug-Induced Cardiac Arrhythmia

**ON-LINE COURSE**

https://www.coursera.org/learn/personalizedmed

**PUBLICATIONS**

# A. ORIGINAL MANUSCRIPTS

1. **Roden DM**, Reele SB, Higgins SB, Mayol R, Gammans R, Oates JA, Woosley RL: Total suppression of ventricular arrhythmias by encainide: Pharmacokinetic and electrocardiographic characteristics. N Eng J Med 1980;302:877–882. PMID:6767186
2. **Roden DM**, Reele SB, Higgins SB, Carr RK, Smith RF, Oates JA, Woosley RL: Tocainide therapy for refractory ventricular arrhyth­mias. Am Heart J 1980;100:15–22. PMID:6770666
3. **Roden DM**, Reele SB, Higgins SB, Wilkinson GR, Smith R, Oates JA, Woosley RL: Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocain­amide in human subjects: Comparison with procainamide. Am J Cardiol 1980;46:463–468. PMID:6158263
4. Higgins SB, Woyce GM, **Roden DM**, Harris TR, Oates JA, Woosley RL: An arrhythmia analysis system with patient by patient validation. Computers in Cardiology, IEEE Computer Society 1980;357–360.
5. **Roden DM**, Duff HJ, Reele SB, Woosley RL, Oates JA, Smith RF, Friesinger GC: Recurrent ventricular tachycardia in the absence of overt heart disease: Clinical characteristics and response to drug therapy. South Med J 1981;74:1090–1094. PMID:7280757
6. **Roden DM**, Duff HJ, Primm RK, Kronenberg MW, Woosley RL: Control of ventricular pre-excitation and associated arrhythmias by encainide. Am Heart J 1981;102:794–797. PMID:6792894
7. Duff HJ, **Roden DM**, Maffucci RJ, Vesper BS, Conard GJ, Higgins SB, Oates JA, Smith RF, Woosley RL: Suppression of resistant ventricular arrhythmias by twice-daily dosing with flecainide. Am J Cardiol 1981;48:1133–1140. PMID:7304461
8. **Roden DM**, Duff HJ, Altenbern D, Woosley RL: Antiarrhythmic activity of the O-demethyl metabolite of encainide. J Pharmacol Exp Ther 1982;221(3):552–557. PMID:6806461
9. Duff HJ, **Roden DM**, Dawson AK, Oates JA, Smith RF, Woosley RL: Comparison of the effects of placebo and encainide on pro­grammed electrical stimulation and ventricular arrhythmia frequency. Am J Cardiol 1982;50:305–312. PMID:6808820
10. Woosley RL, Reele SB, **Roden DM**, Nies AS, Oates JA: Pharm­acologic reversal of hypotensive effect complicating anti­arrhythmic therapy with bretylium. Clin Pharmacol Ther 1982;32:313–321. PMID:7105622
11. Duff HJ, **Roden DM**, Primm RK, Oates JA, Woosley RL: Mexiletine in the treatment of resistant arrhythmias: Enhancement of efficacy and reduction of dose-related side effects by combi­nation with quinidine. Circulation 1983;67:1124–1128. PMID:6831673
12. Duff HJ, Dawson AK, **Roden DM**, Oates JA, Smith RF, Woosley RL: Electrophysiologic actions of O-demethyl encainide: An active metabolite. Circulation 1983;68:385–391. PMID:6861313
13. Duff HJ, **Roden DM**, Brorson L, Wood AJJ, Dawson AK, Primm RK, Oates JA, Smith RF, Woosley RL: Electrophysio­logic actions of high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol 1983;2:1134–1140. PMID:6630784
14. Riddell JG, McAllister CB, Wilkinson GR, Wood AJJ, **Roden DM**: A new method for constant plasma drug concentrations: Application to lidocaine. Ann Intern Med 1983;100:25–28. PMID:6691655
15. Carey EL, Duff HJ, **Roden DM**, Primm RK, Wilkinson GR, Wang T, Oates JA, Woosley RL: Encainide and its metabolites: Comparative effects in man on ventricular arrhythmia and electrocardio­graphic intervals. J Clin Invest 1984;73:539–547. PMID:6421879 PMCID:PMC425046
16. Wang T, **Roden DM**, Wolfenden HT, Woosley RL, Wood AJJ, Wilkinson GR: Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 1984;228:605–611. PMID:6423808
17. **Roden DM**, Dawson AK, Duff HJ, Woosley RL, Smith RF: Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia. J Cardiovasc Pharmacol 1984;6:588–595. PMID:6206311
18. Duff HJ, **Roden DM**, Marney S, Colley DG, Maffucci R, Primm RK, Oates JA, Woosley RL: Molecular basis for the antigenicity of lidocaine analogs: Tocainide and mexiletine. Am Heart J 1984;107:585–589. PMID:6421133
19. Dawson AK, **Roden DM**, Duff HJ, Woosley RL, Smith RF: Differ­ential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. Am J Cardiol 1984;54:654–658. PMID:6475789
20. Duff HJ, Oates JA, **Roden DM**, Woosley RL: The antiarrhythmic activity of meobentine sulfate in man. J Cardiovasc Pharmacol 1984;6:650–656. PMID:6206320
21. Duff HJ, **Roden DM**, Yacobi A, Robertson DH, Wang T, Maffucci RJ, Oates JA, Woosley RL: Bretylium: Relations between plasma concentrations and pharmacologic actions in high frequency ventricular arrhythmias. Am J Cardiol 1985;55:395–401. PMID:3969876
22. **Roden DM**, Hoffman BF: Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length. Circ Res 1985;56:857–867. PMID:4006095
23. Duff HJ, **Roden DM**, Carey EL, Wang T, Primm RK, Woosley RL: Spectrum of antiarrhythmic response to encainide. Am J Cardiol 1985;56:887–891. PMID:3933319
24. Wang T, Bergstrand RH, Thompson KA, Siddoway LA, Duff HJ, Woosley RL, **Roden DM**: Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 1986;57:1160–1166. PMID:3706170
25. Woosley RL, **Roden DM**, Dai GF, Wang T, Altenbern D, Oates J, Wilkinson GR: Co-inheritance of the polymorphic metabolism of encainide and debrisoquine. Clin Pharmacol Ther 1986;39:282–289. PMID:3081292
26. Duff HJ, Kolodgie F, **Roden DM**, Woosley RL: Electropharmacologic synergism with mexiletine and quinidine. J Cardiovasc Pharmacol 1986;8:840–846. PMID:2427827
27. Bergstrand RH, Wang T, **Roden DM**, Stone WJ, Wolfenden HT, Woosley RL, Wilkinson GR, Wood AJJ: Encainide disposition in patients with renal failure. Clin Pharmacol Ther 1986;40:64–70. PMID:3087679
28. Bergstrand RH, Wang T, **Roden DM**, Avant GR, Sutton WW, Siddoway LA, Wolfenden HT, Woosley RL, Wilkinson GR, Wood AJJ: Encainide disposition in patients with chronic cirrhosis. Clin Pharmacol Ther 1986;40:148–154. PMID:3089668
29. **Roden DM**, Woosley RL, Primm RK: Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088–1093. PMID:3716982
30. The CAPS Investigators: The Cardiac Arrhythmia Pilot Study. Am J Cardiol 1986;57:91–95. PMID:2417474
31. Kolodgie FD, Dawson AK, **Roden DM**, Forman MB, Virmani R: Effect of fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. Am Heart J 1986;112:1192–1201. PMID:3788766
32. Hammon JW Jr, Echt DS, Merrill WH, Primm RK, Woosley RL, Smith RF, **Roden DM**, Bender HW: Indications for different modes of surgical therapy in medically refractory ventricular arrhythmias. Ann Surg 1986;203:679–684. PMID:3718030 PMCID:PMC1251204
33. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, **Roden DM**, Woosley RL: Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. Circulation 1987;75:785–791. PMID:3829342
34. Bajaj AK, Kopelman HA, Wikswo JP Jr, Cassidy F, Woosley RL, **Roden DM**: Frequency- and orientation-dependent effects of mexiletine and quinidine on conduction in the intact dog heart. Circulation 1987;75:1065-1073. PMID:2436827
35. Thompson KA, Blair IA, Woosley RL, **Roden DM**: Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. J Pharmacol Exp Ther 1987;241:84–90. PMID:3572799
36. **Roden DM**, Iansmith DHS, Woosley RL: Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther 1987;243:1218–1224. PMID:2447269
37. Wang T, Siddoway LA, Thompson KA, Conard GJ, Bergstrand RH, Kvam D, **Roden DM**, Woosley RL: The development and testing of intravenous dosing regimens: Application to flecainide for the suppression of ventricular arrhythmias. Clin Pharmacol Ther 1988;43:499–508. PMID:3130211
38. Barbey JT, Thompson KA, Echt DS, Woosley RL, **Roden DM**: Antiar­rhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Circulation 1988;77:380–391. PMID:3123092
39. Barbey JT, Thompson KA, Echt DS, Woosley RL, **Roden DM**: Tocainide plus quinidine for treatment of ventricular arrhythmias. Am J Cardiol 1988;61:570–573. PMID:3125737
40. **Roden DM**, Nadeau JH, Primm RK: Electrophysiologic and hemodynamic effects of chronic oral therapy with the a2-agonists clonidine and tiamenidine in hypertensive volunteers. Clin Pharmacol Ther 1988;43:648–654. PMID:2897889
41. Thompson KA, Murray JJ, Blair IA, Woosley RL, **Roden DM**: Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther 1988;43:636–642. PMID:3378385
42. Thompson KA, Iansmith DHS, Siddoway LA, Woosley RL, **Roden DM**: Potent electrophysiologic effects of the major metabolites of pro­pafenone in canine Purkinje fibers. J Pharmacol Exp Ther 1988;244:950–955. PMID:3252042
43. Kopelman HA, Woosley RL, Lee JT, **Roden DM**, Echt DS: Electro­physiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. Am J Cardiol 1988;61:1006–1011. PMID:3284316
44. The CAPS Investigators: Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. Am J Cardiol 1988;61:704–713. PMID:2451414
45. **Roden DM**, Bennett PB, Snyders DJ, Balser JR, Hondeghem LM: Quinidine delays IK activation in guinea pig ventricular myocytes. Circ Res 1988;62:1055–1058. PMID:2452034

1. The CAPS Investigators: Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS. Am J Cardiol 1988;61:501–509. PMID:2894169
2. The Encainide-Ventricular Tachycardia Study Group: Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with life ventricular dysfunction. Am J Cardiol 1988;62:571–575. PMID:3137797
3. Greene HL, Richardson DW, Barker AH, **Roden DM**, Capone RJ, Echt DS, Friedman LM, Gillespie MJ, Hallstrom AP, Verter J, CAPS Investi­gators: Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (The Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989;63:1–6. PMID:2462341
4. Greene HL, Richardson DW, Hallstrom AP, McBride R, Capone RJ, Barker AH, **Roden DM**, Echt DS, the CAPS Investigators: Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989;63:393–398. PMID:2464919
5. Murray KT, Barbey JT, Kopelman HA, Siddoway LA, Echt DS, Woosley RL, **Roden DM**: Mexiletine and tocainide: A comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. Clin Pharmacol Ther 1989;45:553–561. PMID:2498025
6. Funck-Brentano C, Kroemer HK, Pavlou H, Woosley RL, **Roden DM**: Genetic­ally-determined interaction between propafenone and low dose quinidine: Role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 1989;27:435–444. PMID:2719900 PMCID:PMC1379722
7. Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJJ, Eichelbaum M, Woosley RL, **Roden DM**: Stereoselective disposition and pharma­cological activity of propafenone enantiomers. Circulation 1989;79:1068–1076. PMID:2713973
8. Turgeon J, Funck-Brentano C, Gray HT, **Roden DM**: Improved high performance liquid chromatographic assay for encainide and its metabolites in human body fluids: Estimation of accuracy and reproducibility. J Chromatogr 1989;490:165–174. PMID:2503530
9. Funck-Brentano C, Light RT, Lineberry MD, Wright GM, **Roden DM**, Woosley RL: Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. J Cardiovasc Pharmacol 1989;14:364–373. PMID:2476614
10. Funck-Brentano C, Turgeon J, Woosley RL, **Roden DM**: Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: Influence of genetic polymorphism. J Pharmacol Exp Ther 1989;249:134–142. PMID:2496225
11. Bajaj AK, Woosley RL, **Roden DM**: Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation 1989;80:994–1002. PMID:2551538
12. Davies RF, Lineberry MD, Funck-Brentano C, Echt DS, Lee JT, Capuzzi DM, **Roden DM**, Woosley RL: Recainam dose-titration and pharmacokinetics in patients with resistant arrhythmias. Clin Pharmacol Ther 1989;46:324–34. PMID:2673622
13. **Roden DM**, Lee JT, Woosley RL, Echt DS: Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. Circulation 1989;80:1247–1258. PMID:2805262
14. Kroemer HK, Turgeon J, Parker RA, **Roden DM**: Flecainide enantiomers: Disposition in human subjects and electrophysiologic actions *in vitro*. Clin Pharmacol Ther 1989;46:584–590. PMID:2510963
15. The CAST Investigators: Preliminary Report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Eng J Med 1989;321:406–412. PMID:2473403
16. Turgeon J, Kroemer HK, Prakash C, Blair IA, **Roden DM**: Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1990;79:91–95. PMID:2109058
17. Campbell RM, Woosley RL, Iansmith DHS, **Roden DM**: Lack of triggered automaticity despite repolarization abnormalities due to bepridil or lidoflazine. PACE 1990;13:30–36. PMID:1689032
18. Murray KT, Reilly C, Koshakji RP, **Roden DM**, Lineberry MD, Wood AJJ, Siddoway LA, Barbey JT, Woosley RL: Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest 1990;85:836-842. PMID: 2155929 PMCID:PMC296501
19. Balser JR, **Roden DM**, Bennett PB: Global parameter optimization for cardiac potassium channel gating models. Biophys J 1990;57:433–444. PMID:2306494 PMCID:PMC1280738
20. Lee JT, Kroemer HT, Silberstein D, Funck-Brentano C, Lineberry MD, Wood AJJ, **Roden DM**, Woosley RL: The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Eng J Med 1990;322:1764–1768. PMID:1971708
21. Zhou H, Anthony LB, **Roden DM**, Wood AJJ: Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 1990;47:686–693. PMID:2357863
22. Fish F, Prakash C, **Roden DM**: Suppression of repolarization-related arrhythmias *in vitro* and *in vivo* by low dose potassium channel activators. Circulation 1990;82:1362-1369. PMID:1698129
23. Funck-Brentano C, Silberstein DJ, **Roden DM**, Wood AJJ, Woosley RL: A mechanism of d-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism. Br J Clin Pharmacol 1990;30:195–202. PMID:2169833 PMCID:PMC1368218
24. Turgeon J, Pavlou HN, Wong W, Funck-Brentano C, **Roden DM**: Genetically-determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther 1990;255:642–649. PMID:2123007
25. Balser JR, Bennett PB, **Roden DM**: Time-dependent outward current in guinea pig ventricular myocytes: Gating kinetics of the delayed rectifier. J Gen Physiol 1990;96:835–863. PMID:2258717 PMCID:PMC2229010
26. Wikswo JP Jr, Wisialowski T, Altemeier WA, Balser JR, Kopelman HA, **Roden DM**: Virtual cathode effects during stimulation of cardiac muscle: Two-dimensional *in vivo* experiments. Circ Res 1991;68:513–530. PMID:1991354
27. Balser JR, **Roden DM**, Bennett PB: Single inward rectifier potassium channels in guinea pig ventricular myocytes: Effects of quinidine. Biophys J 1991;59:150–161. PMID:2015380 PMCID:PMC1281127
28. Tamkun MM, Knoth KM, Walbridge JA, Kroemer H, **Roden DM**, Glover DM: Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J 1991;5:331–337. PMID:2001794
29. Pavlou HN, Funck-Brentano C, Lineberry MD, Woosley RL, **Roden DM**: Prospective pharmacokinetically-based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug. Clin Pharmacol Ther 1991;49:314–321. PMID:2007325
30. Turgeon J, Funck-Brentano C, Gray H, Pavlou H, Prakash C, Blair I, **Roden D**: Genetically-determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clin Pharmacol Ther 1991;49:488–496. PMID:1903098
31. Ware DL, Lee JT, Murray KT, Hanyok JJ, **Roden DM**, Echt DS: Intravenous 3-methoxy-O-desmethyl-encainide (MODE) in reentrant supraventricular tachycardia: A randomized double-blind placebo-controlled trial in patients undergoing EP study. PACE 1991;14:1343–1350. PMID:1720527
32. Turgeon J, Evans WE, Relling MV, Wilkinson GR, **Roden DM**: Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol 1991;32:283–288. PMID:1685663 PMCID:PMC1368519
33. Balser JR, Bennett PB, Hondeghem LM, **Roden DM**: Suppression of time-dependent outward current in guinea pig ventricular myocytes: Actions of quinidine and amiodarone. Circ Res 1991;69:519–529. PMID:1860189
34. Wong W, Pavlou HN, Birgersdottiir UM, Hilleman DE, Mohiuddin SM, **Roden DM**: Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol 1992;69:206–212. PMID:1731461
35. Li P, Benitez J, **Roden D**, Branch RA: Angiotensin II facilitates tricyclic antidepressant-induced changes in QRS-duration in the rat. J Toxicol Clin Toxicol 1992;30:83–98. PMID:1542151
36. Birgersdottiir UM, Wong W, Turgeon J, **Roden DM**: Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol 1992;33:275–280. PMID:1576047 PMCID:PMC1381275
37. Turgeon J, Wisialowski TA, Wong W, Altemeier WA, Wikswo JP Jr, **Roden DM**: Suppression of longitudinal versus transverse conduction by sodium channel block: Effects of sodium bolus. Circulation 1992;85:2221–2226. PMID:1317273
38. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227–233. PMID:1377359
39. Hallstrom AP, Bigger JT Jr, **Roden D**, Friedman L, Akiyama T, Richardson DW, Rogers WJ, Waldo AL, Pratt CM, Capone RJ, Griffith L, Theroux PA, Barker AH, Woosley RL: Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmia. J Am Coll Cardiol 1992;20:259–264. PMID:1378858
40. Davies RF, Siddoway LA, Shaw L, Barbey JT, **Roden DM**, Woosley RL: Immediate- versus controlled-release disopyramide: Importance of saturable binding. Clin Pharmacol Ther 1993;54:16–22. PMID:8330460
41. Mörike KE, **Roden DM**: Quinidine enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther 1994;55:28–34. PMID:7905369
42. Vorperian VR, Wisialowski TA, Deegan R, **Roden DM**: Effect of hypercapnic acidemia on anisotropic propagation in the canine ventricle. Circulation 1994;90:456–461. PMID:8026032
43. Echt DS, Gremillion ST, Lee JT, **Roden DM**, Murray KT, Borganelli M, Crawford DM, Stewart JR, Hammon JW: Effects of procainamide and lidocaine on defibrillation energy Requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol 1994;5:752–760. PMID:7827714
44. Yang T, Wathen MS, Felipe A, Tamkun MM, Snyders DJ, **Roden DM**: K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res 1994;75:870–878. PMID:7923633
45. Turgeon J, Daleau P, Bennett PB, Wiggins SS, Selby L, **Roden DM**: Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res 1994;75:879–886. PMID:7923634
46. Yang T, Snyders DJ, **Roden DM**: Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells: Concentration-, time-, voltage- and use-dependent effects. Circulation 1995;91:1799–1806. PMID:7882490 [Response-Letter to the Editor Circulation 1995;92:2755-2757]
47. Yang T, Prakash C, **Roden DM**, Snyders DJ: Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 1995;115:267–274. PMID:7670728 PMCID:PMC1908306
48. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, Friedrich T, **Roden DM**: A randomized, double-blind, placebo-controlled dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophys 1995;6:687–699. PMID:8556189
49. Yang T, Kupershmidt S, **Roden DM**: Anti-minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K+ current. Circ Res 1995;77:1246–1253. PMID:7586238
50. Yang T, **Roden DM**: Extracellular potassium modulation of drug block of IKr: Implications for torsades de pointes and reverse use-dependence. Circulation 1996;93:407–411. PMID:8565156
51. Darbar D, Dell'Orto S, Wilkinson GR, **Roden DM**: Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Am J Health-Syst Pharm 1996;53:655–658. PMID:8800971
52. Darbar D, Smith M, Mörike K, **Roden DM**: Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pre-treatment with propranolol and diltiazem. Am J Cardiol 1996;77:1351–1355. PMID:8677878

1. Yang T and **Roden DM**: Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells). Am J Physiol 1996;271:H541–H547. PMID:8770095
2. Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, **Roden DM**: Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 1997;61:292–300. PMID:9084454
3. Yang T, Snyders DJ, **Roden DM**: Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: Comparison with quinidine and dofetilide. J Pharmacol Exp Ther 1997;280:1170–1175. PMID:9067300
4. Yang T, Snyders DJ, **Roden DM**: Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res 1997;80:782–789. PMID:9168780
5. Choy AMC, Lang CC, Chomsky DM, Rayos GH, Wilson JR, **Roden DM**: Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997; 96:2149–2154. PMID:9337183
6. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, **Roden DM**, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289–294. PMID:9435299 PMCID:PMC508566
7. Kupershmidt S, Yang T, **Roden DM**: Modulation of cardiac sodium current phenotype by Beta1-subunit expression. Circ Res 1998;83:441–447. PMID: 9721701
8. Vitola J, Vukanovic J, **Roden DM**: Cisapride-induced Torsades de Pointes. J Cardiovasc Electrophysiol 1998;1109–1113. PMID:9817562
9. Choy AMJ, Lang CC, **Roden DM**, Robertson D, Wood AJJ, Robertson RM, Biaggioni I: Abnormalities of the QT interval in primary disorders of autonomic failure. Am Heart J 1998;136:664–671. PMID:9778070
10. Kupershmidt S, Snyders DJ, Raes A, **Roden DM**: A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly-activating delayed rectifier current. J Biol Chem 1998;273:27231–27235. PMID:9765245

1. Darbar D, Fromm MF, Dell'Orto S, Kim RB, Kroemer HK, Eichelbaum M, **Roden DM**: Modulation by dietary salt of verapamil disposition in humans. Circulation 1998;98:2702–2708. PMID:9851956
2. Fromm MF, Kim RB, Stein CM, Wilkinson GR, **Roden DM**: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552–557. PMID:9927403
3. Fromm MF, Leake B, **Roden DM**, Wilkinson GR, Kim RB: Human MRP3 transporter: identification of the 5'-flanking region, genomic organization, and alternative splice variants. BBA 1999;1415:369–374. PMID:9889399
4. Kupershmidt S, Yang T, Anderson ME, Wessels A, Niswender KD, Magnuson MA, **Roden DM**: Replacement by homologousrecombination of the *minK* gene with *lacZ* reveals restriction of *minK* expression to the mouse cardiac conduction system. Circ Res 1999;84:146–152. PMID:9933245
5. Wu Y, **Roden DM**, Anderson ME: Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res 1999;84:906–912. PMID:10222337
6. Wei J, Wang DW, Alings M, Fish F, Wathen M, **Roden DM**, George AL Jr: Congenital long QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation 1999;99:3165–3171. PMID:10377081
7. Fromm MF, Darbar D, Dell'Orto S, **Roden DM**: Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. J Pharmacol Exp Ther 1999;290:253–258. PMID:10381784
8. Choy AMJ, Darbar D, Dell'Orto S, **Roden DM**: Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396–401. PMID:10440151
9. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, **Roden DM**, Wood AJJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceut Res 1999;16:408–414. PMID:10213372
10. Mazur AM, **Roden DM**, Anderson ME: Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsades de pointes in rabbits. Circulation 1999;100:2437–2442. PMID:10595957
11. Wei J, Fish FA, Myerburg RJ, **Roden DM**, George AL Jr: Novel *KCNQ1* Mutations Associated with Recessive and Dominant Congenital Long QT Syndromes: Evidence for Variable Hearing Phenotype Associated with R518X. Hum Mutation 2000;15:387–388. PMID:10737999
12. Wu J, **Roden DM**, Wikswo JP: Delayed activation and retrograde propagation in cardiac muscle: Implication of virtual electrode effects. Annals of Biomedical Engineering 2000;28:1318–1325. PMID:11212950
13. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, **Roden DM,** George AL Jr, Goldstein SAN: A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proceedings of National Academy of Sciences 2000;97:10613–10618. PMID:10984545 PMCID:PMC27073
14. Demolombe S, Franco D, de Boer P, Kupershmidt S, **Roden DM**, Pereon Y, Jarry A, Moorman AFM, Escande D: Differential Expression of KvLQT1 and its regulator IsK in mouse epithelia. Am J Phys: Cell Phys 2001;280:C359-C372. PMID:11208532
15. Anderson ME, Mazur A, Yang T, **Roden DM:** Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharm Exp Ther 2001;296:806–810. PMID: 11181910
16. Darbar D, Fromm MF, Dell’orto S, **Roden DM:** Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol 2001;12:9–14. PMID:11204091
17. Mazur A, Anderson ME, Bonney S, **Roden DM**: Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol 2001;37:1100–1105. PMID:11263615
18. Franco D, Demolombe, Kupershmidt S, Dumaine R, Dominguez J, **Roden D**, Antzelevitch C, Escande D, Moorman AFM: Divergent expression of delayed rectifier K+ channel subunits during mouse heart development. Cardiovasc Res 2001;52:65–75. PMID:11557234
19. Yang T, Snyders DJ, **Roden DM**: Drug Block of IKr: Model Systems and Relevance to Human Arrhythmias. J Cardiovasc Pharm 2001;38:737–744. PMID:11602820
20. Viswanathan PC, Bezzina CR, George AL Jr, **Roden DM**, Wilde AAM, Balser JR: Gating-Dependent Mechanisms for Flecainide Action in *SCN5A*-Linked Arrhythmia Syndromes. Circulation 2001;104:1200–1205. PMID:11535580
21. Tan HL, Kupershmidt S, Zhang R, Stepanovic S, **Roden DM**, Wilde AAM, Anderson ME, Balser JR: A Calcium Sensor in the Sodium Channel Modulates Cardiac Excitability. Nature 2002;415:442–447. PMID:11807557

1. Gbadebo TD, Trimble RW, Khoo MSC, Temple J, **Roden DM**, Anderson ME: Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 2002;105:770–774. PMID:11839636
2. Kanki H, Yang P, Xie HG, Kim RB, George AL Jr, **Roden DM**: Polymorphisms in beta-adrenergic receptor genes the acquired long QT syndrome. J Cardiovasc Electrophysiol 2002;13:252–256. PMID:11942593
3. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, **Roden DM**: Allelic variants in long QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105:1943–1948. PMID:11997281
4. Kupershmidt S, Yang ICH, Sutherland M, Wells KS, Yang T, Yang P, Balser JR and **Roden DM**: Cardiac-enriched LIM domain protein fhl2 is required to generate IKs in a heterologous system. Cardiovasc Res 2002;56:93–103. PMID:12237170
5. Kupershmidt S, Yang T, Chanthaphaychith S, Wang Z, Towbin JA, **Roden DM**: Defective human Ether-a-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus. J Biol Chem 2002;277:27442–27448. PMID:12021266
6. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med 2002;347:1825–1833. PMID:12466506
7. Wu Y, Temple J, Zhang R, Dzhura I, Zhang W, Trimble R, **Roden DM**, Passier R, Olson EN, Colbran RJ, Anderson ME: Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy. Circulation 2002;106:1288–1293. PMID:12208807
8. Johnson WH, Yang P, Yang T, Lau YR, Mostella BA, Wolff DJ, **Roden DM**, Benson DW: Clinical, Genetic, and Biophysical Characterization of a Homozygous HERG Mutation Causing Severe Neonatal Long QT Syndrome. Ped Res 2003;53:744–8. PMID:12621127

1. Drolet B, Yang T, Daleau P, **Roden DM**, Turgeon J: Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharm 2003;41:934–937. PMID:12775973
2. Kondo RP, Anderson RH, Kupershmidt S, **Roden DM**, Evans SM: Development of the Cardiac Conduction System as Delineated by minK-lacZ. J Cardiovasc Electrophysiol 2003;14:383–391. PMID: 12741710
3. Yang T, Kanki H, **Roden DM**: Phosphorylation of the IKs channel complex inhibits drug block: Novel mechanism underlying variable antiarrhythmic drug actions. Circulation 2003;108:132–134. PMID:12835205
4. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, **Roden DM**, Berul CI, Seidman CE, Seidman JG: Transgenic Mice Overexpressing Mutant *PRKAG2* Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy. Circulation 2003;107:2850–2856. PMID:12782567
5. Laohakunakorn P, Benson DW, Yang P, Yang T, **Roden DM**, Kugler JK: Bidirectional ventricular tachycardia and channelopathy. Am J Cardiol 2003;92:991–5. PMID:14556882
6. Kupershmidt S, Yang ICH, Hayashi K, Wei J, Chanthaphaychith S, Petersen CI, Johns DC, George AL Jr, **Roden DM**, Balser JR: IKr drug response is modulated by *KCR1* in transfected cardiac and noncardiac cell lines. FASEB J 2003;17:2263–5. PMID:14525949
7. Yang P, Kupershmidt S, **Roden DM**: Cloning and initial characterization of the human cardiac sodium channel (*SCN5A*) promoter. Cardiovasc Res 2004;61:56–65. PMID:14732202
8. Kannankeril P, **Roden DM**, Fish FA: Suppression of Bidirectional Ventricular Tachycardia and Unmasking of Prolonged QT interval with Verapamil in Andersen’s Syndrome. J Cardiovasc Electrophysiol 2004;15:119. PMID:15028088
9. Drolet B, Simard C, **Roden DM**: Unusual effects of a QT prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2004;109:26–9. PMID:14691044
10. Brame CJ, Boutaud O, Davies SS, Yang T, Oates JA, **Roden DM**, Roberts LJ: Modification of Proteins by Isoketal-Containing Oxidized Phospholipids. J Biol Chem 2004;279:13447–13451. Published online ahead of print January 10, 2004; manuscript # M313349200. PMID:14715668
11. Jay PY, Harris BS, Maguire CT, Buerger A, Wakimoto H, Tanaka M, Kupershmidt S, **Roden DM**, Schultheiss TM, O’Brien TX, Gourdie RG, Berul CI, Izumo S: Nkx2-5 Mutation Causes Anatomic Hypoplasia of the Cardiac Conduction System. J Clin Invest 2004;113:1130–1137. PMID:15085192 PMCID:PMC385399
12. Kanki H, Kupershmidt S, Yang T, Wells S, **Roden DM**: A Structural Requirement for Processing the Cardiac K+ Channel KCNQ1. J Biol Chem 2004;279:33976–83. PMID:15140888
13. Darbar D, **Roden DM**, Ali MF, Yang T, Wathen MS: Himalayan T waves in the Congenital Long QT Syndrome. Circulation 2005;111:e161. PMID:15781747
14. Petersen CI, McFarland TR, Stepanovic SZ, Yang P, Reiner DJ, Hayashi K, George AL, **Roden DM**, Thomas JH, Balser JR: *In vivo* identification of genes that modify *Ether-a-go-go Related Gene* activity in *Caenorhabditis elegans* may also affect human cardiac arrhythmia. Proc Nat Acad 2004;101:11773–11778. PMID:15280551 PMCID:PMC511051
15. Moskowitz IP, Pizard A, Patel VV, Bruneau BG, Kim JB, Kupershmidt S, **Roden D**, Berul CI, Seidman CE, Seidman JG: The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system. Development 2004;131:4107–16. PMID:15289437
16. Simard C, Drolet B, Yang P, Kim RB, **Roden DM**: Polymorphism screening in the cardiac K+ channel *KCNA5*. Clin Pharm Ther 2005;77:138–44. PMID:15735608
17. Kannankeril PJ, **Roden DM**, Norris KJ, Whalen SP, George AL Jr, Murray KT: Genetic Susceptibility to Acquired Long QT Syndrome: Pharmacologic Challenge in First Degree Relatives. Heart Rhythm 2005;2:134–140. PMID:15851285
18. Khoo MSC, Kannankeril PJ, Li J, Zhang R, Kupershmidt S, Zhang W, Atkinson JB, Colbran RJ, **Roden DM**, Anderson ME: Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm 2005;2:634–640. PMID: 15922273
19. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, Vicentini A, Yang P, **Roden DM**, George AL Jr, Schwartz PJ: *KCNH2-*K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. Circulation 2005;112:1251–1258. PMID:16116052
20. Temple J, Frias P, Rottman J, Yang T, Wu Y, Verheijck EE, Zhang W, Chanthaphaychith S, Kanki H, Atkinson JB, King P, Anderson ME, Kupershmidt S, **Roden DM**:Atrial fibrillation in *KCNE1* null mice. Circ Res 2005;97:62–69. PMID:15947250
21. Drolet B, Simard C, Mizoue L, **Roden DM**: Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest 2005;115:2209–2213. PMID:16025157 PMCID:PMC1174915
22. Todd SJ, Campbell MJ, **Roden DM**, Kannankeril PJ: Novel Brugada SCN5A mutation causing sudden death in children. Heart Rhythm 2005;2:540–543. PMID:15840483

1. Darbar D, Yang T, Churchwell K, Wilde AAM, **Roden DM**: Unmasking of Brugada Syndrome by Lithium. Circulation 2005;112:1527–1531 [Epub 2005 Sep 6]. PMID:16144991 PMCID:PMC1350464
2. Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, Gildenhuys G, Vanoli E, Bacchini S, Spazzolini C, Lundquist AL, **Roden DM**, George AL Jr, Schwartz PJ: Phenotypic Variability and Unusual Clinical Severity of Congenital Long QT Syndrome in a Founder Population. Circulation 2005;112:2602–2610. PMID:16246960
3. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, **Roden DM**, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J: Cardiac-specific overexpression of AT1 receptor mutant lacking Gaq/Gai coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005;115:3045–3056. PMID:16276415 PMCID:PMC1265872

1. Liu K, Yang T, Viswanathan PC, **Roden DM**: New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 Mutant. Circulation 2005; 112:3239–3246. PMID: 16301357
2. Zhang M, Houamed K, Kupershmidt S, **Roden D**, Satin LS: Pharmacological properties and functional role of Kslow current in mouse pancreatic beta-cells: SK channels contribute to Kslow tail current and modulate insulin secretion. J Gen Physiol 2005;126:353–63. PMID:16186562 PMCID: PMC2266621
3. Bezzina CR, Shimizu W, Yang P, Koopmann T, Tanck MWT, Miyamoto Y, Kamakura S, **Roden DM**, Wilde AAM: Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 2006;113:338–344. PMID:16415376
4. Simard C, Drolet B, **Roden DM**: PharmGKB Submission Update: VII. PAT Submissions of Genetic Variation in KCND3 to the PharmGKB Network. Pharmacol Rev 2006;58:136–7.

1. Hasdemir C, Olukman M, Ulucan C, **Roden DM**: Brugada-type ECG Pattern and Extreme QRS Complex Widening with Propafenone Overdose. J Cardiovasc Electrophysiol 2006;17:565–6. PMID:16684037
2. Kannankeril PJ, Bhuiyan ZA, Darbar D, Mannens MMAM, Wilde AAM, **Roden DM**: Arrhythmogenic Right Ventricular Cardiomyopathy due to a Novel Plakophilin 2 Mutation: Wide Spectrum of Disease in Mutation Carriers Within a Family. Heart Rhythm 2006;3:939–944. PMID:16876743
3. Kannankeril PJ, Mitchell BM, Goonasekera SA, Chelu MG, Zhang W, Sood S, Kearney DL, DAnila C, De Biasi M, Wehrens X, Pautler RG, **Roden DM**, Taffett GE, Dirksen RT, Anderson ME, Hamilton SL: Mice with the R176Q Cardiac Ryanodine Receptor Mutation Exhibit Catecholamine-Induced Ventricular Tachycardia and cardiomyopathy. Proc Nat Acad Sci USA 2006;103:12179–84. Epub 2006 Jul 27. PMID:16873551 PMCID:PMC1567715
4. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K, Knollmann BEC, Horton KD, Weissman NJ, Holinstat IA, Zhang W, **Roden DM**, Jones LR, Franzini-Armstrong C, Pfeifer K: *Casq2* Deletion Causes Sarcoplasmic Reticulum Volume Increase, Premature Ca2+ Release, And Catecholaminergic Polymorphic Ventricular Tachycardia. J Clin Invest 2006;116:2510–2520. Epub 2006 Aug 24. PMID:16932808 PMCID:PMC1551934
5. Liu K, Hipkens S, Yang T, Abraham R, Zhang W, Chopra N, Knollmann B, Magnuson MA, **Roden DM**: Recombinase-Mediated Cassette Exchange to rapidly and efficiently generate mice with human cardiac sodium channels. Genesis 2006;44:556–64. PMID:17083109
6. Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Driskell IM, Schott J-J, Norris K, Leenhardt A, Kim RB, Escande D, **Roden DM**: Defining the Cellular Phenotype of "Ankyrin-B Syndrome" Variants: Human ANK2 Variants Associated With Clinical Phenotypes Display a Spectrum of Activities in Cardiomyocytes. Circulation 2007;115:432–441. PMID:17242276
7. Darbar D, Hardin B, Harris P, **Roden DM**: A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:636–41. PMID:17488270
8. Darbar D, Motsinger AA, Ritchie MD, Gainer JV, **Roden DM**: Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm 2007;4:743–9. Epub 2007 Feb 9. PMID:17556195 PMCID:PMC1948880
9. Pretorius M, Donahue B, Yu C, Greelish JP, **Roden DM**, Brown, NJ: Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 2007;116:S-I, 1–7. PMID:17846288
10. Smith AH, Norris KJ, **Roden DM**, Kannankeril PJ: Autonomic Tone Attenuates Drug-Induced QT Prolongation. J Cardiovasc Electrophysiol 2007:960–4. PMID:17666066
11. Chopra SS, Watanabe H, Zhong TP, **Roden DM**: Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: Implications for the evolution of electrical signaling in vertebrates. BMC Evolutionary Biology, BMC Evolutionary Biology 2007;7:113. PMID:17623065 PMCID:PMC1971062
12. Skinner JR, Yang T, Purvis D, Chung SK, Wilson C, **Roden DM**, Rees MI: Co-inheritance of long QT syndrome and Kearns-Sayre syndrome. Heart Rhythm 2007; 4:1568–1572. PMID:17980675
13. Darbar D, Kimbrough J, Jawaid A, McCray R, Ritchie MD, **Roden DM**: Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol 2008;51:836-42. PMID:18294569 PMCID: PMC2271078
14. Monahan K, Clair W, **Roden DM**: A memorable experience. Europace 2007;9:1091–2. PMID:17921515
15. Fitch RW, Gregory A, Darbar D, **Roden DM**: A Shock in Time. Clin J Sport Med 2007;17:497–9. PMID:17993795
16. Yang P, Koopman T, Pfeufer A, Jalilzadeh S, Schulze-Bahr E, Kääb S, Wilde AA, **Roden DM**, Bezzina CR: Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genetics 2008;16:350–357. Epub 2007 Dec 5. PMID:18059420
17. Darbar D, Hardy A, Haines JL, **Roden DM**: Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J Am Coll Cardiol 2008;51:1083–1089. PMID:18342226 PMCID:PMC2279191
18. Rhodes TE, Abraham RL, Welch RC, Vanoya CG, Crotti L, Arnestad M, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Rognum T, **Roden DM**, Schwartz PJ, George AL Jr: Cardiac Potassium Channel Dysfunction in Sudden Infant Death Syndrome. J Mol Cell Cardiology 2008;44:571–581. PMID:18222468 PMCID:PMC2386856
19. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, **Roden DM**, Stein CM: Genetic determinants of response to warfarin during initial anticoagulation. New Engl J Med 2008;358:999–1008. PMID:18322281
20. Watanabe H, Tanabe N, Watanabe T, Darbar D, **Roden DM**, Sasaki S, Aizawa Y: Metabolic Syndrome and Risk of Development of Atrial Fibrillation: The Niigata Preventive Medicine Study. Circulation 2008;117:1255–1260. PMID:18285562 PMCID:PMC2637133
21. Darbar D, Kannankeril PJ, Donahue B, Kucera G, Stubblefield T, Haines JL, George AL Jr, **Roden DM**: Cardiac Sodium Channel (SCN5A) Variants Associated with Atrial Fibrillation. Circulation 2008;117:1927–1935. PMID:18378609 PMCID:PMC2365761
22. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhura S, Mochizuki N, Makiyama T, Itoh L, Christiansen M, McKeown P, Miyamoto K, Kamakura S, Tsutsui H, Schwartz PJ, George AL Jr, **Roden DM**: The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 2008;118:2219–29. PMID:18451998 PMCID:PMC2350431
23. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott J-J, Demolombe S, Probst V, Anselme F, Escande D, Weisfeld ACP, Pfeufer A, Kääb S, Wichmann H-E, Hasdemir C, Aizawa Y, Wilde AAM, **Roden DM,** Bezzina CR: Sodium Channel beta1-subunit Mutations Associated with Brugada Syndrome and Cardiac Conduction Disease. J Clin Invest 2008;118:2260–8. PMID:18464934 PMCID:PMC2373423

1. **Roden DM**, Pulley JM, Basford M, Bernard GR, Clayton EW, Balser JR, Masys DR: Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008;84:362–369. PMID:18500243
2. CooperGM, Johnson JA, Langaee TY, Feng H, Stanaway IB, SchwarzU, Ritchie MD, Stein CM, **RodenDM**, SmithJD, VeenstraDL, Rettie AE, Rieder MJ: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008;112:1022–1027. PMID:18535201 PMCID:PMC2515139
3. Kannankeril PJ, Harris PA, Norris KA, Warsy I, Smith PD, **Roden DM**: Rate-Independent QT Shortening During Exercise in Healthy Subjects: Terminal Repolarization Does Not Shorten with Exercise. J Cardiovasc Electrophysiol 2008;19:1284–8. PMID:18665873 PMCID: PMC2811883
4. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, **Roden DM**, Wagner MJ, Caldwell MD, Johnson JA: Estimation of the warfarin dose with clinical and pharmacogenetic data. New Engl J Med 2009;360:753–764. PMID:19228618 PMCID:PMC2722908
5. Li C, Schwarz UI, Ritchie MD, **Roden DM**, Stein CM, Kurnik D: Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009;113:3925–3930. PMID:19074728 PMCID:PMC2673121
6. Kääb S,\* Darbar D,\* van Noord C,\* Dupuis J,\* Pfeufer A, Newton-Cheh C, Schnabel R, Makino S, Sinner MF, Kannankeril PJ, Beckmann BM, Choudry S, Donahue BS, Heeringa J, Perz S, Lunetta KL, Larson MG, Levy D, MacRae CA, Ruskin JN, Wacker A, Schömig A, Wichmann HE, Steinbeck G, Meitinger T, Uitterlinden AG, Witteman JC, **Roden DM**, Benjamin EJ, Ellinor PT: Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009;30: 813–9. PMID:19141561 PMCID:PMC2663727
7. Husser D, Stridh M, Sörnmo L, **Roden DM**, Darbar D, Bollmann A: A Genotype Dependent Intermediate ECG Phenotype in Patients with Persistent Lone Atrial Fibrillation. Genotype ECG-Phenotype correlation in atrial fibrillation. Circ Arrhythmia Electrophysiol 2009;2:24–28. PMID:19305639 PMCID:PMC2658819
8. McBride BF, Yang T, **Roden DM**: Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide induced block of HERG. Pharmacogenomics J 2009;9:194–201. PMID:19204737 PMCID:PMC3775644
9. Watanabe H, Darbar D, Kaiser D, Jiramongkolchai K, Chopra S, Donahue BS, Kannankeril PJ, **Roden DM**: Mutations in Sodium Channel Beta-1 and Beta-2 Subunits associated with Atrial Fibrillation. Circ Arrhythmia Electrophysiol 2009;2:268–75. PMID:19808477 PMCID:PMC2727725
10. Watanabe H, Chopra N, Laver D, Hwang H, Davies SS, Roach DE, Duff HJ, **Roden DM**, Wilde AA, Knollmann BC: Flecainide prevents Catecholaminergic Polymorphic Ventricular Tachycardia in Mice and Humans. Nature Medicine 2009;15:380–3. PMID:19330009 PMCID:PMC2904954
11. McBride BF, Yang T, Liu K, Urban TJ, Giacomini K, Kim RB, **Roden DM**: The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium Channel. J Cardiovasc Pharmacol 2009;54:63–71. PMID:19528813 PMCID:PMC3745652
12. Yang T, Chung S-K, Zhang W, Mullins JGL, McCulley CH, Crawford J, MacCormick J, Eddy C-A, Shelling AN, French JK, Yang P, Skinner JR, **Roden DM**, Rees MI: Biophysical Properties of 9 KCNQ1 Mutations Associated with Long QT Syndrome. Circ Arrhythmia Electrophysiol 2009;2:417–26. PMID:19808498 PMCID: PMC2748886
13. Yang T, Kanki H, Zhang W, **Roden DM**: Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac IKs block by protein kinase A-mediated IKs phosphorylation. Br J Pharmacol 2009;157:952–61. PMID:19522859 PMCID:PMC2737654
14. Bush WS, Crawford DC, Alexander C, George AL Jr, **Roden DM**, Ritchie MD: Genetic Variation in the Rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias. Pharmacogenomics 2009;10:1043–53. PMID:19530973 PMCID:PMC2746955
15. Body SC, Collard CD, Shernan SK, Fox AA, Liu K-Y, Ritchie MD, Perry TE, Muehlschlegel JD, Aranki SF, Donahue BS, Pretorius M, Estrada JC, Ellinor PT, Newton-Cheh C, Seidman CE, Seidman JG, Herman DS, Lichtner P, Meitinger T, Pfeufer A, Kääb S, Brown NJ, **Roden DM**, Darbar D: Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation after Coronary Artery Bypass Graft Surgery. Circ Cardiovasc Genet 2009;2:499–506. PMID:20031626 PMCID:PMC2801871
16. Postma PG, Wolpert C, Amin AS, Probst V, Borgreffe M, **Roden DM**, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AAM: Drugs and Brugada syndrome patients: review of the literature, recommendations and an up-to-date website (www.brugadadrugs.org) Heart Rhythm 2009;6:1335–41. PMID:19716089 PMCID:PMC2779019
17. Abraham RL, Yang T, Blair M, **Roden DM**, Darbar D: Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J Mol Cell Cardiol 2010;48:181–90. Epub ahead of print 2009 July 30. PMID:19646991 PMCID:PMC2813326
18. Milan DJ, Kim AM, Winterfield JR, Jones IL, Pfeufer A, Sanna S, Arking DE, Amsterdam AH, Sabeh KM, Mably JD, Rosenbaum DS, Peterson RT, Chakravarti A, Kääb S, **Roden DM**, MacRae CA: Drug-Sensitized Zebrafish Screen Identifies Multiple Genes, Including GINS3, as Regulators of Myocardial Repolarization. Circulation 2009; 120:553–9. Epub ahead of print 2009 Aug 3. PMID:19652097 PMCID:PMC2771327
19. Watanabe H, Kaiser DW, Makino S, MacRae CA, Ellinor PT, Wasserman BS, Kannankeril PJ, Donahue BS, **Roden DM**, Darbar D: ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: Implications for electrical remodeling. Heart Rhythm 2009;6:1327–32. Epub 2009 May 15. PMID:19648063 PMCID:PMC2740737
20. Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters GB, Thorgeirsson G, Gulcher J, Mathiesen E, Njølstad I, Nyrnes A, Wilsgaard T, Hald E, Hveem K, Stoltenberg C, Kucera G, Stubblefield T, Carter S, **Roden D**, Ng MCY, Baum L, So WY, Wong KS, Chan JCN, Gieger C, Wichmann H-E, Gschwendtner A, Dichgans M, Kuhlenbäumer G, Berger K, Ringelstein B, Bevan S, Markus H, Kostulas K, Hillert J, Sveinbjörnsdóttir S, Valdimarsson EM, Løchen M-L, Ma RCW, Darbar D, Kong A, Arnar DO, Thorsteinsdottir U, Stefansson K: A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009;41:876–8. Epub 2009 Jul 13. PMID:19597491 PMCID:PMC2740741
21. Watanabe H, Watanabe T, Sasaki S, Nagai K, **Roden DM**, Aizawa Y: Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158:629–636. PMID:19781424
22. Pulley J, Clayton E, Bernard GR, **Roden DM**, Masys DR: Principles of human subjects protections applied in an opt-out, de-identified biobank. Clinical and Translational Science 2010;3:42–8. PMID:20443953 PMCID:PMC3075971
23. Chopra SS, Stroud DM, Watanabe H, Bennett JS, Burns CG, Wells S, Yang T, Zhong T, **Roden DM**: Voltage-gated sodium channels are required for heart development in zebrafish. Circ Res 2010;106:1342–50. PMID: 20339120 PMCID:PMC2869449
24. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, deBakker P, Mueller M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel R, Soliman EZ, Rice KM, Van Wagoner DR, Beckmann BM, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen S, Steinbeck G, Smith AV, Launer LJ, Harris TB, Makino S, Nelis M, Milan DJ, Perz S, Esko T, Köttgen A, Moebus S, Newton-Cheh C, Li M, Möhlenkamp S, Wang TJ, Kao WHL, Vasan R, Nöthen M, MacRae CA, Stricker BH, Hofman A, Uitterlinden AG, Levy D, Boerwinkle E, Metspalu A, Topol EJ, Chakravarti A, Gudnason V, Psaty BM, **Roden DM**, Meitinger T, Wichmann HE, Witteman JC, Barnard J, Arking DE, Benjamin EJ, Heckbert SR, Kääb S: Common Variants in KCNN3 are Associated with Lone Atrial Fibrillation. Nature Genetics 2010;42:240–4. PMID:20173747 PMCID:PMC2871387
25. Ritchie MD,\* Denny JC,\* Crawford DC,\* Ramirez AH, Weiner JB, Pulley JM, Basford MA, Brown-Gentry K, Balser JR, Masys DR, Haines JL, **Roden DM**: Robust replication of genotype-phenotype associations across multiple diseases in an Electronic Medical Record. Am J Human Genetics 2010;86:560–72. PMID:20362271 PMCID:PMC2850440
26. Denny JC, Ritchie MD, Basford M, Pulley J, Bastarache L, Brown-Gentry K, Wang D, Masys DR, **Roden DM**, Crawford DC: PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 2010;26:1205–10. PMID:20335276 PMCID:PMC2859132
27. Yang T, Yang P, **Roden DM**, Darbar D: Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm 2010;7:1246–52. PMID:20638934 PMCID:PMC2932792
28. Dumitrescu L, Ritchie MD, Brown-Gentry K, Pulley JJ, Basford M, Denny JC, Oksenberg JR, **Roden DM**, Haines JL, Crawford DC: Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet Med 2010;12:648–50. PMID: 20733501 PMCID:PMC2952033
29. Yang T, McBride BF, Leake BF, Kim RB, **Roden DM**: Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Br J Pharmacology 2010;161:1023–33. PMID:20977453 PMCID:PMC2998684
30. Barrett TW, Martin AR, Storrow AB, Jenkins CA, Harrell FE, Russ S, **Roden DM**, Darbar D: A Clinical Prediction Model to Estimate Risk for 30-Day Adverse Events in Emergency Department Patients with Symptomatic Atrial Fibrillation. Ann Emerg Med 2011 Jan;57:1–12. Epub 2010 Aug 21. PMID:20728962 PMCID:PMC3008754
31. Schildcrout JS, Basford M, Pulley J, Masys DR, **Roden DM**, Wang D, Chute CG, Kullo IJ, Carrell D, Peissig P, Kho A, Denny JC: An analytical approach to assess the comparability of large, geographically distinct populations for clinical and genetic research. J Biomedical Informatics 2010;43:914–23. PMID:20688191 PMCID:PMC2991387
32. Bezzina CR, Pazoki R, Bardai A, Marsman RF, de Jong JSSG, Blom MT, Scicluna BP, Jukema JW, Bindraban NR, Lichtner P, Pfeufer A, Bishopric N, **Roden DM**, Meitinger T, Chugh SS, Myerburg RJ, Jouven X, Kääb S, Dekker LRC, Tan HL, Tanck MWT, Wilde AAM: Genome-wide association study identifies a susceptibility locus 21q21 for ventricular fibrillation in acute myocardial infarction. Nature Genetics 2010;42:688–91. PMID:20622880 PMCID:PMC3966292
33. Denny JC, Ritchie MD, Crawford DC, Schildcrout JS, Ramirez AH, Pulley JM, Basford MA, Masys DR, Haines JL, **Roden DM**: Identification of genomic predictors of atrioventricular conduction: Using electronic medical records as a tool for genome science. Circulation 2010;122:2016–21. PMID:21041692 PMCID:PMC2991609
34. Ramirez AH, Schildcrout JS, Blakemore DL, Masys DR, Pulley JM, Basford MA, **Roden DM**, Denny JC: Modulators of normal electrocardiographic intervals identified in a large electronic medical record. Heart Rhythm 2011 Feb;8:271–7. Epub 2010 Oct 29. PMID:21044898 PMCID:PMC3057498
35. Skinner JR, Crawford J, Smith W, Aitken A, Heaven D, Evans CA, Hayes I, Neas KR, Stables S, Koelmeyer T, Denmark L, Vuletic J, Maxwell F, White K, Yang T, **Roden DM**, Leren TP, Shelling A, Love DR: Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm 2011;8:412–9. PMID:21070882
36. Pendergrass S, Dudek SM, **Roden DM**, Crawford DC, Ritchie MD: Visual integration of results from a large DNA biobank (biovu) using synthesis-view. Pac Symp Biocomput 2011:265–75. PMID:21121054 PMCID:PMC3065108
37. Jeff JM, Brown-Gentry K, Buxbaum SG, Sarpong DF, Taylor HA, George AL Jr, **Roden DM**, Crawford DC: SCN5A variation is associated with electrocardiographic traits in the Jackson Heart Study. Circ Cardiovasc Genet 2011;4:139–44. PMID:21325150 PMCID:PMC3080430
38. Holm H, Gudbjartsson DF, Sulem P, Masson G, Helgadottir HT, Zanon C, Magnusson OT, Helgason A, Saemundsdottir J, Gylfason A, Stefansdottir H, Gretarsdottir S, Matthiasson SE, Thorgeirsson G, Jonasdottir A, Sigurdsson A, Stefansson H, Werge T, Rafnar T, Kiemeney LA, Parvez B, Muhammad R, **Roden DM**, Darbar D, Thorleifsson G, Walters GB, Kong A, Thorsteinsdottir U, Arnar DO, Stefansson K: A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nature Genetics 2011;43:316–20. PMID:21378987 PMCID:PMC3066272
39. Kannankeril PJ, Norris KJ, Carter S, **Roden DM**: Factors Affecting the Degree of QT Prolongation with Drug Challenge in a Large Cohort of Normal Volunteers. Heart Rhythm 2011;8:1530-34. PMID:21420510 PMCID:PMC3154568
40. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, Yue P, Tsau PS, Kohane I, **Roden DM**, Altman RB: Detecting drug interactions from adverse-event reports: Interaction between paroxetine and pravastatin increase blood glucose levels. Clin Pharmacol Ther 2011;90:133–42. PMID:21613990 PMCID:PMC3216673
41. Xu H, Jiang M, Oetjens M, Bowton EA, Ramirez AH, Jeff JM, Basford MA, Pulley JM, Cowan JD, Wang X, Ritchie MD, Masys DR, **Roden DM**, Crawford DC, Denny JC: Facilitating Pharmacogenetic Studies using Electronic Health Records and Natural Language Processing: A Case Study of Warfarin. J Am Med Inform Assoc 2011;18:387–91. PMID:21672908 PMCID:PMC3128409

1. Atack TC, Stroud DM, Watanabe H, Yang T, Hall L, Hipkens S, Lowe JS, Leake B, Magnuson M, Yang P, **Roden DM**: Informatic and functional approaches to identifying a regulatory region for the cardiac sodium channel. Circ Res 2011;109:38–46. PMID:21566215 PMCID:PMC3135383
2. Shoemaker MB, Hemnes AR, Robbins IM, Langberg JJ, Ellis CR, Aznaurov SG, Fredi JL, Slosky DA, **Roden DM**, Murray KT, Piana RN, Mendes LA, Whalen SP: Left Atrial Hypertension After Repeated Catheter Ablations for Atrial Fibrillation. J Am Coll Cardiol 2011;57:1918–1919. PMID:21545950
3. Turner SD, Berg RL, Linneman JG, Peissig PL, Crawford DC, Denny JC, **Roden DM**, McCarty CA, Ritchie MD, Wilke RA: Knowledge-Driven Multi-Locus Analysis Reveals Gene-Gene Interactions Influencing HDL Cholesterol Level in Two Independent EMR-Linked Biobanks. PLoS ONE 2011;6(5):e19586. PMID:21589926 PMCID:PMC3092760
4. Watanabe H, Yang T, Stroud DM, Lowe JS, Harris L, Atack TC, Wang DW, Hipkens S, Leake B, Hall L, Kupershmidt S, Chopra N, Magnuson M, Tanabe N, Knollmann BC, George AL Jr, **Roden DM**: Striking in vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes invitro. Circulation 2011;124:1001–1011. PMID:21824921 PMCID:PMC3297976
5. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G, Castro RA, Johns SJ, Stryke D, Sali A, Ferrin TE, Witte JS, Kwok PY, **Roden DM**, Wilke RA, McCarty CA, Davis RL, Giacomini KM: A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011 Nov;90(5):674–84. doi: 10.1038/clpt.2011.165. Epub 2011 Sep 28. PMID:21956618 PMCID:PMC3329222
6. Relling MV, Guchelaar HJ, **Roden DM**, Klein TE: Pharmacogenetics: Call to Action. (letter). Clin Pharmacol Ther 2011;90:507. PMID:21881564

1. Barrett TW, Storrow AB, Jenkins CA, Harrell FE, Miller KF, Moser KM, Russ S, **Roden DM**, Darbar D: Atrial fibrillation and Flutter Outcomes and Risk Determination (AFFORD): Design and rationale. J Cardiol 2011;58:124–30. PMID:21820279 PMCID:PMC3169197
2. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, LaRue S, Langlois N, Lazo-Langner A, Zou G, **Roden DM**, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB: Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011;118;3163–3171. [Epub ahead of print July1] PMID:21725053
3. Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout J, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, **Roden DM**, Crawford DC, Denny JC: Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record. Clin Pharmacol Ther 2012;91:257–63. PMID:22190063 PMCID:PMC3621954
4. Denny JC, Crawford DC, Ritchie MD, Bielinski SJ, Basford MA, Bradford Y, Chai HS, Bastarache L, Zuvich R, Peissig P, Carrell D, Ramirez AH, Pathak J, Wilke R, Rasmussen L, Wang X, Pacheco J, Kho A, Hayes MG, Weston N, Matsumoto M, Kopp PA, Newton KM, Jarvik GP, Li R, Manolio T, Kullo IJ, Chute C, Chisholm R, Larson EB, McCarty CA, Masys DR, **Roden DM**, de Andrade M: Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: Using electronic medical records for genome- and phenome-wide studies. Am J Human Genetics 2011;89:529–42. PMID:21981779 PMCID:PMC3188836
5. Fox AA, Pretorius M, Liu KY, Collard CD, Perry TE, Shernan SK, De Jager PL, Hafler DA, Herman DS, DePalma SR, **Roden DM**, Muehlschlegel JD, Donahue BS, Darbar D, Seidman JG, Body SC, Seidman CE: Genome-wide assessment for genetic variants associated with ventricular dysfunction after primary coronary artery bypass graft surgery. PLoS One 2011;6:e24593 [Epub 2011 Sep 30]. PMID:21980348 PMCID:PMC3184087
6. Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, **Roden DM**, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG: Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One 2011;6:e27808. PMID:22114699 PMCID:PMC3218053
7. Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, **Roden DM**, Darbar D: A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 2012 Jan 3;59:49–56. PMID:22192668 PMCID:PMC3245828
8. Kääb S, Crawford DC, Sinner M, Behr ER, Kannankeril PJ, Wilde AA, Bezzina C, Schulze-Bahr E, Guicheney P, Bishopric N, Myerburg R, Schott JJ, Pfeufer A, Beckmann BM, Martens E, Zhang T, Stallmeyer B, Zumhagen S, Denjoy I, Bardai A, Van Gelder IC, Jamshidi Y, Dalageorgou C, Marshall VC, Jeffrey S, Shakir S, Camm AJ, Steinbeck G, Perz S, Lichter P, Meitinger T, Peters A, Wichmann HE, Ingram C, Bradford Y, Carter S, Norris K, Crawford DC, Ritchie MD, George AL Jr, **Roden DM**: A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2012;5:91–99. PMID:22100668 PMCID: PMC3288202
9. Ramirez AH, Shi Y, Schildcrout JS, Delaney J, Xu H, Oetjens MT, Zuvich R, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, **Roden DM**, Crawford DC, Denny JC: Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012;13:407–18. PMID:22329724 PMCID:PMC3361510
10. Liu M, Jiang M, Kawai VK, Stein CM, **Roden DM**, Denny JC, Xu H: Modeling drug exposure data in electronic medical records: an application to warfarin. AMIA Annu Symp Proc 2011;2011:815–23. PMID: 22195139 PMCID:PMC3243123
11. Makita N, Seki A, Sumitomo N, Chkourko H, Fukuhara S, Watanabe H, Shimizu W, Bezzina C, Hasdemir C, Mugishima H, Makiyama T, Baruteau A, Baron E, Horie M, Hagiwara N, Wilde AAM, Probst V, Le Marec H, **Roden DM**, Mochizuki N, Schott JJ, Delmar M: A Connexin40 Mutation Associated with a Malignant Variant of Progressive Familial Heart Block Type 1. Circ Arrhythm Electrophysiol 2012;5:163–72. PMID:22247482 PMCID:PMC4274644
12. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks H, Wilke R, Clayton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, **Roden DM**: Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012;9:87–95. PMID:22588608 PMCID:PMC3581305
13. Delaney JT, Jeff JM, Brown NJ, Pretorius M, Okafor HE, Darbar D, **Roden DM**, Crawford DC: Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PLoS One 2012;7:e32338. PMID:22384221 PMCID:PMC3285683
14. Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, Ruddy S, Talbott D, Norris KP, Snieder H, George AL Jr, Marshall V, Shakir S, Kannankeril PJ, Munroe PB, Camm AJ, Jeffery S, **Roden DM**, Behr ER: Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012;60:841–50. PMID:22682551 PMCID: PMC3753216
15. Parvez B, Vaglio JC, Rowan S, Muhammad R, Kucera G, Stubblefield T, Carter S, **Roden DM**, Darbar D. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012;60:539–45. PMID:22726630 PMCID:PMC3411889
16. Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S, **Roden DM**, Darbar D: Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. J Am Coll Cardiol 2012;60:1173–81. PMID:22818067 PMCID:PMC3448817
17. Delaney J, Muhammad R, Blair MA, Kor K, Fish FA, **Roden DM**, Darbar D: A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace 2012;14:1428–1432. PMID:22562657 PMCID:PMC3458578
18. Monahan K, Brewster J, Wang L, Parvez B, Goyal S, **Roden DM**, Darbar D: Relation of the Severity of Obstructive Sleep Apnea in Response to Anti-Arrhythmic Drugs in Patients With Atrial Fibrillation or Atrial Flutter. Am J Cardiol 2012 Aug 1;110:369–72. PMID:22516529 PMCID:PMC3398182
19. Schildcrout JS,\* Denny JC,\* Bowton E, Gregg W, Pulley JM, Basford M, Cowan J, Xu H, Ramirez AH, Crawford DC, Ritchie MD, Peterson JF, Masys DR, Wilke RA, **Roden DM**: Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clin Pharmacol Ther 2012;92;235–242. PMID:22739144 PMCID:PMC3785311. *Response to letter to the Editor*: Clin Pharmacol Ther 2013 Mar;93(3):234. doi: 10.1038/clpt.2012.223. [Epub 2012 Nov 7] PMID:23249779
20. Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, Nickerson DA, George AL Jr, **Roden DM**: Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J August 2013;13(4):325–329. Published online 2012 May 15. doi: 10.1038/tpj.2012.14. PMID:22584458 PMCID:PMC3422407
21. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Müller-Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dörr M, Ozaki K, Roberts JD, Smith JG, Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer LJ, Davies RW, Borkovich M, Harris TB, Lin H, Völker U, Völzke H, Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen D, Tsunoda T, Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, Parvez B, Mahida S, Furie KL, Rosand J, Muhammad R, Psaty BM, Meitinger T, Perz S, Wichmann HE, Witteman JC, Kao WH, Kathiresan S, **Roden DM**, Uitterlinden AG, Rivadeneira F, McKnight B, Sjögren M, Newman AB, Liu Y, Gollob MH, Melander O, Tanaka T, Stricker BH, Felix SB, Alonso A, Darbar D, Barnard J, Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, Kääb S: Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nature Genetics 2012;44:670–5. PMID:22544366 PMCID:PMC3366038
22. Lowe JS,\* Stroud DM,\* Yang T, Hall L, Atack TC, **Roden DM**: Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res 2012;95:300–7. PMID:22562703 PMCID:PMC3633400.
23. Behr E, January C, Schulze-Bahr E, Grace AA, Kääb S, Fiszman M, Gathers S, Buckman S, Youssef A, Pirmohamed M, **Roden DM**: The International Severe Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Heart J. 2013 Jul;34(26):1958-63. doi: 10.1093/eurheartj/ehs172. Epub 2012 Jul 2. PMID:22752616 PMCID:PMC3703308 [*Response-Letter to the Editor* European Heart Journal 2012]
24. Yang T, Atack TC, Stroud DM, Zhang W, Hall L, **Roden DM**: Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res 2012;111:322–332. PMID:22723299 PMCID:PMC3412150
25. Lipworth L, Okafor H, Mumma MT, Edwards TL, **Roden D**, Blot WJ, Darbar D: Race-Specific Impact of Atrial Fibrillation Risk Factors in Blacks and Whites in the Southern Community Cohort Study. Am J Cardiol 2012;110:1637–1642. PMID:22922000 PMCID:PMC3496834
26. Rasmussen-Torvik LJ, Pacheco JA, Wilke RA, Thompson WK, Ritchie ME, Kho MN, Muthalagu A, Hayes MG, Armstrong LL, Scheftner DA, Wilkins JT, Zuvich RL, Crosslin D, **Roden DM**, Denny JC, Jarvik GP, Carlson CS, Kullo IJ, Bielinski SJ, McCarty CA, Li R, Manolio TA, Crawford DC, Chisholm RL: High Density GWAS for LDL Cholesterol in African Americans Using Electronic Medical Records Reveals a Strong Protective Variant in APOE. Clinical and Translational Science 2012;5:394–399. PMID:23067351 PMCID:PMC3521536
27. Shoemaker MB, Muhammad R, Parvez B, White BW, Streur M, Song Y, Stubblefield T, Kucera G, Blair M, Rytlewski J, Parvathaneni S, Nagarakanti R, Saavedra P, Ellis C, Whalen SP, **Roden DM**, Darbar D: Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm 2012;10:394–400 [Epub 2012 Nov 23]. PMID:23178686 PMCID:PMC3587357
28. Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M, Stubblefield T, Rytlewski J, Parvathaneni S, Nagarakanti R, **Roden DM**, Saavedra P, Ellis C, Whalen SP, Darbar D: Relation of Morbid Obesity and Female Gender to Risk of Procedural Complications in Patients Undergoing Atrial Fibrillation Ablation. Am J Cardiol 2013;111:368—73. PMID:23168290 PMCID:PMC3546280
29. Yang T, Smith JA, Leake BF, Sanders CR, Meiler J, **Roden DM**: An Allosteric Mechanism for Drug Block of the Human Cardiac Potassium Channel KCNQ1. Mol Pharmacol 2013;83:481–9. PMID:23193163 PMCID:PMC3558809
30. McGregor TL, Van Driest SL, Brothers KB, Bowton EA, Muglia LJ, **Roden DM**: Inclusion of Pediatric Samples in an Opt-Out Biorepository Linking DNA to De-Identified Medical Records: Pediatric BioVU. Clin Pharmacol Ther 2013 Feb;93(2):204–11. 2012 Nov 21. doi: 10.1038/clpt.2012.230. [Epub ahead of print]. PMID:23281421 PMCID:PMC3686097
31. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, **Roden DM**, Wilke RA, McCarty CA, Davis RL, Brett CM, Giacomini KM: The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacol Ther 2012;93:186–194. Oct 17. doi: 10.1038/clpt.2012.210. [Epub ahead of print]. PMID:23267855 PMCID:PMC3671611
32. Müller II, Melville DB, Tanwar V, Rybski WM, Mukherjee A, Shoemaker BM, Wang WD, Schoenhard JA, **Roden DM**, Darbar D, Knapik EW, Hatzopoulos AK: Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. Dis Model Mech 2012 Dec 7;6:332–341 [Epub ahead of print]. PMID:23223679 PMCID:PMC3597016
33. Ritchie MD, Denny JC, Zuvich RL, Crawford DC, Schildcrout JS, Bastarache L, Ramirez AH, Mosley JD, Pulley JM, Basford MA, Bradford Y, Rasmussen LV, Pathak J, Chute CG, Kullo IJ, McCarty CA, Chisholm RL, Kho AN, Carlson CS, Larson EB, Jarvik GP, Sotoodehnia N, on behalf of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) QRS Group, Manolio TA, Li R, Masys DR, Haines JL, **Roden DM**: Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation 2013 Apr 2;127:1377–85 [Epub 2013 Mar 5]. PMID:23463857 PMCID:PMC3713791
34. Heatherly RD, Loukides G, Denny JC, Haines JL, **Roden DM**, Malin BA: Enabling Genomic-Phenomic Association Discovery without Sacrificing Anonymity. PLoS One. 2013;8:e53875. PMID:23405076 PMCID:PMC3566194
35. Weeke P, Kannankeril PJ, Ramirez AH, Norris K, Carter S, Kucera G, Stubblefield T, Van Driest S, Delaney J, **Roden DM**: Variability in QT interval prolongation during initial exposure to sotalol: experience based on a large electronic medical record. Europace 2013 Dec;15(12):1791—7. doi: 10.1093/europace/eut153. Epub 2013 Jun 19. PMID: 23787903 PMCID: PMC3888125
36. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AHB, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, **Roden DM**, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA: Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. The Lancet 2013;382(9894):790–6. [Online June 5, 2013] http://dx.doi.org/10.1016/S0140-6736(13)60681-9 PMID:23755828 PMCID:PMC3759580
37. Ding K, de Andrade M, Manolio T, Crawford DC, Rasmussen-Torvik L, Ritchie MD, Denny JC, Masys DR, Jouni H, Pachecho JA, Kho AN, **Roden DM**, Chisholm R, Kullo IJ: Genetic Variants that Confer Resistance to Malaria are Associated with Red Blood Cell Traits in African Americans: An Electronic Medical Record-based Genome Wide Association Study. G3: Genes, Genomes, Genetics 2013;3:1061–8. doi: 10.1534/g3.113.006452 [Online May 20, 2013]. PMID:23696099 PMCID:PMC3704235
38. Altman RB, Clayton EW, Kohane IS, Malin BA, **Roden DM**: Data re-identification: societal safeguards. Science 2013;339:1032–3 (Letter to the editor). PMID:23449577 PMCID:PMC3740512
39. Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, Sanderson SC, Kannry J, Zinberg R, Basford MA, Brilliant M, Carey DJ, Chisholm RL, Chute CG, Connolly JJ, Crosslin D, Denny JC, Gallego CJ, Haines JL, Hakonarson H, Harley J, Jarvik GP, Kohane I, Kullo I, Larson EB, McCarty C, Ritchie MD, **Roden D**, Smith ME, Böttinger EP, Williams MS: The Electronic Medical Records and Genomics (eMERGE) Network: Past, Present and Future. Genet Med 2013 Oct;15(10):761–71. Genetics in Medicine [Published online 06 June 2013] doi:10.1038/gim.2013.72. PMID:23743551 PMCID:PMC3795928
40. Oetjens MT, Denny JC, Ritchie MD, Gillani NB, Richardson DM, Restrepo NA, Pulley JM, Dilks HH, Basford MA, Bowton E, Masys DR, Wilke RA, **Roden DM**, Crawford DC: Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics 2013 May;14:735–44. doi: 10.2217/pgs.13.64. PMID:23651022 PMCID:PMC3725600
41. Jeff JM, Ritchie MD, Denny JC, Kho AN, Ramirez AH, Crosslin D, Armstrong L, Basford MA, Wolf WA, Pacheco JA, Chisholm RL, **Roden DM**, Hayes G, Crawford DC: Generalization of Variants Identified by Genome-wide Association Studies for Electrocardiographic Traits in African Americans. Ann Hum Genet 2013 Mar 28;77:321–332. doi: 10.1111/ahg.12023. Epub 2013 Mar 28. PMID:23534349 PMCID:PMC3743946
42. Peterson JF, Bowton EA, Field JR, Beller M, Mitchell JK, Schildcrout JS, Johnson K, Jirjis JN, **Roden DM**, Pulley JM, Denny JC: Electronic Health Record Design and Implementation for Pharmacogenomics: a Local Perspective. Genetics in Medicine 2013;15:833–841. doi:10.1038/gim.2013.109. Epub 2013 Sep 5. PMID:24009000 PMCID:PMC3925979
43. Parvez B, Shoemaker MB, Muhammad R, Richardson R, Jiang L, Blair MA, **Roden DM**, Darbar D. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm 2013;10:849–55. doi: 10.1016/j.hrthm.2013.02.018 Epub 2013 Feb 19. PMID:23428961 PMCID:PMC3690553
44. Bennett JS, Stroud DM, Becker JR, **Roden DM**: Proliferation of embryonic cardiomyocytes in zebrafish requires the sodium channel scn5Lab. Genesis 2013 Aug;51(8):562-74. doi: 10.1002/dvg.22400. Epub 2013 Jun 25. PMID:23650201 PMCID:PMC3750094
45. Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, Verkerk AO, Schwartz PJ, Crotti L, Guicheney P, Fressart V, Leenhardt A, Antzelevitch C, Bartkowiak S, Schulze-Bahr E, Zumhagen S, Behr E, Tfelt-Hanson J, Kaab S, Weeke P , **Roden DM**, Watanabe H, Endo N, Horie M, Ohno S, Hasegawa K, Makita N, Mine S, Shimizu W, Aiba T, Froguel P, Balkau B, Wiese C, Wolswinkel R, Coronel R, Boukens BJ, Charpentier E, Chatel S, Despres A, Gros F, Kyndt F, Lecointe S, Lindenbaum P, Porter V, Violleau J, Gessler M, Tan HL, Christoffels VM, Le Marec H, Wilde AA, Probst V, Schott JJ, Dina C, Redon R: Common variants at SCN5A/SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013 Sep;45:1044–9. doi: 10.1038/ng.2712. Epub 2013 Jul 21. PMID:23872634 PMCID:PMC3869788
46. Wells Q, Becker J, Su YR, Mosley J, Weeke P, D’Aoust L, Ausborn NL, Ramirez AH, Pfotenhauer J, Naftilan AJ, Markham L, Exil V, **Roden DM**, Hong CC: Whole exome sequencing identifies a causal RBM20 mutation in a large pedigree with familial dilated cardiomyopathy. Circ Cardiovasc Genet. 2013 Aug;6(4):317-26. doi: 10.1161/CIRCGENETICS.113.000011. Epub 2013 Jul 16. PMID:23861363 PMCID:PMC3895490
47. Rosenbloom ST, Madison JL, Brothers KB, Bowton EA, Clayton EW, Malin BA, **Roden DM**, Pulley J: Ethical and Practical Challenges to Studying Patients Who Opt-out of Large-Scale Biorepository Research. J Am Med Inform Assoc 2013 Dec;20(e2):e221-5. doi: 10.1136/amiajnl-2013-001937. Epub 2013 Jul 25. PMID:23886923 PMCID:PMC3861935
48. Behr ER, Ritchie MD, Tanaka T, Kääb S, Crawford DC, Nicoletti P, Floratos A, Sinner MF, Kannankeril PJ, Wilde AAM, Bezzina CR, Schulze-Bahr E, Zumhagen S, Guicheney P, Bishopric NH, Marshall V, Shakir S, Dalageorgou C, Bevan S, Jamshidi Y, Bastiaenen R, Myerburg RJ, Schott JJ, Camm AJ, Steinbeck G, Norris K, Altman RB, Tatonetti N, Jeffery S, Kubo M, Nakamura Y, Shen Y, George AL Jr, **Roden DM**: Genome wide analysis of drug-induced Torsades de Pointes: lack of common variants with large effect sizes. PLoS ONE 8(11): e78511. doi:10.1371/journal.pone.0078511. PMID:24223155 PMCID:PMC3819377
49. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley JM, Ramirez AH, Bowton E, Basford MA, Carrell D, Peissig PL, Kho AN, Pacheco JA, Rasmussen LV, Crosslin DR, Crane PK, Pathak J, Bielinski SJ, Pendergrass SA, Xu H, Hindorff LA, Li R, Manolio TA, Chute CG, Chisholm RL, Larson EB, Jarvik GP, Brilliant MH, McCarty CA, Kullo IJ, Haines JL, Crawford DC, Masys DR, **Roden DM**: Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013 Dec;31(12):1102-10. PMID:24270849 PMCID:PMC3969265
50. Wei WQ, Feng Q, Jiang L,Waitara MS, Iwuchukwu OF, **Roden DM**, Jiang M, Xu H, Krauss RM, Rotter JI, Nickerson DA, Davis RL, Berg RL, Peissig PL, McCarty CA, Wilke RA, and Denny JC: Characterization of Statin Dose-response within Electronic Medical Records. Clin Pharmacol Ther. 2014 Mar;95(3):331-8. doi: 10.1038/clpt.2013.202. Epub 2013 Oct 4. PMID:24096969 PMCID:PMC3944214
51. Delaney JT, Muhammad R, Shi Y, Schildcrout JS, Blair M, Short L, **Roden DM**, Darbar D: Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. Europace 2014 Apr;16(4):485-90. doi: 10.1093/europace/eut278. Epub 2013 Sep 26. PMID:24072447 PMCID:PMC3977588
52. Weeke P, Parvez B, Blair M , Short L, Ingram C, Kucera G, Stubblefield T, Bush W, **Roden DM**, Darbar D: Candidate Gene Approach To Identifying Rare Genetic Variants Associated with Lone Atrial Fibrillation. Heart Rhythm. 2014 Jan;11(1):46-52. doi: 10.1016/j.hrthm.2013.10.025. Epub 2013 Oct 10. PMID:24120998 PMCID:PMC3947369
53. Shameer K, Denny JC, Ding K, Jouni H, Crosslin DR, de Andrade M, Chute CG, Peissig P, Pacheco JA, Li R, Bastarache L, Kho AN, Ritchie MD, Masys DR, Chisholm RL, Larson EB, McCarty CA, **Roden DM**, Jarvik GP, Kullo IJ: A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum Genet. 2014 Jan;133(1):95-109. doi: 10.1007/s00439-013-1355-7. Epub 2013 Sep 12. PMID:24026423 PMCID:PMC3880605
54. Caudle KE, Klein TE, Hoffman JM, Müller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuh K, Thorn CF, Schwab M, Agúndez JAG, Freimuth RR, Huser V, Lee MTM, Iwuchukwu OF, Crews KR, Scott SA, Wadelius M, Swen JJ, Tyndale RF, Stein CM, **Roden D**, Relling MV, Williams MC, Johnson SG: Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Curr Drug Metab Feb 2014;15(2):209–217. PMID:24479687 PMCID:PMC3977533
55. Jeff JM, Donahue BS, Brown-Gentry K, **Roden DM**, Crawford DC, Stein CM, Kurnik D: Genetic variation in the β1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. Heart J 2014 Jan;167(1):101-108.e1. doi: 10.1016/j.ahj.2013.09.016. Epub 2013 Oct 17. PMID:24332148 PMCID:PMC3868008
56. Becker JR, Chatterjee S, Robinson TY, Bennett JS, Panáková D, Galindo CL, Zhong L, Shin JT, Coy SM, Kelly AE, **Roden DM**, Lim CC, MacRae CA: Differential Activation of the Natriuretic Peptide Receptors Modulates Cardiomyocyte Proliferation During Development. Development 2014 Jan;141(2):335-45. doi: 10.1242/dev.100370. Epub 2013 Dec 18. PMID:24353062 PMCID:PMC3879815
57. Mosley JD, Van Driest SL, Larkin EK, Weeke PE, Witte JS, Wells QS, Karnes JH, Guo Y, Bastarache L, Olson LM, McCarty CA, Pacheco JA, Jarvik GP, Carrell DS, Larson EB, Crosslin DR, Kullo IJ, Tromp G, Kuivaniemi H, Carey DJ, Ritchie MD, Denny JC, **Roden DM**: Mechanistic Phenotypes: An Aggregative Phenotyping Strategy to Identify Disease Mechanisms Using GWAS Data. PLoS ONE 2014; 8(12):e81503. doi:10.1371/journal.pone.0081503. eCollection 2013. PMID:24349080 PMCID:PMC3861317
58. Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, Denny JC, **Roden DM**: Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014 Apr;95(4):423-31. doi: 10.1038/clpt.2013.229. [Epub ahead of print] PMID:24253661 PMCID:PMC3961508. Response to letter to the editor: Van Driest SL, **Roden DM**. Clin Pharmacol Ther. 2014 Jul;96(1):26. doi: 10.1038/clpt.2014.71. Epub 2014 Mar 28. PMID:24253661 PMCID:PMC3961508
59. Weeke P, Mosley JD, Hanna D, Shaffer C, Delaney JT, Wells QS, Van Driest S, Karnes JH, Ingram C, Guo Y, Shyr Y, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis ER, Nickerson D, George AL, **Roden DM**: Exome Sequencing Implicates the Burden of Rare Potassium Channel Variants in the Risk of Drug Induced Long QT Syndrome. J Am Coll Cardiol. 2014 Apr 15;63(14):1430-7. doi: 10.1016/j.jacc.2014.01.031. Epub 2014 Feb 19. PMID:24561134 PMCID:PMC4018823
60. Bowton E, Field JR, Wang S, Schildcrout JS, Van Driest SL, Delaney JT, Cowan J, Weeke P, Mosley JD, Wells QS, Karnes JH, Shaffer C, Peterson JF, Denny JC, **Roden DM**, Pulley JM: Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med 2014 Apr 30;6(234):234cm3. doi: 10.1126/scitranslmed.3008604. PMID:24786321 PMCID:PMC4226414
61. Jeff JM, Armstrong LL, Ritchie MD, Denny JC, Kho AN, Basford MA, Wolf WA, Pacheco JA, Li R, Chisholm RL, **Roden DM**, Hayes MG, Crawford DC: Admixture mapping and subsequent fine-mapping suggests a biologically relevant and novel association on chromosome 11 for type 2 diabetes in African Americans. PLoS One. 2014 Mar 3;9(3):e86931. doi: 10.1371/journal.pone.0086931. eCollection 2014. PMID:24595071 PMCID:PMC3940426
62. Weeke P, Muhammad R, Delaney JT, Shaffer C, Mosley JD, Blair M, Short L, Stubblefield T, **Roden DM**, Darbar D, National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project: Whole-exome sequencing in familial atrial fibrillation. Eur Heart J 2014 Apr 11. Epub 2014 Apr 11. PMID:24727801 PMCID:PMC4169871
63. Oetjens M, Bush WS, Birdwell KA, Dilks HH, Bowton EA, Denny JC, Wilke RA, **Roden DM**, Crawford DC. Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients. Pac Symp Biocomput 2014:253-64. PMID:24297552 PMCID:PMC3923429
64. Kolek MJ, Parvez B, Muhammad R, Shoemaker MB, Blair MA, Stubblefield T, Kucera GA, Denny JC, **Roden DM**, Darbar D. A common variant on chromosome 4q25 is associated with prolonged PR interval in subjects with and without atrial fibrillation. Am J Cardiol 2014 Jan 15;113(2):309-13. doi: 10.1016/j.amjcard.2013.08.045. Epub 2013 Oct 3. PMID:24161141 PMCID:PMC3947341
65. Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, **Roden DM**: Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 2014;130:224-34. pii: CIRCULATIONAHA. 113.007765. Epub 2014 Jun 3.PMID:24895457 PMCID:PMC4101031
66. Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, Brett C, Maeda S, Simpson MD, Hedderson MM, Davis RL, **Roden DM**, Giacomini KM, Savic RM: Genetic Variants in Transcription Factors Associate with the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacol Ther 2014 May 22. doi: 10.1038/clpt.2014.109. Epub 2014 May 22. PMID:24853734 PMCID:PMC4171106
67. Kolek MJ, Edwards TL, Muhammad R, Balouch A, Shoemaker MB, Blair MA, Kor KC, Takahashi A, Kubo M, **Roden DM**, Tanaka T, Darbar D: A Genome-Wide Association Study to Identify Genomic Modulators of Rate Control Therapy in Patients with Atrial Fibrillation. Am J Cardiol. 2014 Aug 15;114(4):593-600. doi: 10.1016/j.amjcard.2014.05.040. Epub 2014 Jun 6. PMID:25015694 PMCID:PMC4119836

1. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, **Roden DM**, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M: The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.PMID:24918167 PMCID:PMC4169720
2. Mosley JD, Van Driest SL, Weeke PE, Delaney JT, Wells QS, Bastarache L, **Roden DM**, Denny JC: Integrating EMR-Linked and In Vivo Functional Genetic Data to Identify New Genotype-Phenotype Associations. PLoS One 2014 Jun 20;9(6):e100322. doi: 10.1371/journal.pone.0100322. eCollection 2014. PMID:24949630 PMCID:PMC4065041
3. Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, Sotoodehnia N, Rossin EJ, Morley M, Wang X, Johnson AD, Lundby A, Gudbjartsson DF, Noseworthy PA, Eijgelsheim M, Bradford Y, Tarasov KV, Dörr M, Müller-Nurasyid M, Lahtinen AM, Nolte IM, Smith AV, Bis JC, Isaacs A, Newhouse SJ, Evans DS, Post WS, Waggott D, Lyytikäinen LP, Hicks AA, Eisele L, Ellinghaus D, Hayward C, Navarro P, Ulivi S, Tanaka T, Tester DJ, Chatel S, Gustafsson S, Kumari M, Morris RW, Naluai AT, Padmanabhan S, Kluttig A, Strohmer B, Panayiotou AG, Torres M, Knoflach M, Hubacek JA, Slowikowski K, Raychaudhuri S, Kumar RD, Harris TB, Launer LJ, Shuldiner AR, Alonso A, Bader JS, Ehret G, Huang H, Kao WH, Strait JB, Macfarlane PW, Brown M, Caulfield MJ, Samani NJ, Kronenberg F, Willeit J; CARe Consortium; COGENT Consortium, Smith JG, Greiser KH, Meyer Zu Schwabedissen H, Werdan K, Carella M, Zelante L, Heckbert SR, Psaty BM, Rotter JI, Kolcic I, Polašek O, Wright AF, Griffin M, Daly MJ; DCCT/EDIC, Arnar DO, Hólm H, Thorsteinsdottir U; eMERGE Consortium, Denny JC, **Roden DM**, Zuvich RL, Emilsson V, Plump AS, Larson MG, O'Donnell CJ, Yin X, Bobbo M, D'Adamo AP, Iorio A, Sinagra G, Carracedo A, Cummings SR, Nalls MA, Jula A, Kontula KK, Marjamaa A, Oikarinen L, Perola M, Porthan K, Erbel R, Hoffmann P, Jöckel KH, Kälsch H, Nöthen MM; HRGEN Consortium, den Hoed M, Loos RJ, Thelle DS, Gieger C, Meitinger T, Perz S, Peters A, Prucha H, Sinner MF, Waldenberger M, de Boer RA, Franke L, van der Vleuten PA, Beckmann BM, Martens E, Bardai A, Hofman N, Wilde AA, Behr ER, Dalageorgou C, Giudicessi JR, Medeiros-Domingo A, Barc J, Kyndt F, Probst V, Ghidoni A, Insolia R, Hamilton RM, Scherer SW, Brandimarto J, Margulies K, Moravec CE, Fabiola, Fuchsberger C, O'Connell JR, Lee WK, Watt GC, Campbell H, Wild SH, El Mokhtari NE, Frey N, Asselbergs FW, Leach IM, Navis G, van den Berg MP, van Veldhuisen DJ, Kellis M, Krijthe BP, Franco OH, Hofman A, Kors JA, Uitterlinden AG, Witteman JC, Kedenko L, Lamina C, Oostra BA, Abecasis GR, Lakatta EG, Mulas A, Orrú M, Schlessinger D, Uda M, Markus MR, Völker U, Snieder H, Spector TD, Arnlöv J, Lind L, Sundström J, Syvänen AC, Kivimaki M, Kähönen M, Mononen N, Raitakari OT, Viikari JS, Adamkova V, Kiechl S, Brion M, Nicolaides AN, Paulweber B, Haerting J, Dominiczak AF, Nyberg F, Whincup PH, Hingorani AD, Schott JJ, Bezzina CR, Ingelsson E, Ferrucci L, Gasparini P, Wilson JF, Rudan I, Franke A, Mühleisen TW, Pramstaller PP, Lehtimäki TJ, Paterson AD, Parsa A, Liu Y, van Duijn CM, Siscovick DS, Gudnason V, Jamshidi Y, Salomaa V, Felix SB, Sanna S, Ritchie MD, Stricker BH, Stefansson K, Boyer LA, Cappola TP, Olsen JV, Lage K, Schwartz PJ, Kääb S, Chakravarti A, Ackerman MJ, Pfeufer A, de Bakker PI, Newton-Cheh C: Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet. 2014 Aug;46(8):826-36. doi: 10.1038/ng.3014. Epub 2014 Jun 22. PMID:24952745 PMCID:PMC4124521
4. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ, Brautbar A, Brilliant M, Carrell DS, Connolly J, Crosslin DR, Doheny KF, Gallego CJ, Gottesman O, Kim DS, Leppig KA, Li R, Lin S, Manzi S, Mejia AR, Pacheco JA, Pan V, Pathak J, Perry CL, Peterson JF, Prows CA, Ralston J, Rasmussen LV, Ritchie MD, Sadhasivam S, Scott SA, Smith M, Vega A, Vinks AA, Volpi S, Wolf WA, Bottinger E, Chisholm RL, Chute CG, Haines JL, Harley JB, Keating B, Holm IA, Kullo IJ, Jarvik GP, Larson EB, Manolio T, McCarty CA, Nickerson DA, Scherer SE, Williams MS, **Roden DM**, Denny JC: Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multi-Center Pilot for Pre-Emptive Pharmacogenomics in Electronic Health Record Systems. Clin Pharmacol Ther. 2014 Oct;96(4):482-9. doi: 10.1038/clpt.2014.137. Epub 2014 Jun 24. PMID:24960519 PMCID:PMC4169732
5. Heatherly R, Denny JC, Haines JL, **Roden DM**, Malin BA: Size matters: How population size influences genotype-phenotype association studies in anonymized data. J Biomed Inform. 2014 Dec;52:243-50. doi: 10.1016/j.jbi.2014.07.005. Epub 2014 Jul 16. PMID:25038554 PMCID:PMC4260994
6. Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, Levy M, Shah A, Han X, Ruan X, Jiang M, Li Y, Julien JS, Warner J, Friedman C, **Roden DM**, Denny JC: Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015 Jan;22(1):179-91. doi: 10.1136/amiajnl-2014-002649. Epub 2014 Jul 22. PMID:25053577 PMCID:PMC4433365
7. Savio-Galimberti E, Weeke P, Muhammad R, Blair M, Ansari S, Short L, Atack TC, Kor K, Vanoye CG, Olesen MS; LuCamp, Yang T, George AL Jr, **Roden DM**, Darbar D: SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. Cardiovasc Res. 2014 Nov 1;104(2):355-63. doi: 10.1093/cvr/cvu170. Epub 2014 Jul 22. PMID:25053638 PMCID:PMC4271018
8. Naidoo D, Wu AC, Brilliant MH, Denny H, Ingram C, Kitchner TE, Linneman JG, McGeachie MJ, **Roden DM**, Shaffer CM, Shah A, Weeke P, Weiss SC, Xu H, Medina MW: A polymorphism in HLA-G modifies statin benefit in asthma. Pharmacogenomics J. 2015 Jun;15(3):272-7. doi: 10.1038/tpj.2014.55. Epub 2014 Sep 30. PMID:25266681 PMCID:PMC4379135
9. Iwuchukwu OF, Feng Q, Wei W, Jiang L, Jiang M, Xu H, Denny JC, Wilke RA, Krauss RM, **Roden DM**, Stein CM: Genetic Variation in the UGT1A Locus is Associated with Simvastatin Efficacy in a Clinical Practice Setting. Pharmacogenomics. 2014 Nov;15(14):1739-1747. PMID:25493567 PMCID:PMC4292894
10. Malinowski JR, Denny JC, Bielinski SJ, Basford MA, Bradford Y, Peissig PL, Carrell D, Crosslin DR, Pathak J. Rasmussen L, Pacheco J, KhoA, Newton KM, Li R, Kullo IJ, Chute CG, Chisholm RL, Jarvik GP, Larson EB, McCarty CA, Masys DR, **Roden DM**, de Andrade M, Ritchie MD, Dana C Crawford: Genetic variants associated with serum thyroid stimulating hormone (TSH) levels in European Americans and African Americans from the eMERGE Network. PLoS One. 2014 Dec 1;9(12):e111301. doi: 10.1371/journal.pone.0111301. eCollection 2014. PMID:25436638 PMCID:PMC4249871
11. Williams V, Cresswell CJ, Ruspi G, Yang T, Atack TC, McLoughlin M, Ingram C, Ramirez AH, **Roden DM**, Armstrong M: MLPA copy number variant analysis in patients with acquired long QT syndrome. Europace. 2015 Apr;17(4):635-41. doi: 10.1093/europace/euu288. Epub 2015 Jan 6. PMID:25564553
12. Weeke P, Denny JC, Bastarache L, Shaffer C, Bowton E, Ingram C, Darbar D, **Roden DM**: Examining rare and Low-Frequency Genetic Variants Previously Associated with Lone or Familial Forms of Atrial Fibrillation in an Electronic Medical Record System: A Cautionary Note. Circ Cardiovasc Genet. 2015 Feb;8(1):58-63. doi: 10.1161/CIRCGENETICS.114.000718. Epub 2014 Nov 19. PMID:25410959 PMID:PMC4334677
13. Vijayakumar R, Silva JNA, Desouza KA, Abraham RL, Strom M, Sacher F, Van Hare GF, Haissaguerre H, **Roden DM**, Rudy Y: Electrophysiologic Substrate in Congenital Long QT Syndrome: Noninvasive Mapping with Electrocardiographic Imaging (ECGI). Circulation. 2014 Nov 25;130(22):1936-43. doi: 10.1161/CIRCULATIONAHA.114.011359. Epub 2014 Oct 7. PMID:25294783 PMCID:PMC4245321
14. Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, König I, Asselta R, Merlini P, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh K, Meitinger T, Kessler T, Koch W, Kastrati A, Siscovick D, Rotter JI, Hazen S, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne D, O’Donnell CJ, Abecasis G, Sunyaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Ye Z, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, **Roden DM**, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S: Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014 Nov 27;371(22):2072-82. doi: 10.1056/NEJMoa1405386. Epub 2014 Nov 12. PMID:25390462 PMCID:PMC4335708
15. Kawai VK, Cunningham A, Vear SI, Van Driest SL, Oginni A, Xu H, Jiang M, Li C, Denny JC, Shaffer C, Bowton E, Gage BF, Ray WA, **Roden DM**, Stein CM. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014 Dec;15(16):1973-83. doi: 10.2217/pgs.14.153. PMID:25521356 PMCID:PMC4304738
16. Cronin RM, Field JR, Bradford Y, Shaffer CM, Carroll RM, Mosley JD, Bastarache L, Edwards TL, Hebbring SJ, Lin S, Hindorff LA, Crane PK, Pendergrass SA, Ritchie MD, Crawford DC, Pathak J, Bielinski SJ,. Carrell DS, Crosslin DR, Ledbetter DH, Carey DJ, Tromp G, Williams1 MS, Larson EB, Jarvik GP, Peissig PL, Brilliant MH, McCarty CA, Chute CG, Kullo IJ, Bottinger E, Chisholm R, Smith ME, **Roden DM**, Denny JC: Phenome-wide association studies demonstrating pleiotropy of genetic variants within FTO with and without adjustment for body mass index. Front Genet. 2014 Aug 5;5:250. <http://dx.doi.org/10.3389/fgene.2014.00250>. eCollection 2014. PMID:25177340 PMCID:PMC4134007
17. Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Schaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bajchoul T, Denny JC, Greinacher A, Gruel Y, **Roden DM**: A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb Haemost. 2015 Apr;113(4):772-81. doi: 10.1160/TH14-08-0670. Epub 2014 Dec 11. PMID:25503805 PMCID:PMC4433536
18. Kolek MJ, Muehlschlegel JD, Bush WS, Parvez B, Murray KT, Stein CM, Shoemaker MB, Blair MA, Kor KC, **Roden DM**, Donahue BS, Fox AA, Shernan SK, Collard CD, Body SC, Darbar D: Genetic and Clinical Risk Prediction Model for Postoperative Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2015 Feb;8(1):25-31. doi: 10.1161/CIRCEP.114.002300. Epub 2015 Jan 7. PMID:25567478 PMCID:PMC4334678
19. Jeff JM, Brown-Gentry K, Goodloe R, Ritchie MD, Denny JC, Kho AN, Armstrong LL, McClellan B Jr, Mayo P, Allen M, Jin H, Gillani NB, Schnetz-Boutaud N, Dilks HH, Basford MA, Pacheco JA, Jarvik GP, Chisholm RL, **Roden DM**, Hayes MG, Crawford DC: Replication of SCN5A Associations with Electrocardio-graphic Traits in African Americans from Clinical and Epidemiologic Studies. Evol Comput Mach Learn Data Min Bioinform. 2014;2014:939-951. PMID:25590050 PMCID:PMC4290789
20. Shoemaker MB, Bollmann A, Lubitz SA, Ueberham L; Saini H, Montgomery J, Edwards T, Yoneda Z, Sinner MF, Arya A, Sommer P, Delaney J, Goyal SK, Saavedra P, Kanagasundram A, Whalen SP, **Roden DM**, Hindricks G, Ellis CR, Ellinor PT, Darbar D, Husser D: Common Genetic Variants and Response to Atrial Fibrillation Ablation. Circ Arrhythm Electrophysiol. 2015 Apr;8(2):296-302. doi: 10.1161/CIRCEP.114.001909. Epub 2015 Feb 14. PMID:25684755 PMCID:PMC4731871
21. Barrett TW, Storrow AB, Jenkins CA, Abraham RL, Liu D, Miller KF, Moser KM, Russ S, **Roden DM**, Harrell, Jr FE, Darbar D: The AFFORD Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events. Am J Cardiol. 2015 Mar 15;115(6):763-70. doi: 10.1016/j.amjcard.2014.12.036. Epub 2015 Jan 6. PMID:25633190 PMCID:PMC4346475
22. Kolder ICRM, Tanck MWT, Postema PG, Barc J, Sinner MF, Zumhagen S, Husemann A, Stallmeyer B, Koopmann TT, Hofman N, Pfeufer A, Lichtner P, Meitinger T, Beckmann BM, Myerburg RJ, Bishopric NH, **Roden DM**, Kääb S, Wilde AMM, Schott JJ, Schulze-Bahr E, Bezzina CR: Analysis for genetic modifiers of disease severity in patients with Long QT Syndrome Type 2 Circ Cardiovasc Genet. 2015 Jun;8(3):447-56. doi: 10.1161/CIRCGENETICS.114.000785. Epub 2015 Mar 3. PMID:25737393 PMCID:PMC4770255
23. Wei WQ, Feng Q, Weeke P, Bush W, Waitara MS, Iwuchukwu OF, **Roden DM**, Wilke RA, Stein CM, Denny JC: Creation and Validation of an EMR-based Algorithm for Identifying Major Adverse Cardiac Events while on Statins. AMIA Jt Summits Transl Sci Proc. 2014 Apr 7;2014:112-9. eCollection 2014. PMID:25717410 PMCID:PMC4333709
24. Behr ER, Savio-Galimberti E, Barc J, Holst AG, Petropoulou E, Prins BP, Jabbari J, Torchio M, Berthet M, Mizusawa Y, Yang T, Nannenberg EA, Dagradi F, Weeke P, Bastiaenan R, Ackerman MJ, Haunso S, Leenhardt A, Kääb S, Probst V, Redon R, Sharma S, Wilde A, Tfelt-Hansen J, Schwartz P, **Roden DM**, Bezzina CR, Olesen M, Darbar D, Guicheney P, Crotti L, UK10K Consortium, Jamshidi Y: Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovasc Res. 2015 Jun 1;106(3):520-9. doi: 10.1093/cvr/cvv042. Epub 2015 Feb 17. PMID:25691538 PMCID:PMC4447806
25. McGeachie MJ, Wu AC, Tse SM, Clemmer GL, Sordillo J, Himes BE, Lasky-Su J, Martinez FD, Weeke P, Shaffer CM, Denny JC, **Roden DM**, Raby BA, Weiss ST, Tantisira KG: CTNNA3 and SEMA3D: promising loci for asthma exacerbation identified through multiple GWAS. J Allergy Clin Immunol. 2015 Dec;136(6):1503-10. doi: 10.1016/j.jaci.2015.04.039. Epub 2015 Jun 12. PMID:26073756 PMCID:PMC4676949
26. Sun J, Zhao M, Jia P, Wang L, Wu Y, Iverson C, Zhou Y, Bowton E, **Roden DM**, Denny JC, Aldrich MC, Xu H, Zhao Z: Deciphering Signaling Pathway Networks to Understand Molecular Mechanism of Metformin Action. PLoS Comput Biol. 2015 Jun 17;11(6):e1004202. doi: 10.1371/journal.pcbi.1004202. eCollection 2015. PMID:26083494 PMCID:PMC4470683
27. Sanders ML, Karnes JH, Denny JC, Crawford DC, **Roden DM**, Ikizler TA, Birdwell KA: Clinical and Genetic Predictors of Cutaneous Squamous Cell Carcinoma in Kidney and Heart Transplant Recipients. Transplant Direct. 2015 May;1(4). doi: 10.1097/TXD.0000000000000521. PMID:26146661 PMCID:PMC4486315
28. Bowton EA, Collier SP, Wang X, Sutcliffe CB, Couch LJ, Herrera M, Van Driest SL, Jerome RN, Slebos RJC, Alborn WE, Liebler D, McNaughton CD, Mernaugh RL, Wells QS, Brown NJ, **Roden DM**, Pulley JM: Phenotype-driven plasma biobanking strategies and methods. J Pers Med. 2015 May 14;5(2):140-52. doi: 10.3390/jpm5020140. PMID:26110578 PMCID:PMC4493492
29. Van Driest SL, McGregor TL, Velez-Edwards DR, Lu Z, Saville BR, Kitchner TE, Hebbring SJ, Brilliant M, Jouni H, Kullo IJ, Creech CB, Kannankeril PJ, Vear SI, Brothers KB, Bowton EA, Patel N, Delaney JT, Bradford Y, Wilson S, Olson L, Crawford DC, Ho R, Potts AL, **Roden DM**, Denny JC: Genome Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy. PLoS One. 2015 Jun 1;10(6):e0127791. doi: 10.1371/journal.pone.0127791. eCollection 2015. PMID:26030142 PMCID:PMC4452656
30. Dahlin A, Denny J, **Roden DM**, Brilliant MH, Ingram C, Kitchner TE, Linneman JG, Shaffer CM, Shah A, Weeke P, Xu H, Kubo M, Tamari M, Nakamura Y, Tantisira K, Weiss ST, Wu AC: CMTR1 is Associated With Increased Asthma Exacerbations in Patients Taking Inhaled Corticosteroids. Immun Inflamm Dis. 2015 Jul 14;3(4):350-9. doi: 10.1002/iid3.73. eCollection 2015. PMID:26734457 PMCID:PMC4693729
31. Mosley JD, Shaffer CM, Van Driest SL, Weeke PE, Wells QS, Karnes JH, Velez Edwards DR, Wei WQ, Teixeira PI, Bastarache L, Crawford DC, Li R, Manolio TA, Bottinger EP, McCarty CA, Linneman J, Brilliant MH, Pacheco JA, Thompson W, Chisholm RL, Jarvik GP, Crosslin DR, Carrell DS, Baldwin E, Ralston J, Larson EB, Grafton J, Scrol A, Jouni H, Kullo IJ, Tromp G, Borthwick KM, Kuivaniemi H, Carey DJ, Ritchie MD, Chute CG, Veluchamy A, Siddiqui MK, Palmer CAN, Morris AD, Doney A, MahmoudPour SH, Maitland-van der Zee AH, Denny JC, **Roden DM**: A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. Pharmacogenomics J. 2016 Jun;16(3):231-7. doi: 10.1038/tpj.2015.51. Epub 2015 Jul 14. PMID:26169577 PMCID:PMC4713364
32. Hoh BL, Gong Y, Waters MF, Royster AJ, Sheehan TO, Burkley B, LangaeeTY, McDonough CW, Mocco J, Zuckerman SL, Mummareddy N, Stephens III ML, Ingram C, Shaffer CM, Denny JC, Brilliant MH, Kitchner TE, Linneman JG, **Roden DM**, Johnson JA: CYP2C19 and CES1 Polymorphisms and Efficacy of Clopidogrel and Aspirin Dual Antiplatelet Therapy in Patients with Symptomatic Intracranial Atherosclerotic Disease. J Neurosurg. 2016 Jun;124(6):1746-51. doi: 10.3171/2015.6.JNS15795. Epub 2015 Nov 20. PMID:26587656 PMCID:PMC4915569
33. Peterson J, Field J, Shi Y, Schildcrout J, Denny J, McGregor T, Van Driest S, Pulley J, Lubin I, Laposata M, **Roden D**, Clayton E: Attitudes of Clinicians Following Large-Scale Pharmacogenomics Implementation. Pharmacogenomics J. Aug;16(4):393-8. doi: 10.1038/tpj.2015.57. Epub 2015 Aug 11. PMID:26261062 PMCID:PMC4751074
34. Gallego CJ, Burt A, Sundaresan AS, Ye Z, Shaw C, Crosslin DR, Crane PK, Fullerton SM, Hansen K, Carrell D, Kuivaniemi H, Derr K, de Andrade M, McCarty CA, Kitchner TE, Ragon BK, Stallings SC, Papa G, Bochenek J, Smith ME, Aufox SA, Pacheco JA, Patel V, Friesema EM, Erwin AL, Gottesman O, Gerhard GS, Ritchie M, Motulsky AG, Kullo IJ, Larson EB, Tromp G, Brilliant MH, Bottinger E, Denny JC, **Roden DM**, Williams MS, Jarvik GP: Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.Cys282Tyr/p.His63Asps in the eMERGE Network. Am J Hum Genet. 2015 Oct 1;97(4):512-20. doi: 10.1016/j.ajhg.2015.08.008. Epub 2015 Sep 10. PMID:26365338 PMCID: PMC4596892
35. Herr TM, Bielinski SJ, Bottinger E, Brautbar A, Brilliant M, Chute CG, Denny J, Freimuth RR, Hartzler A, Kannry J, Kohane IS, Kullo IJ, Lin S, Pathak J, Peissig P, Pulley J, Ralston J, Rasmussen L, **Roden D**, Tromp G, Williams MS, Starren J: A conceptual model for translating omic data into clinical action. J Pathol Inform. 2015 Aug 31;6:46. doi: 10.4103/2153-3539.163985. eCollection 2015. PMID:26430534 PMCID:PMC4584438
36. Schildcrout J, Shi Y, Danciu I, Bowton E, Field JR, Pulley JM, Basford M, Gregg W, Cowan J, Harrell FE, **Roden DM,** Peterson JF, Denny JC: A prognostic model based on readily available clinical data enriched a preemptive pharmacogenetic testing program. J Clin Epidemiol. 2016 Apr;72:107-15. doi: 10.1016/j.jclinepi.2015.08.028. Epub 2015 Nov 25. PMID:26628336 PMCID:PMC4779720
37. Friedman EA, Texeira L, Delaney J, Weeke PE, Lynch Jr. DR, Kasasbeh E, Song Y, Harrell Jr. FE, Denny JC, Hamm HE, **Roden DM**, Cleator JH: Evaluation of the F2R IVS-14A/T PAR1 Polymorphism with Subsequent Cardiovascular Events and Bleeding in Patients who have undergone Percutaneous Coronary Intervention. J Thromb Thrombolysis. 2016 May;41(4):656-62. doi: 10.1007/s11239-015-1285-4. PMID:26446588
38. Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, Basford M, Bastarache L, **Roden DM** , Denny JC, Larsen E, Winick N, Carroll WL, Cheng C, Pei D, Fernandez CA, Liu C, Smith C, Loh ML, Raetz MA, Hunger SP, Scheet P, Jeha S, Pui CH, Evans WE, Devidas M, Mattano Jr LA, and Relling MV: Genetics of Glucocorticoid-Associated Osteonecrosis in Children with Acute Lymphoblastic Leukemia. Blood. 2015 Oct 8;126(15):1770-6. doi: 10.1182/blood-2015-05-643601. Epub 2015 Aug 11. PMID:26265699 PMCID:PMC4600016
39. Mo H, Thompson WK, Rasmussen LV, Pacheco JA, Jiang G, Kiefer R, Zhu Q, Xu J, Montague E, Carrell DS, Lingren T, Mentch FD, Ni Y, Wehbe FH, Peissig PL, Tromp G, Larson EB, Chute CG, Pathak J, Denny JC, Speltz P, Kho AN, Jarvik GP, Bejan CA, Williams MS, Borthwick K, Kitchner TE, **Roden DM**, Harris PA: Desiderata for computable representations of electronic health records-driven phenotype algorithms. J Am Med Inform Assoc. 2015 Nov;22(6):1220-30. doi 10.1093/jamia/ocv112. Epub 2015 Sep 5. PMID:26342218 PMCID: PMC4639716
40. Herr TM, Bielinski SJ, Bottinger E, Brautbar A, Brilliant M, Chute CG, Cobb BL, Denny JC, Hakonarson H, Hartzler AL, Hripcsak G, Kannry K, Kohane IS, Kullo IJ, Lin S, Manzi S, Marsolo K, Overby CL, Pathak J, Peissig P, Pulley J, Ralston J, Rasmussen L, **Roden DM**, Tromp G, Uphoff T, Weng C, Wolf W, Williams MS, Starren J: Practical considerations in genomic decision support: The eMERGE experience. J Pathol Inform. 2015 Sep 28;6:50. doi: 10.4103/2153-3539.165999. eCollection 2015. PMID:26605115 PMCID:PMC4629307
41. Stitziel NO, Stirrups KE, Masca NGD, Erdmann J, Ferrario PG, König IR, Weeke PE, Webb TR, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kanoni S, Kruppa Mahajan JKA, Scott RA, Willenborg C, Braund PS, van Capelleveen JC, Doney ASF, Donnelly LA, Asselta R, Merlini P, Duga S, Marziliano N, Denny JC, Shaffer C, El-Mokhtari NE, Franke A, Gottesman O, Heilmann S, Hengstenberg C, Hoffmann P, Holmen OL, Hveem K, Jansson JH, Jöckel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, McCarthy MI, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Müller-Nurasyid M, Nikpay M, Olivieri O, Perreault LPL, Qarawi A, Robertson NR, Akinsansya KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson R, Stahl E, Strauch K, Varga TV, Waldenberger M, Wellcome Trust Case Control Consortium, Zeng L, Kraja AT, Liu C, Ehret GB, Newton-Cheh C, Chasman DI, Chowdhury R, Ferrario M, Ford I, Jukema JW, Kee F, Kuulasmaa K, MORGAM Investigators, Nordestgaard BG, Perola M, Saleheen D, Sattar N, Surendran P, Tregouet D, Young R, Howson JMM, Butterworth AS, Danesh J, Ardissino D, Bottinger EP, Erbel R, Franks PW, Girelli D, Hall AS, Hovingh GK, Kastrati A, Lieb W, Meitinger T, Kraus WE, Shah SH, McPherson R, Orho-Melander M, Melander O, Metspalu A, Palmer CNA, Peters A, Rader DJ, Reilly MP, Loos RJF, Reiner AP, **Roden DM**, Tardif JC, Thompson JR, Wareham NJ, Watkins H,Wiler CJ, Kathiresan S, Deloukas P, Samani NJ, Schunkert H: Coding variation in ANGPTL4, LPL, and SVEP1 and risk of coronary disease. N Engl J Med. 2016 Mar 24;374(12):1134-44. doi: 10.1056/NEJMoa1507652. Epub 2016 Mar 2. PMID:26934567 PMCID:PMC4850838
42. Van Driest SL, Wells QS, Stallings S, Bush WS, Gordon A, Nickerson D, Kim JH, Crosslin DR, Jarvik GP, Carrell DS, Ralston J, Larson EB, Bielinski SJ, Olson JE, Ye Z, Kullo IJ, Abul-Husn NS, Scott SA, Bottinger E, Castillo BA, Connolly J, Chiavacci R, Hakonarson H, Rasmussen-Torvik LJ, Pan V, Persell S, Smith M, Chisholm R, Kitchner T, He M, Brilliant M, Wallace JR, Doheny KF, Shoemaker MB, Li R, Manolio TA, Callis TE, Macaya D, Williams M, Carey D, Kapplinger JD, Ackerman MJ, Ritchie MD, Denny JC, **Roden DM**: Association Of Arrhythmia Related Genetic Variants With Phenotypes Documented in Electronic Health Records. JAMA. 2016;315(1):47-57. PMID:26746457 PMCID:PMC4758131 (Letter to the editor reply: Van Driest SL, Wells QS, Roden DM: Long QT Syndrome and Potentially Pathogenic Genetic Variants--In Reply. JAMA. 2016 Jun 14;315(22):2467-8. doi: 10.1001/jama.2016.2921. PMID: 27299624)
43. Peterson JF , Field JR, Unertl K, Schildcrout JS, Johnson DC, Shi Y, Danciu I, Cleator JH, Pulley JM, McPherson JA, Denny JC, Laposata M, **Roden DM**, Johnson KM: Response to Implementation of Genotype-Tailored Antiplatelet Therapy. Clin Pharmacol Ther. 2016 Jul;100(1):67-74. doi: 10.1002/cpt.331. Epub 2016 Feb 17. PMID:26693963 PMCID:PMC4899238
44. Bush WS, Crosslin DR, Obeng AO, Wallace J, Almoguera B, Basford MA, Bielinski SJ, Carrell DS, Connolly JJ, Crawford D, Doheny KF, Gallego CJ, Gordon AS, Keating B, Kirby J, Kitchner T, Manzi S, Mejia AR, Pan V, Perry CL, Peterson JF, Prows CA, Ralston J, Scott SA, Scrol A, Smith M, Stallings SC, Veldhuizen T, Wolf W, Volpi S, Wiley K, Li R, Manolio T, Bottinger E, Brilliant MH, Carey D, Chisholm RL, Chute CG, Haines JL, Hakonarson H, Harley JB, Holm IA, Kullo IJ, Jarvik GP, Larson EB, McCarty CA, Williams MS, Denny JC, Rasmussen-Torvik LJ, **Roden DM**, Ritchie MD: Genetic Variation among 82 Pharmacogenes: the PGRN-Seq data from the eMERGE Network. Clin Pharmacol Ther. Clin Pharmacol Ther. 2016 Aug;100(2):160-9. doi: 10.1002/cpt.350. Epub 2016 Jun 1. PMID:26857349 PMCID:PMC5010878
45. Simonti CN, Vernot B, Bastarache L, Bottinger E, Carrell DS, Chisholm RL, Crosslin DR, Hebbring SJ, Jarvik GP, Kullo IJ, Li R, Pathak J, Ritchie MD, **Roden DM**, Verma SS, Tromp G, Prato JD, Bush WS, Akey JM, Denny JC, Capra JA: The phenotypic legacy of admixture between modern humans and Neandertals. Science. 2016 Feb 12;351(6274):737-41. doi: 10.1126/science.aad2149. PMID:26912863 PMCID:PMC4849557
46. Mosley JD, Witte JS, Larkin EK, Bastarache L, Shaffer CM, Karnes JH, Stein CM, Phillips E, Hebbring SJ, Brilliant MH, Mayer J, Ye Z, **Roden DM**, Denny JC: Identifying genetically-driven clinical phenotypes using linear mixed models. Nat Commun. 2016 Apr 25;7:11433. doi: 10.1038/ncomms11433. PMID:27109359 PMCID:PMC4848547
47. Kirby JC, Speltz P, Rasmussen LV, Basford M, Gottesman O, Peissig PL, Pacheco JA, Tromp G, Pathak J, Carrell DS, Ellis SB, Lingren T, Thompson WK, Savova G, Haines J, **Roden DM**, Harris PA, Denny JC: PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc. 2016 Mar 28. pii: ocv202. doi: 10.1093/jamia/ocv202. [Epub ahead of print] PMID:27026615 PMCID:PMC5070514
48. Joshi AD, Andersson C, Buch S, Stender S, Noordam R, Weng LC, Weeke PE, Auer PL, Boehm B, Chen C, Choi H, Curhan G, Denny JC, De Vivo I, Eicher JD, Ellinghaus D, Folsom AR, Fuchs C, Gala M, Haessler J, Hofman A, Hu F, Hunter DJ, Janssen HL, Kang JH, Kooperberg C, Kraft P, Kratzer W, Lieb W, Lutsey PL, Murad SD, Nordestgaard BG, Pasquale LR, Reiner AP, Ridker PM, Rimm E, Rose LM, Shaffer CM, Schafmayer C, Tamimi RM, Uitterlinden AG, Völker U, Völzke H, Wakabayashi Y, Wiggs JL, Zhu J, **Roden DM**, Stricker BH, Tang W, Teumer A, Hampe J, Tybjærg-Hansen A, Chasman DI, Chan AT, Johnson AD: Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-wide Association Studies. Gastroenterology. 2016 Aug;151(2):351-363.e28. doi: 10.1053/j.gastro.2016.04.007. Epub 2016 Apr 16. PMID:27094239 PMCID:PMC4959966
49. Bersell K, Montgomery JA, Kanagasundram AN, Campbell C, Chung WK, Macaya D, Konecki D, Venter E, Shoemaker MB, **Roden DM**: Partial duplication and poly(A) insertion in KCNQ1 not detected by next-generation sequencing in Jervell and Lange-Nielsen Syndrome. Circ Arrhythm Electrophysiol. 2016 Jun;9(6). pii: e004081. doi: 10.1161/CIRCEP.116.004081. PMID:27286732 PMCID:PMC4905601
50. Teixeira PL, Wei WQ, Cronin RM, Mo H, VanHouten JP, Carroll RJ, LaRose E, Bastarache LA, Rosenbloom ST, Edwards TL, Roden DM, Lasko TA, Dart RA, Nikolai AM, Peissig PL, Denny JC: Evaluating electronic health record data sources and algorithmic approaches to identify hypertensive individuals. J Am Med Inform Assoc. 2016 Aug 7. pii: ocw071. doi: 10.1093/jamia/ocw071. [Epub ahead of print] PMID:27497800 PMCID:PMC5201185
51. Daneshjou R, Cavallari LH, Weeke PE, Karczewski KJ, Drozda K, Perera MA, Johnson JA, Klein TE, Bustamante CD, **Roden DM**, Shaffer C, Denny JC, Zehnder JL, Altman RB: Population-specific single nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. Molecular Genetics & Genomic Medicine Mol Genet Genomic Med. 2016 Jun 21;4(5):513-20. doi: 10.1002/mgg3.226. PMID:27652279 PMCID:PMC5023936
52. Yagihara N, Watanabe H, Barnett P, Duboscq-Bidot L, Atack TC, Yang P, Ohno S, Hasegawa K, Kuwano R, Chatel S, Redon R, Schott JJ, Probst V, Koopmann TT, Bezzina CR, Wilde AAM, Nakano Y, Aiba T, Miyamoto Y, Kamakura S, Darbar D, Donahue BS, Shigemizu D, Tanaka T, Tsunoda T, Suda M, Sato A, Minamino T, Endo N, Shimizu W, Horie M, **Roden DM**, Makita N: Variants in the SCN5A promoter associated with various arrhythmia phenotypes. J Am Heart Assoc. 2016 Sep 13;5(9). pii: e003644. doi: 10.1161/JAHA.116.003644. PMID:22370247 PMCID:PMC3375373
53. Wrobel E, Rothenberg I, Krisp C, Hundt F, Fränzel B, Eckey K, Linders J, Gallacher D, Towart R, Pott L, Pusch M, Yang T, **Roden DM**, Kurata HT, Schulze-Bahr E, Strutz-Seebohm N, Wolters D, Seebohm G: KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting. Nature Communications 2016 Oct 12;7:12795. doi: 10.1038/ncomms12795. PMID:27731317 PMCID:PMC5064022
54. Stroud DM, Yang T, Bersell K, Kryshtal DO, Nagao S, Shaffer C, Short L, Hall L, Atack TA, Zhang W, Knollmann BC, Baudenbacher F, **Roden DM**: Contrasting Nav1.8 activity in Scn10a-/- ventricular myocytes and the intact heart. Journal of the American Heart Association J Am Heart Assoc. 2016 Nov 2;5(11). pii: e002946. PMID:27806966 PMCID:PMC5210363
55. Lubitz S, Yin X, Lin HJ, Kolek M, Smith JG, Trompet S, Rienstra M, Rost N, Teixeira P, Almgren P, Anderson C, Chen L, EngströmG, Ford I, Furie K, Guo X, Larson M, Lunetta K, MacFarlane P, Psaty B, Soliman E, Sotoodehnia N, Stott D, Taylor K, Weng LC, Yao J, Geelhoed B, Verweij N, Siland J, Kathiresan S, Roselli C, **Roden D**, van der Harst P, Darbar D, Jukema JW, Melander O, Rosand J, Rotter J, Ellinor P, Heckbert S, Alonso A, Benjamin E: Genetic Risk Prediction of Atrial Fibrillation. Circulation Circulation. 2016 Oct 28. pii: CIRCULATIONAHA.116.024143. [Epub ahead of print] PMID:27793994 PMCID:PMC5380586
56. Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, Kubo M, Maeda S, Davis RL, **Roden DM**, Hedderson MM, Giacomini KM, Savic RM: A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin. Clin Pharmacol Ther. 2016 Nov;100(5):537-547. doi: 10.1002/cpt.428. PMID:27415606 PMCID:PMC5534241
57. Heit JA, Armasu SM, McCauley BM, Kullo IJ, Sicotte H, Pathak J, Chute CG, Gottesman O, Bottinger EP, Denny JC, **Roden DM**, Li R, Ritchie MD, de Andrade M: Identification of Unique Venous Thromboembolism-Susceptibility Variants in African-Americans. Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0652. [Epub ahead of print] PMID:28203683 PMCID:PMC5831339
58. Iwuchukwua OF, Ramirez AH, Shi Y, Bowton EA, Kawai VK, Schildcrout JS, **Roden DM**, Denny JC, Stein CM: Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics. 2016 Nov;26(11):510-516. PMID:27632229 PMCID:PMC5300764
59. Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, Hartwig FP, Horta BL, Hyppönen E, Power C, Moldovan M, van Iperen E, Hovingh GK, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Liu T, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott R, Luan J, Bobak M, Malyutina S, Pająk A, Kubinova R, Tamosiunas A, Pikhart H, Husemoen LL, Grarup N, Pedersen O, Hansen T, Linneberg A, Simonsen KS, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Kirchner HL, Larson EB, Crosslin DR, de Andrade M, **Roden DM**, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Donnell MO, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H; LifeLines Cohort study group., Christen T, Mook-Kanamori DO, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Smith DJ, Meade T, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Balkau B, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Ridker PM, Chasman DI, Reiner AP, Lange LA, Ritchie MD, Asselbergs FW, Casas JP, Keating BJ, Preiss D, Hingorani AD; UCLEB consortium., Sattar N: PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2016 Nov 28. pii: S2213-8587(16)30396-5. doi: 10.1016/S2213-8587(16)30396-5. [Epub ahead of print] PMID:27908689 PMCID:PMC5266795
60. Wiley LK, Vanhouten JP, Samuels DC, Aldrich MC, **Roden DM**, Peterson JF, Denny JC: Strategies for equitable pharmacogenomic-guided warfarin dosing among European and African American individuals in a clinical population. Pac Symp Biocomput. 2016;22:545-556. PMID:27897005 PMCID:PMC5389380
61. Kolek MJ, Graves AJ, Xu M, Bian A, Teixeira PL, Shoemaker MB, Parvez B, Xu H, Heckbert SR, Ellinor PT, Benjamin EJ, Alonso A, Denny JC, Moons KG, Shintani AK, Harrell FE Jr, **Roden DM**, Darbar D: Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. JAMA Cardiol. 2016 Oct 12. doi: 10.1001/jamacardio.2016.3366. [Epub ahead of print] PMID:27732699 PMCID:PMC5293184
62. Husser D, Ueberham L, Dinov B, Kosiuk J, Kornej J, Hindricks G, Shoemaker MB, **Roden DM**, Bollmann A, Büttner P: Genomic contributors to atrial electroanatomical remodeling and atrial fibrillation progression: Pathway enrichment analysis of GWAS data. Sci Rep. 2016 Nov 18;6:36630. doi: 10.1038/srep36630. PMID:27857207 PMCID:PMC5114680
63. Shekhar A, Lin X, Liu F-Y, Zhang J, Mo H, Bastarache L, Denny JC, Cox NJ, Delmar M, **Roden DM**, Fishman GI, Park DS: ETV1 is essential for rapid conduction in the heart. J Clin Invest. 2016 Dec 1;126(12):4444-4459. doi: 10.1172/JCI87968. PMID:27775552 PMCID:PMC5127680
64. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker J, Slosky DA, Phillips EA, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, **Roden DM**, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz Jr LA, Anders RA, Sosman JA, Moslehi JJ: Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 Nov 3;375(18):1749-1755. PMID:27806233 PMCID:PMC5247797
65. Mosley JD, Van Driest SL, Wells QS, Shaffer CM, Edwards TL, Bastarache L, McCarty CA, Thompson W, Chute CG, Jarvik GP, Crosslin DR, Larson EB, Kullo IJ, Pacheco JA, Peissig PL, Brilliant MH, Linneman JG, Denny JC, **Roden DM**: Defining a contemporary ischemic heart disease genetic risk profile using historical data. Circulation Cardiovascular Genetics 2016 Oct 25. pii: CIRCGENETICS.116.001530. [Epub ahead of print] PMID:27780847 PMCID:PMC5177499
66. Yang Z, Chopra N, Knollmann BC, George Jr AL, Campbell C, Pickett RA, **Roden DM**, Murray KT: Azithromycin Causes a Novel Proarrhythmic Syndrome. Circ Arrhythm Electrophysiol. 2017 Apr;10(4). pii: e003560. doi: 10.1161/CIRCEP.115.003560. PMID:28408648 PMCID:PMC5396181
67. Dumitrescu L, Ritchie MD, Denny JC, El Rouby NM, McDonough CW, Bradford Y, Ramirez AH, Bielinski SJ, Basford MA, Chai HS, Peissig P, Carrell D, Pathak J, Rasmussen LV, Wang X, Pacheco JA, Kho AN, Hayes MG, Matsumoto M, Smith ME, Li R, Cooper-DeHoff RM, Kullo IJ, Chute CG, Chisholm RL, Jarvik GP, Larson EB, Carey D, McCarty CA, Williams MS, **Roden DM**, Bottinger E, Johnson J, de Andrade M, Crawford DC: Genome-wide study of resistant hypertension identified from electronic health records. PLoS One. 2017 Feb 21;12(2):e0171745. doi: 10.1371/journal.pone.0171745. eCollection 2017. PMID:28222112 PMCID:PMC5319785
68. Zhang Bo, Novitskaya T, Wheeler DG, Xu Z, Chepurko E, Huttinger R, He H, Varadharaj S, Zweier JL, Song Y, Xu M, Harrell, Jr FE, Su YR, Absi T, Kohr MJ, Ziolo MT, Roden DM, Shaffer CM, Galindo CL, Wells QS, Gumina RJ: Kcnj11 Ablation Is Associated With Increased Nitro-Oxidative Stress During Ischemia Reperfusion Injury Implications for Human Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Feb;10(2). pii: e003523. doi: 10.1161/CIRCHEARTFAILURE.116.003523. PMID:28209764 PMCID:PMC5319711
69. Webb TR, Erdmann J, Stirrups KE,Stitziel NO, Makozaksca NGD, Jansen H, Kanoni S, Nelson CP, Ferrario PG, König IR, Eicher JD, Johnson AD, Hamby SE, Betsholtz C, Ruusalepp A, Franzén O, Schadt EE, Björkegren JLM, Weeke PE, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kruppa J, Mahajan A, Scott RA, Willenborg C, Braund PS, van Capelleveen JC, Doney ASF, Donnelly LA, Asselta R, Merlini PA, Duga S, Marziliano N, Denny JC, Shaffer C, El-Mokhtari NE, Franke A, Heilmann S, Hengstenberg C, Hoffmann P, Holmen OL, Hveem K, Jansson JH, Jöckel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, McCarthy MI, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Virtamo J, Nikpay M, Olivieri O, Provost S, AlQarawi A, Robertson NR, Akinsansya KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson RD, Stahl E, Müller-Nurasyid M, Strauch K, Varga TV, Waldenberger M, Wellcome Trust Case Control Consortium, Zeng L, Chowdhury R, Salomaa V, Ford I, Jukema JW, Amouyel P, Kontto J, MORGAM Investigators, Nordestgaard BG, Ferrières J, Saleheen D, Sattar N, Surendran P, Wagner A, Young R, Howson JMM, Butterworth AS, Danesh J, Ardissino D, Bottinger EP, Erbel R, Franks PW, Girelli D, Hall AS, Hovingh GK, Kastrati A, Lieb W, Meitinger T, Kraus WE, Shah SH, McPherson R, Orho-Melander M, Melander O, Metspalu A, Palmer CNA, Peters A, Rader DJ, Reilly MP, Loos RJF, Reiner AP, **Roden DM**, Tardif JC, Thompson JR, Wareham NJ, Watkins H, Willer CJ, Samani NJ, Schunkert H, Deloukas P, Kathiresan S, for the Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators: Systematic Evaluation of Pleiotropy Identiﬁes 6 Further Loci Associated With Coronary Artery Disease. J Am Coll Cardiol. 2017 Feb 21;69(7):823-836. doi: 10.1016/j.jacc.2016.11.056. PMID:28209224 PMCID:PMC5314135
70. Nadkarni GN, Galarneau G, Ellis SB, Nadukuru R, Zhang J, Scott SA, Schurmann C, Li R, Rasmussen-Torvik LJ, Kho AN, Hayes MG, Pacheco JA, Manolio TA, Chisholm RL, **Roden DM**, Denny JC, Kenny EE, Bottinger EP: Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans. J Am Coll Cardiol. 2017 Mar 28;69(12):1564-1574. doi: 10.1016/j.jacc.2017.01.040. PMID:28335839 PMCID:PMC5479565
71. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program: The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017 Jan 16. doi: 10.1002/cpt.630. [Epub ahead of print] PMID:28090649 PMCID:PMC5511786
72. Kozak PM, Harris AK, McPherson JA, **Roden DM**: Torsades de pointes with high-dose loperamide. J Electrocardiol. 2017 Jan 16. pii: S0022-0736(17)30014-6. doi: 10.1016/j.jelectrocard.2017.01.011. [Epub ahead of print] PMID:28109524
73. Mosley JD, Shoemaker MB, Wells QS, Darbar D, Shaffer CM, Edwards TL, Bastarache L, McCarty CA, Thompson W, Chute CG, Jarvik GP, Crosslin DR, Larson EB, Kullo IJ, Pacheco JA, Peissig PL, Brilliant MH, Linneman JG, Denny JC, **Roden DM**: Defining the genetic architecture of the PR interval using clinical phenotypes. Circ Cardiovasc Genet. 2017 Apr;10(2). pii: e001482. doi: 10.1161/CIRCGENETICS.116.001482. PMID:28416512 PMCID:PMC5434456
74. Strauss DG, Vicente J, Johannesen L, Blinova K, Mason JW, Weeke P, Behr ER, **Roden D**, Woosley R, Kosova G, Rosenberg MA, Newton-Cheh C: Common Genetic Variants Predict Drug-Induced QT Prolongation and Torsade de Pointes Risk: a Pilot Study. Circulation. 2017 Apr 4;135(14):1300-1310. doi: 10.1161/CIRCULATIONAHA.116.023980. Epub 2017 Feb 17. PMID:28213480 PMCID:PMC5380476
75. Karnes JH, Shaffer CM, Bastarache L, Gaudieri S, Glazer AM, Steiner H, Mosley JD, Mallal S, Denny JC, Phillips EJ, **Roden DM**: Comparison of HLA Allelic Imputation Programs. PLoS One. 2017 Feb 16;12(2):e0172444. doi: 10.1371/journal.pone.0172444. eCollection 2017. PMID:28207879 PMCID:PMC5312875
76. Karnes JH,\* Bastarache L,\* Shaffer CM, Gaudieri S, Xu Y, Glazer A, Mosley JD, Zhao S, Raychaudhuri S, Mallal S,Ye Z, Mayer JG, Brilliant MH, Hebbring SJ, **Roden DM** Phillips EJ, Denny JC: Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci Transl Med. 2017 May 10;9(389). pii: eaai8708. doi: 10.1126/scitranslmed.aai8708. PMID:28490672 PMCID:PMC5563969
77. Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, Lin H, Arking DE, Smith AV, Albert CM, Chaffin M, Tucker NR, Li M, Klarin D, Bihlmeyer NA, Low SK,Weeke PE, Müller-Nurasyid M, Smith JG, Brody JA, Niemeijer MN, Dörr M, Trompet S, Huffman J, Gustafsson S, Schurman C, Kleber ME, Lyytikäinen LP, Seppälä I, Malik R, Horimoto ARVR, Perez M, Sinisalo J, Aeschbacher S, Thériault S, Yao J, Radmanesh F, Weiss S, Teumer A, Choi SH, Weng LC, Clauss S, Deo R, Rader DJ, Shah S, Sun A, Hopewell JC, Debette S, Chauhan G, Yang Q, Worrall BB, Paré G, Kamatani Y, Hagemeijer YP, Verweij N, Siland JE, Kubo M, Smith JD, Van Wagoner DR, Bis JC, Perz S, Psaty BM, Ridker PM, Magnani JW, Harris TB, Launer LJ, Shoemaker MB, Padmanabhan S, Haessler J, Bartz TM, Waldenberger M, Lichtner P, Arendt M, Krieger JE, Kähönen M, Risch L, Mansur AJ, Peters A, Smith BH, Lind L, Scott SA, Lu Y, Bottinger EB, Hernesniemi J, Lindgren CM, Wong J, Huang J, Eskola M, Morris AP, Ford I, Reiner AP, Delgado G, Chen LY, Chen YDI, Sandhu RK, Li M, Boerwinkle E, Eisele L, Lannfelt L, Rost N, Anderson CD, Taylor KD, Campbell A, Magnusson PK, Porteous D, Hocking LJ, Vlachopoulou E, Pedersen NL, Nikus E, Orho-Melander M, Hamsten A, Heeringa J, Denny JC, Kriebel J, Darbar D, Newton-Cheh C, Shaffer C, Macfarlane PW, Heilmann S, Almgren P, Huang PL, Sotoodehnia N, Soliman EZ, Uitterlinden AG, Hofman A, Franco OH, Völker U, Jöckel KH, Sinner MF, Lin HJ, Guo X, METASTROKE Consortium of the ISGC, Neurology Working Group of the CHARGE Consortium, Dichgans M, Ingelsson E, Kooperberg C, Melander O, Loos RJF, Laurikka J, Conen D, Trompet S, Rosand J, van der Harst P, Lokki ML, Kathiresan S, Pereira A, Jukema JW, Hayward C, Rotter JI, März W, Lehtimäki T, Stricker BH, Chung MK, Felix SB, Gudnason V, Alonso A, **Roden DM**, Kääb S, Chasman DI, Heckbert SR, Benjamin EJ, Tanaka T, Lunetta KL, Lubitz SA, Ellinor PT, on behalf of the AFGen Consortium: Large-scale analyses of Common and Rare Variant identify 12 new Loci Associated with Atrial Fibrillation. Nat Genet. 2017 Jun;49(6):946-952. doi: 10.1038/ng.3843. Epub 2017 Apr 17. PMID:28416818 PMCID:PMC5585859. Erratum: Nat Genet. 2017 Jul 27;49(8):1286. doi: 10.1038/ng0817-1286c. No abstract available. PMID:28747752
78. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, Batra AS, Kaufman ES, Fairbrother DL, Saarel EV, Etheridge SP, Kanter RJ, Carboni MP, Dzurik MV, Fountain D, Chen H, Ely EW, **Roden DM**, Knollmann BC: Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. JAMA Cardiol. 2017 Jul 1;2(7):759-766. doi: 10.1001/jamacardio.2017.1320. PMID:28492868 PMCID:PMC5548393
79. Wei WQ, Bastarache L, Carroll RJ, Marlo JE, Osterman T, Gamazon ER, Cox NJ, **Roden DM**, Denny JC: Evaluating Phecodes, Clinical Classification Software, and ICD-9-CM codes for Phenome-wide Association Studies in the Electronic Health Record. PLoS One. 2017 Jul 7;12(7):e0175508. doi: 10.1371/journal.pone.0175508. eCollection 2017. PMID:28686612 PMCID:PMC5501393
80. Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, Bastarache L, Niu X, Holroyd KJ, **Roden DM**, Skaar EP, Niswender CM, Marnett LJ, Lindsley CW, Ekstrom LB, Bentley AR, Bernard GR, Hong CC, Denny JC: Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay Drug Dev Technol. 2017 Apr 5. doi: 10.1089/adt.2016.772. [Epub ahead of print] PMID:28379727 PMCID:PMC5399743
81. Wells QS, Veatch OJ, Fessel JP, Joon AY, Levinson RT, Mosley JD, Held EP, Lindsay CS, Shaffer CM, Weeke PE, Glazer AM, Bersell KR, Van Driest SL, Karnes JH, Blair MA, Lagrone LW, Su YR, Bowton EA, Feng Z, Ky B, Lenihan DJ, Fisch MJ, Denny JC, **Roden DM**: Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenet Genomics. 2017 May 24. doi: 10.1097/FPC.0000000000000284. [Epub ahead of print] PMID:28542097 PMCID:PMC5502740
82. Karnes JH, Shaffer CM, Cronin R, Bastarache L, Gaudieri S, James I, Pavlos R, Steiner H, Mosley JD, Mallal S, Denny JC, Phillips EJ, **Roden DM**: Influence of HLA alleles and KIR types on Heparin-Induced Thrombocytopenia. Pharmacotherapy. 2017 Jul 8. doi: 10.1002/phar.1983. [Epub ahead of print] PMID:28688202 PMCID:PMC5600645
83. Weng LC, Lunetta K, Nurasyid MM, Smith A, Thériault A, Weeke P, Barnard J, Bis J, Lyytikäinen LP, Kleber M, Martinsson A, Lin H, Rienstra M, Trompet S, Krijthe B, Dörr M, Klarin D, Chasman D, Sinner M, Waldenberger M, Launer L, Harris T, Soliman E, Alonso A, Paré G, Teixeira P, Denny J, Shoemaker MB, Van Wagoner D, Smith J, Psaty B, Sotoodehnia N, Taylor K, Kähönen M, Nikus K, Delgado G, Melander O, Engström G, Yao J, Guo X, Christophersen I, Ellinor P, Geelhoed G, Verweij N, Ford I, MacFarlane P, Heeringa J, Franco O, Uitterlinden A, Völker U, Teumer A, Rose L, Kääb S, Gudnason V, Arking D, Conen D, **Roden D**, Chung M, Heckbert S, Benjamin E, Lehtimäki T, März, Smith G, Rotter J, van der Harst P, Jukema JW, Stricker B, Felix SB, Albert C, Lubitz S: Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. Sci Rep. 2017 Sep 12;7(1):11303. doi: 10.1038/s41598-017-09396-7. PMID:28900195 PMCID:PMC5595875
84. Husser D, Weeke P, Shoemaker MB, Hindricks G, **Roden DM**, Büttner P, Bollmann A: Association of rare and very rare SCN5A-encoded cardiac sodium channel variants with atrial fibrillation – comparison of 761 cases and 33,370 reference samples Rare SCN5A variants in AF. PLoS One. 2017 Aug 24;12(8):e0183690. doi: 10.1371/journal.pone.0183690. eCollection 2017. PMID:28837624 PMCID:PMC5570360
85. Farrell\* M, Yoneda\* A, Montgomery J, Crawford D, Wray LL, Xu M, Kolek MJ, Richardson T, Lugo R, Metawee M, Michaud G, Estrada JC, Saavedra P, Shen S, Kanagasundram A, Ellis C, Crossley G, **Roden D**, Shoemaker MB: Non-pulmonary vein mediated atrial fibrillation: A novel sub-phenotype. PLoS One. 2017 Sep 7;12(9):e0184354. doi: 10.1371/journal.pone.0184354. eCollection 2017. PMID:28880943 PMCID:PMC5589236
86. Hellwege JN, Jeff JM, Wise LA, Gallagher CS, Wellons M, Hartmann KE, Jones SH, Torstenson ES, Dickinson S, Ruiz-Narváez EA, Rohland N, Allen A, Reich D, Tandon A, Pasanius B, Mancuso N, Im HK, Hinds DA, Palmer JR, Rosenberg L, Denny JC, **Roden DM**, Stewart EA, Morton CC, Kenny EE, Edwards TL, Velez-Edwards DR: A Multi-stage Genome-wide Association Study of Uterine Fibroids in African Americans. Hum Genet. 2017 Oct;136(10):1363-1373. doi: 10.1007/s00439-017-1836-1. Epub 2017 Aug 23. PMID:28836065 PMCID:PMC5628188. Erratum: Hum Genet. 2017 Nov;136(11-12):1497-1498. doi: 10.1007/s00439-017-1846-z. PMID: 28975356
87. Liu DJ, Peloso GM, Yu H, Butterworth A, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves DC, Amouyel P, di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen4 YDI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dubé MP, Ebeling T, Eiriksdottir G, Esko T, Farmaki AE, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche L, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop N, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin MJ, Jensen GB, Jørgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg CL, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJF, Lu Y, Lu X, Mägi R, Malarstig A,Manichaikul A, Manning AK, Mäntyselkä P, Marouli E, Mascal NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, Müller-Nurasyid M,. Munroe PB, Neville MJ, Nielsen J, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O’Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Raumaraa R, Reilly D, Reiner, Renström F, Rich SS, Ridker PM, Rioux JD, Robertson NR, **Roden DM**, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM,. Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, Stirrups KE, Stitziel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, Tardif JC, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam NR, Varbo A, Varga TV, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, Weeke PE, Weinstock J, Wessel J, Wilson JG, Wilson PWF, Xu M, Yaghootkar H, Young R, Zeggini E, Zhang H, Zheng NS, Zhang W, Zhang Y Zhou W, Zhou Y, Zoledziewska M, Charge Diabetes Working Group, The EPIC-InterAct consortium, EPIC-CVD Consortium, GOLD Consortium, VA Million Veteran Program, Howson JMM, Danesh J, McCarthy MI, Cowan C, Abecasis G, Deloukas P, Musunuru K, Willer CJ, Kathiresan S: Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017 Dec;49(12):1758-1766. doi: 10.1038/ng.3977. Epub 2017 Oct 30. PMID:29083408 PMCID:PMC5709146
88. Jerome RN, Pulley JM, **Roden DM**, Shirey-Rice JK, Bastarache LA, Bernard G, Ekstrom L, Lancaster WJ, Denny JC: Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. Drug Saf. 2017 Nov 28. doi: 10.1007/s40264-017-0616-0. [Epub ahead of print]. PMID:29185237 PMCID:PMC5828879
89. Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, **Roden DM**, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR, ICPC Investigators: Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J. 2018 Apr;198:152-159. doi: 10.1016/j.ahj.2017.12.010. Epub 2017 Dec 17. PMID:29653637 PMCID:PMC5903579
90. Goldstein JA, Bastarache LA, Denny JC, **Roden DM**, Pulley JM, Aronoff DM: Calcium Channel Blockers as Drug Repurposing Candidates for Gestational Diabetes: Mining large scale genomic and electronic health records data to repurpose medications. Pharmacol Res. 2018 Feb 12. pii: S1043-6618(17)31008-3. doi: 10.1016/j.phrs.2018.02.013. [Epub ahead of print] PMID:29448118 PMCID: PMC5965292
91. Kroncke BM, Yang T, Kannankeril P, Shoemaker MB, **Roden DM**: Exploiting ion channel structure to assess rare variant pathogenicity. Heart Rhythm. 2018 Jan 9. pii: S1547-5271(18)30021-3. doi: 10.1016/j.hrthm.2018.01.021. [Epub ahead of print]. PMID:29330128 PMCID:PMC5965292
92. Bastarache L, Hughey J, Hebbring S, Marlo J, Zhao W, Ho WT, Van Driest S, McGregor T, Mosley JD, Wells QS, Temple M, Ramirez AH, Carroll R, Osterman T, Edwards T, Ruderfer D, Velez Edwards DR, Hamid R, Cogan J, Glazer A, Wei WQ, Feng QP, Brilliant M, Zhao ZJ, Cox NJ, **Roden DM**, Denny JC: Phenotype risk scores to identify rare variants associated with unrecognized Mendelian disease patterns. Science. 2018 Mar 16;359(6381):1233-1239. doi: 10.1126/science.aal4043. PMID:29590070 PMCID:PMC5959723
93. Roselli C\*, Chaffin MD\*, Weng LC\*, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso A, Anderson CD, Aragam KG, Arking DE, Barnard J, Bartz TM, Benjamin EJ, Bihlmeyer NA, Bis JC, Bloom HL, Boerwinkle E, Bottinger EB, Brody JA, Calkins H, Campbell A, Cappola TP, Carlquist J, Chasman DI, Chen LY, Chen YDI, Choi EK, Choi SH, Christophersen IE, Chung MK, Cole JW, Conen D, Cook J, Crijns HJ, Cutler MJ, Damrauer SM, Daniels BR, Darbar D, Delgado G, Denny JC, Dichgans M, Dörr M, Dudink EA, Dudley SC, Esa N, Esko T, Eskola M, Fatkin D, Felix SB, Ford I, Franco OH, Geelhoed B, Grewal R, Gudnason V, Guo X, Gupta N, Gustafsson S, Gutmann R, Hamsten A, Harris TB, Hayward C, Heckbert SR, Hernesniemi J, Hocking LJ, Hofman A, Horimoto ARVR, Huang J, Huang PL, Huffman J, Ingelsson E, Ipek EC, Ito K, Jimenez-Conde J, Johnson R, Jukema JW, Kääb S, Kähönen M, Kamatani Y, Kane JP, Kastrati A, Kathiresan S, Katschnig-Winter P, Kavousi M, Kessler T, Kietselaer BL, Kirchhof P, Kleber ME, Knight S, Krieger JE, Kubo M, Launer LJ, Laurikka J, Lehtimäki T, Leineweber K, Lemaitre RN, Li M, Lim HE, Lin HJ, Lin H, Lind L, Lindgren CM, Lokki ML, London B, Loos RJF, Low SK, Lu Y, Lyytikäinen LP, Macfarlane PW, Magnusson PK, Mahajan A, Malik R, Mansur AJ, Marcus GM, Margolin L, Margulies KB, März W, McManus DD, Melander O, Mohanty S, Montgomery JA, Morley MP, Morris AP, Müller-Nurasyid M, Natale A, Nazarian S, Neumann B, Newton-Cheh C, Niemeijer MN, Nikus K, Nilsson P, Noordam R, Oellers H, Olesen MS, Orho-Melander M, Padmanabhan S, Pak HN, Paré G, Pedersen NL, Pera J, Pereira A, Porteous D, Psaty BM, Pulit SL, Pullinger CR, Rader DR, Refsgaard L, Ribasés M, Ridker PM, Rienstra M, Risch L, **Roden D**, Rosand J, Rosenberg MA, Rost N, Rotter JI, Saba S, Sandhu RK, Schnabel RB, Schramm K, Schunkert H, Schurman C, Scott SA, Seppälä I, Shaffer S, Shah S, Shalaby AA, Shim J, Shoemaker MB, Siland JE, Sinisalo J, Sinner MF, Slowik A, Smith AV, Smith BH, Smith JG, Smith JD, Smith NL, Soliman EZ, Sotoodehnia N, Stricker BH, Sun A, Sun H, Svendsen JH, Tanaka T, Tanriverdi K, Taylor KD, Teder-Laving M, Teumer A, Thériault S, Trompet S, Tucker NR, Tveit A, Uitterlinden AG, Van Der Harst P, Van Gelder IC, Van Wagoner DR, Verweij N, Vlachopoulou E, Völker E, Wang B, Weeke PE, Weijs B, Weiss R, Weiss S, Wells Q, Wiggins KL, Wong J, Woo D, Worrall BB, Yang PS, Yao J, Yoneda ZT, Zeller T, Zeng L, Lubitz SA\*, Lunetta KL\*, Ellinor PE\*: Multi-Ethnic Genome-wide Association Study for Atrial Fibrillation. Nature Genetics 2018 Jun 11. doi: 10.1038/s41588-018-0133-9. [Epub ahead of print] PMID:29892015 PMCID:PMC6136836
94. Mosley JD, Levinson RT, Brittain EL, Gupta DK, Farber-Eger E, Shaffer CM, Denny JC, **Roden DM**, Wells QS: Clinical Features Associated with Nascent Left Ventricular Diastolic Dysfunction in a Population Aged 40-55 Years. Am J Cardiol. 2018 Jun 15;121(12):1552-1557. doi: 10.1016/j.amjcard.2018.02.042. Epub 2018 Mar 13. PMID:29627106 PMCID:PMC5975107
95. Yang T, Meoli DF, Moslehi J, **Roden DM**: Inhibition of the α-subunit of phosphoinositide 3-kinase (PI3K) in heart increases late sodium current and is arrhythmogenic. J Pharmacol Exp Ther 2018 Jun;365(3):460-466. doi: 10.1124/jpet.117.246157. Epub 2018 Mar 21. PMID:29563327 PMCID:PMC5931436
96. Kroncke BM,\* Glazer AM,\* Smith D, Blume J, **Roden DM**: SCN5A (NaV1.5) Variant Functional Perturbation and Clinical Presentation: Variants of a Certain Significance. Circ Genom Precis Med. 2018;11:e002095. DOI: 10.1161/CIRCGEN.118.002095. PMID:29728395 PMCID:PMC5941942
97. Wei WQ, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, Karlson EW, Jarvik GP, Lee MTM, Shang N, Larson EA, Edwards T, Shaffer C, Mosley JD, Maeda S, Horikoshi M, Ritchie M, Williams MS, Larson EB, Crosslin DR, Bland ST, Pacheco JA, Rasmussen-Torvik LJ, Cronkite D, Hripcsak G, Cox NJ, Wilke RA, Stein CM, Rotter JI, Momozawa Y, **Roden DM**\*, Krauss RM\*, Denny JC: LPA variants are associated with residual cardiovascular risk in patients receiving statins. Circulation. 2018 Oct 23;138(17):1839-1849. doi: 10.1161/CIRCULATIONAHA.117.031356.PMID:29703846 PMC6202211
98. Grouthier V, Touraine P, Glazer A, Funck-Brentano C, Bachelot A, **Roden DM**, Moslehi J, Salem JE: Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 2018 May 2. pii: heartjnl-2017-312934. doi: 10.1136/heartjnl-2017-312934. [Epub ahead of print] PMID:29720397
99. Smith JC, Chen Q, Denny JC, **Roden DM**, Johnson KB, Miller RA: Evaluation of a Novel System to Enhance Clinicians’ Recognition of Preadmission Adverse Drug Reactions. Applied Clinical Informatics Appl Clin Inform. 2018;9:313-325. doi: 10.1055/s-0038-1646963. Epub 2018 May 9. PMID:29742757 PMCID:PMC5943080
100. Mosley JD, Feng Q , Wells QS, Van Driest SL, Shaffer CM, Edwards TL, Bastarache L, Wei WQ, Davis LK, McCarty CA, Thompson W, Chute CG, Jarvik GP, Gordon AS, Palmer MA, Crosslin DR, Larson EB, Carrell DS, Kullo IJ, Pacheco JA, Peissig PL, Brilliant MH, Linneman JG, Namjou B, Williams MS, Ritchie MD, Borthwick KM, Verma SS, Karnes JK, Weiss ST, Wang TJ, Stein CM, Denny JC, **Roden DM**: A study paradigm to integrate prospective epidemiologic cohorts and electronic health records to identify new disease biomarkers. Nat Commun. 2018 Aug 30;9(1):3522. doi: 10.1038/s41467-018-05624-4. PMID:30166544 PMC6117367
101. Salem JE, Waintraub X, Courtillot C, Schaffer C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer A, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, **Roden DM**, Bachelot A, Funck-Brentano C: Hypogonadism as a reversible cause of Torsade de Pointes in men. Circulation 2018;138:110-113. PMID:29967236 PMC6053686
102. Choi L, Carroll RC, Beck C, Mosley JD, **Roden DM**, Denny JC, Van Driest SL: Evaluating statistical approaches to leverage large clinical datasets for uncovering therapeutic and adverse medication effects. Bioinformatics. 2018 Apr 18. doi: 10.1093/bioinformatics/bty306. PMID:29912272 PMCID:PMC6129383
103. Büttner P, Ueberham L, Shoemaker MB, **Roden DM**, Dinov B, Hindricks G, Bollmann A, Husser D: Identification of Central Regulators of Calcium Signaling and ECM-Receptor Interaction Genetically Associated With the Progression and Recurrence of Atrial Fibrillation. Front Genet. 2018 May 16;9:162. doi: 10.3389/fgene.2018.00162. eCollection 2018. PMID:29868113 PMCID:PMC5964985
104. Van Driest SL, Jooste EH, Shi Y, Choi L, Darghosian L, Hill KD, Smith AH, Kannankeril PJ, **Roden DM**, Ware LB: Association Between Early Postoperative Acetaminophen Exposure and Acute Kidney Injury in Pediatric Patients Undergoing Cardiac Surgery. JAMA Pediatr. 2018;172:655-663. PMID:29799947 PMCID:PMC6110290
105. Husser D, Ueberham L, Hindricks G, Büttner P, Ingram C, Weeke P, Shoemaker MB, Adams V, Arya A, Sommer P, Darbar D, **Roden DM**, Bollmann A: Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLoS One. 2017 Aug 24;12(8):e0183690. doi: 10.1371/journal.pone.0183690. eCollection 2017. PMID:28837624 PMCID:PMC5570360
106. Lee HJ, Jiang M, Wu Y, Shaffer CM, Cleator JH, Friedman EA, Lewis JP, **Roden DM**, Denny J, Xu H: A comparative study of different methods for automatic identification of clopidogrel-induced bleedings in electronic health records. AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:185-192. eCollection 2017. PMID:28815128 PMCID:PMC5543340
107. Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Helgadottir A, Gretarsdottir S, Benonisdottir S, Magnusdottir A, Davidsson OB, Rajamani S, **Roden DM**, Darbar D, Pedersen TR, Sabatine MS, Jonsdottir I, Arnar DO, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson KA: Missense Variant in PLEC Increases Risk of Atrial Fibrillation. J Am Coll Cardiol. 2017 Oct 24;70(17):2157-2168. doi: 10.1016/j.jacc.2017.09.005. PMID:29050564 PMCID:PMC5704994
108. Feng Q, Wei WQ, Chung CP, Levinson RT, Sundermann AC, Mosley JD, Bastarache L, Ferguson JF, Cox NJ, **Roden DM**, Denny JC, Linton MF, Velez Edwards D, Stein CM: Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Med. 2018 Aug 28;15(8):e1002642. doi: 10.1371/journal.pmed.1002642. eCollection 2018 Aug. PMID: 30153257 PMCID: PMC6112635
109. Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen K, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett CF, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala MM, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley JB, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, Ross RVM, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins IM, **Roden DM**, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AT, Thenappan T, Torres F, Toshner MR, Treacy CM, Noordegraaf AV, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR: Genetic determinants of risk in pulmonary arterial hypertension: international case-control studies and meta-analysis. Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5. PMID:30527956 PMCID:PMC6391516
110. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi SH, Shoemaker MB, Haas M, Weng LU, Lindsay ME, Smith JG, Newton-Cheh CH, **Roden DM**, London B, Wells QS, Ellinor PT, Kathiresan S: Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery. Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.035774. [Epub ahead of print]. PMID:30586722 PMCID:PMC6511334
111. Choi SH, Weng LC, Roselli C, Lin H, Haggerty CM, Shoemaker MB, Barnard J, Arking DE, Chasman DI, Albert CM, Chaffin M, Tucker NR, Smith JD, Gupta N, Gabriel S, Margolin L, Shea MA, Shaffer CM, Yoneda ZA, Boerwinkle E, Smith NL, Silverman EK, Redline S, Vasan RS, Burchard EG, Gogarten SM, Laurie C, Blackwell TW, Abecasis G, Carey DJ, Fornwalt BK, Smelser DT, Bara A, Dewey FE, Jaquish CE, Papanicolaou GJ, Sotoodehnia N, Van Wagoner DR, Psaty BM, Kathriesen S, Darbar D, Alonso A, Heckbert SR, Chung MK, **Roden DM**, Benjamin EJ, Murray MF, Lunetta KL, Lubitz SA, Ellinor PT, on behalf of the DiscoveEHR study and NHLBI Trans-Omics Precision Medicine (TOPMed) Consortium: Association between titin loss-of-function variants and early-onset atrial fibrillation. JAMA. 2018 Dec 11;320(22):2354-2364. doi: 10.1001/jama.2018.18179. PMID:30535219 PMCID:PMC6436530
112. Salem JE, Shoemaker MB, Bastarache L, Shaffer CM, Glazer AM, Kroncke B, Wells QS, Shi M, Straub P, Jarvik GP, Larson EB, Velez-Edwards DR, Edwards TL, Davis LK, Hakonarson H, Weng C, Fasel D, Knollmann BC, Wang TJ, Denny JC, Ellinor PT, **Roden DM**, Mosley JD: Association of Thyroid Function Genetic Predictors With Atrial Fibrillation: A Phenome-Wide Association Study and Inverse-Variance Weighted Average Meta-analysis. JAMA Cardiol. 2019 Jan 23. doi: 10.1001/jamacardio.2018.4615. [Epub ahead of print]. PMID:30673079 PMCID:PMC6439628
113. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, **Roden DM**, Johnson DB, Moslehi JJ: Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 Nov 9. pii: S1470-2045(18)30608-9. doi: 10.1016/S1470-2045(18)30608-9. [Epub ahead of print] PMID:30442497 PMCID: PMC6287923
114. Gonsalves S, Dirksen R, Sangkuhl K, Pulk R, Alvarellos M, Vo T, Hikino K, **Roden D**, Klein T, S. Poler S, Patel S, Caudle K, Gordon R, Brandom B, Biesecker L: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of anesthetic agents in the context of RYR1 or CACNA1S genotype. Clin Pharmacol Ther. 2018 Nov 30. doi: 10.1002/cpt.1319. [Epub ahead of print]. PMID:30499100 PMCID: PMC6513720
115. van Setten J, Brody JA, Jamshidi Y, Swenson BR, Butler AM, Campbell H, Del Greco FM, Evans DS, Gibson Q, Gudbjartsson DF, Kerr KF, Krijthe BP, Lyytikäinen LP, Müller C, Müller-Nurasyid M, Nolte IM, Padmanabhan S, Ritchie MD, Robino A, Smith AV, Steri M, Tanaka T, Teumer A, Trompet S, Ulivi S, Verweij N, Yin X, Arnar DO, Asselbergs FW, Bader JS, Barnard J, Bis J, Blankenberg S, Boerwinkle E, Bradford Y, Buckley BM, Chung MK, Crawford D, den Hoed M, Denny JC, Dominiczak AF, Ehret GB, Eijgelsheim M, Ellinor PT, Felix SB, Franco OH, Franke L, Harris TB, Holm H, Ilaria G, Iorio A, Kähönen M, Kolcic I, Kors JA, Lakatta EG, Launer LJ, Lin H, Lin HJ, Loos RJF, Lubitz SA, Macfarlane PW, Magnani JW, Leach IM, Meitinger T, Mitchell BD, Munzel T, Papanicolaou GJ, Peters A, Pfeufer A, Pramstaller PP, Raitakari OT, Rotter JI, Rudan I, Samani NJ, Schlessinger D, Silva Aldana CT, Sinner MF, Smith JD, Snieder H, Soliman EZ, Spector TD, Stott DJ, Strauch K, Tarasov KV, Thorsteinsdottir U, Uitterlinden AG, Van Wagoner DR, Völker U, Völzke H, Waldenberger M, Jan Westra H, Wild PS, Zeller T, Alonso A, Avery CL, Bandinelli S, Benjamin EJ, Cucca F, Dörr M, Ferrucci L, Gasparini P, Gudnason V, Hayward C, Heckbert SR, Hicks AA, Jukema JW, Kääb S, Lehtimäki T, Liu Y, Munroe PB, Parsa A, Polasek O, Psaty BM, **Roden DM**, Schnabel RB, Sinagra G, Stefansson K, Stricker BH, van der Harst P, van Duijn CM, Wilson JF, Gharib SA, de Bakker PI, Isaacs A, Arking DE, Sotoodehnia N: PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity. Nat Commun. 2018 Jul 25;9(1):2904. doi: 10.1038/s41467-018-04766-9. PMID:30046033 PMCID:PMC6060178
116. Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Nielsen JB, Jonsson S, Halldorsson GH, Melsted P, Ivarsdottir EV, Davidsson OB, Kristjansson RP, Thorleifsson G, Helgadottir A, Gretarsdottir S, Norddahl G, Rajamani S, Torfason B, Valgardsson AS, Sverrisson JT, Tragante V, Holmen OL, Asselbergs FW, **Roden DM**, Darbar D, Pedersen TR, Sabatine MS, Willer CJ, Løchen ML, Halldorsson BV, Jonsdottir I, Hveem K, Arnar DO, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson K. Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Commun Biol. 2018 Jun 12;1:68. doi: 10.1038/s42003-018-0068-9. eCollection 2018. PMID:30271950 PMCID:PMC6123807
117. Ellervik C, Roselli C, Christophersen IE, Alonso A, Pietzner M, Sitlani CM, Trompet S, Arking DE, Geelhoed B, Guo X, Kleber ME, Lin HJ, Lin H, MacFarlane P, Selvin E, Shaffer C, Smith AV, Verweij N, Weiss S, Cappola AR, Dörr M, Gudnason V, Heckbert S, Mooijaart S, März W, Psaty BM, Ridker PM, **Roden D**, Stott DJ, Völzke H, Benjamin EJ, Delgado G, Ellinor P, Homuth G, Köttgen A, Jukema JW, Lubitz SA, Mora S, Rienstra M, Rotter JI, Shoemaker MB, Sotoodehnia N, Taylor KD, van der Harst P, Albert CM, Chasman DI\*on behalf of the AFGen Consortium: Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study. JAMA Cardiol. 2019 Jan 23. doi: 10.1001/jamacardio.2018.4635. [Epub ahead of print]. PMID:30673084 PMCID:PMC6396813
118. Pacheco JA, Rasmussen LV, Kiefer RC, Campion TR, Speltz P, Carroll RJ, Stallings SC, Mo H, Ahuja M, Jiang G, LaRose ER, Peissig PL, Shang N, Benoit B, Gainer VS, Borthwick K, Jackson KL, Sharma A, Wu AY, Kho AN, **Roden DM**, Pathak J, Denny JC, Thompson WK. A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments. J Am Med Inform Assoc. 2018 Nov 1;25(11):1540-1546. doi: 10.1093/jamia/ocy101. PMID:30124903 PMCID:PMC6213083
119. Kroncke B, Yang T, **Roden DM**: Multiple mechanisms underlie increased cardiac late sodium current. Heart Rhythm. 2019 Jan 21. pii: S1547-5271(19)30031-1. doi: 10.1016/j.hrthm.2019.01.018. [Epub ahead of print]. PMID:30677491
120. Safarova MS\*, Satterfield BA\*, Fan X, Austin EE, Ye Z, Bastarache L, Zheng N, Ritchie MD, Borthwick KM, Williams MS, Larson EB, Scrol A, Jarvik GP, Crosslin DR, Leppig K, Rasmussen-Torvik LJ, Pendergrass SA, Sturm AC, Namjou B, Shah AS, Carroll RJ, Chung WK, Wei WQ, Feng Q, Stein CM, **Roden DM**, Manolio TA, Schaid DJ, Denny JC, Hebbring SJ, de Andrade M, Kullo IJ: A Phenome-Wide Association Study to Discover Pleiotropic Effects of PCSK9, APOB, and LDLR. NPJ Genom Med. 2019 Feb 11;4:3. doi: 10.1038/s41525-019-0078-7. eCollection 2019. PMID:30774981 PMCID:PMC6370860
121. Andersson C, Krogager ML, Skals RK, Appel VP, Schnurr TM, Engelbrechtsen L, Have CT, Pedersen O, Engstrøm T, **Roden DM**, Gislason G, Poulsen ME, Køber L, Stender S, Hansen T, Grarup N, Torp-Pedersen C, Weeke PE: Association of genetic variants previously implicated in coronary artery disease with age at onset of coronary artery disease requiring revascularizations. PLoS One. 2019 Feb 6;14(2):e0211690. doi: 10.1371/journal.pone.0211690. eCollection 2019. PMID:30726294 PMCID:PMC6364925
122. Oshikoya K, Neely K, Carroll RJ, Aka IT, Maxwell-Horn AC, **Roden DM,** Van Driest SL: CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res. 2019 Apr;85(5):602-606. doi: 10.1038/s41390-019-0305-z. Epub 2019 Jan 19. PMID:30661084 PMCID:PMC6435416
123. Wells QS,\* Gupta DK,\* Smith JG, Collins SP, Storrow AB, Ferguson J, Smith ML, Pulley JM, Collier S, Wang X, **Roden DM**, Gerszten RE, Wang TJ: Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics. J Am Coll Cardiol. 2019 May 7;73(17):2195-2205. doi: 10.1016/j.jacc.2019.01.074. PMID: 31047008 PMCID:PMC6501811
124. \*Kroncke BM, \*Mendenhall J, Smith DK, Sanders CR, Capra JA, George, Jr. AL, Blume JD, Meiler J, **Roden DM**: Protein structure aids predicting functional perturbation of missense variants in SCN5A and KCNQ1. Comput Struct Biotechnol J. 2019 Feb 1;17:206-214. doi: 10.1016/j.csbj.2019.01.008. eCollection 2019. PMID:30828412 PMCID:PMC6383132
125. Brackman D, Yee SW, Enogieru O, Shaffer C, Ranatunga D, Denny J, Wei WQ, Kamatani Y, Kubo M, Roden D, Jorgenson E, Giacomini K: Genome-wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. Clin Pharmacol Ther. 2019 Mar 28. doi: 10.1002/cpt.1439. [Epub ahead of print]. PMID:30924126
126. Unlu G\*, Gamazon ER\*, Qi X, Levic DS†, Bastarache L, Denny JC, **Roden DM**, Mayzus I, Breyer M, Zhong X, Konkashbaev AI, Rzhetsky A, Knapik EW, Cox NJ: GRIK5 Genetically Regulated Expression Associated with Eye and Vascular Phenomes: Discovery through Iteration among Biobanks, Electronic Health Records, and Zebrafish. Am J Hum Genet. 2019 Mar 7;104(3):503-519. doi: 10.1016/j.ajhg.2019.01.017. Epub 2019 Feb 28. PMID:30827500 PMCID:PMC6407495
127. Mosley JD, Benson MD, Smith JG, Melander O, Ngo D, Shaffer CM, Ferguson JF, Herzig MS, McCarty CA, Chute CG, Jarvik GP, Gordon AS, Palmer MR, Crosslin DR, Larson EB, Carrell DS, Kullo IJ, Pacheco JA, Peissig PL, Brilliant MH, Kitchner TE, Linneman JG, Namjou B, Williams MS, Ritchie MD, Borthwick KM, Kiryluk K, Mentch FD, Sleiman PM, Karlson EW, Verma SS, Zhu Y, Vasan RS, Yang Q, Denny JC, **Roden DM**, Gerszten RE, Wang TJ: Probing the Virtual Proteome to Identify Novel Disease Biomarkers. Circulation. 2018 Nov 27;138(22):2469-2481. doi: 10.1161/CIRCULATIONAHA.118.036063. PMID:30571344
128. Oshikoya KA, Carroll R, Aka I, **Roden DM**, Van Driest SL. Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Study using Electronic Health Records. Drugs Real World Outcomes. 2019 Mar 27. doi: 10.1007/s40801-019-0151-7. [Epub ahead of print]. PMID:30919267 PMCID:PMC6520321
129. Hellwege JN, Stallings S, Torstenson ES, Carroll R, Borthwick KM, Brilliant MH, Crosslin D, Gordon A, Hripcsak G, Jarvik GP, Linneman JG, Devi P, Peissig PL, Sleiman PAM, Hakonarson H, Ritchie MD, Verma SS, Shang N, Denny JC, **Roden DM**, Velez Edwards DR, Edwards TL: Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the 1 eMERGE network. Sci Rep. 2019 Apr 15;9(1):6077. doi: 10.1038/s41598-019-42427-z. PMID:30988330 PMCID:PMC6465359
130. Lukács Krogager M, Skals RK, Appel EVR, Schnurr TM, Engelbrechtsen L, Have CT, Pedersen O, Engstrøm T, **Roden DM**, Gislason G, Poulsen HE, Køber L, Stender S, Hansen T, Grarup N, Andersson C, Torp-Pedersen C, Weeke PE: Hypertension genetic risk score is associated with burden of coronary heart disease among patients referred for coronary angiography. PLoS One. 2018 Dec 19;13(12):e0208645. doi: 10.1371/journal.pone.0208645. eCollection 2018. PMID:30566436 PMCID:PMC6300273
131. Edwards TL, Giri A, Hellwege JN , Hartmann KE, Stewart EA, Jeff JM, Bray MJ, Pendergrass SA, Torstenson ES, Keaton JM, Jones SH, Gogoi RP, Kuivaniemi H, Jackson KL, Kho AN, Kullo IJ, McCarty CA, Im HK, Pacheco JA, Pathak J, Williams MS, Tromp G, Kenny EE, Peissig PL, Denny JC, **Roden DM**, Velez-Edwards DR: A Trans-Ethnic Genome-Wide Association Study of Uterine Fibroids. Front Genet. 2019 Jun 12;10:511. doi: 10.3389/ fgene.2019.00511. eCollection 2019. PMID: 31249589 PMCID: PMC6582231
132. Daniel LL\*, Yang T\*, Kroncke B\*, Hall L, Stroud D, **Roden DM**: SCN5A Variant R222Q generated abnormal changes in cardiac sodium current and action potentials in murine myocytes and Purkinje cells. Heart Rhythm. 2019 May 21. pii: S1547-5271(19)30458-8. doi: 10.1016/j.hrthm.2019.05.017. [Epub ahead of print]. PMID:31125670 PMCID: PMC6825529
133. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, **Roden DM**. Androgenic therapy effects on QT and ventricular repolarization: A translational characterization study from pharmacovigilance databases to iPSC-cardiomyocytes. Circulation. 2019 Aug 5. doi: 10.1161/CIRCULATIONAHA.119.040162. [Epub ahead of print] PMID:31378084 PMCID:PMC6756939
134. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, **Roden DM**, Moslehi JJ: Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol 2019 Oct, 74 (13) 1667-1678. doi: 10.1016/j.jacc.2019.07.056. PMID:31558250
135. Van Driest SL, Wang L, McLemore MF, Bridges BC, Fleming GM, McGregor TL, Jones DP, Shirey-Rice J, Gatto CL, Gay JC, Byrne DW, Weitkamp A, **Roden DM**, Bernard GR: Acute Kidney Injury Risk-based Screening in Pediatric Inpatients: A Randomized Clinical Trial. Pediatr Res. 2019 Aug 27. doi: 10.1038/s41390-019-0550-1. [Epub ahead of print]. PMID:31454829
136. Schmidt AF\*, Holmes MV\*, Preiss D\*, Swerdlow D, Denaxas S, Fatemifar G, Faraway R, Finan C, Valentine D, Fairhurst- Hunter Z, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh K, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Lill CM, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, BenShlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott RA, Luan J, Bobak M, Malyutina S, Pajak A, Kubinova R, Tamosiunas A, Pikhart H, Grarup N, Pedersen O, Hansen T, Linneberg A, Jess T, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Lester KH, Larson EB, Crosslin DR, de Andrade M, **Roden DM**, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Scott R, Schofield P, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H, Lifelines Cohort authors, Christen T, Mook-Kanamori DO, the ICBP Consortium, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Meade T, Christophersen IE, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, FrogueL P, Thuillier D, Roussel R, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Hopewell JC, Seshadri S, the METASTROKE Consortium of the ISGC, Dale C, Costa RPE, Ridker PM, Chasman DI, Reiner AP, Ritchie MD, Lange LA, Cornish AJ, Dobbins SE, Hemminki K, Kinnersley B, Sanson M, Labreche K, Simon M, Bondy M, Law P, Speedy H, Allan J, Li N, Went M, Weinhold N, Morgan G, Sonneveld P, Nilsson B, Goldschmidt H, Hemminki K, Sud A, Engert A, Hansson M, Hemingway H, Asselbergs FW, Patel RS, Keating BJ, Sattar N, Houlston R, Casas JP, Hingorani AD: Safety and efficacy of PCSK9 inhibition supported by genetic variation in PCSK9. BMC Cardiovasc Disord. 2019 Oct 29;19(1):240. doi: 10.1186/s12872-019-1187-z. PMID: 31664920
137. Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, **Roden DM**, Winter S, Altman R, Alexopoulos D, Kim HS, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR: Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients. Eur Heart J Cardiovasc Pharmacother. 2019 Sep 3. pii: pvz045. doi: 10.1093/ehjcvp/pvz045. [Epub ahead of print] PMID:31504375
138. Shi Y, Graves JA, Garbett SP, Zhou Z, Marathi R, Wang X, Harrell FE, Lasko TA, Denny JC, **Roden DM**, Peterson JF, Schildcrout JS: A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping. MDM Policy Pract. 2019 Aug 17;4(2):2381468319864337. doi: 10.1177/2381468319864337. eCollection 2019 Jul-Dec. PMID:31453360 PMCID:PMC6699004

1. The eMERGE Consortium: Harmonizing clinical sequencing and interpretation for the EMERGE III Network. Am J Hum Genet. 2019 Sep 5;105(3):588-605. doi: 10.1016/j.ajhg.2019.07.018. Epub 2019 Aug 22. PMID:31447099 PMCID:PMC6731372
2. Bernal C, Aka I, Carroll R, Coco J, Lima J, Acra S, **Roden DM**, Van Driest S: CYP2C19 phenotype and risk of proton pump inhibitor associated infections. Pediatrics. 2019 Nov 7. pii: e20190857. doi: 10.1542/peds.2019-0857. [Epub ahead of print]. PMID:31699831
3. Bastarache L, Hughey JJ, Goldstein JA, Bastraache JA, Das S, Zaki NC, Zeng C, Tang LA, **Roden DM**, Denny JC. Improving the phenotype risk score as a scalable approach to identifying patients with Mendelian disease. J Am Med Inform Assoc. 2019 Dec 1;26(12):1437-1447. doi: 10.1093/jamia/ocz179. PMID: 31609419
4. Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, **Roden DM**, Moslehi JJ, Salem JE: Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2019 Nov 1. pii: S1875-2136(19)30172-X. doi: 10.1016/j.acvd.2019.09.006. [Epub ahead of print]. PMID:31685432
5. Robinson JRR, Carroll RJ, Bastarache L, Chen Q, Mou Z, B Wei WQ, Connolly JJ, Mentch F, Sleiman P, Crane PK, Hebbring SJ, Stanaway IB, Crosslin DR, Gordon AS, Ph.D.8, Rosenthal EA, Carrell D, Hayes MG, Wei W, Petukhova L, Namjou B, Zhang G, Safarova MS, Walton NA, Still C, Bottinger EP, Loos RJF, Murphy SN, Jackson GP, Kullo IJ, Hakonarson H, Jarvik GP, Larson EB, Weng C, **Roden DM**, Denny JC. Association of Genetic Risk for Obesity with Postoperative Complications Using Mendelian Randomization. World J Surg. 2019 Oct 11. doi: 10.1007/s00268-019-05202-9. [Epub ahead of print]. PMID:31605180
6. Glessner JT, Li J, Desai A, Palmer M, Kim D, Lucas AM, Chang X, Connolly JJ, Almoguera B, Harley JB, Jarvik GP, Ritchie MD, Sleiman PMA, **Roden DM**, Crosslin D, Hakonarson H. CNV Association of Diverse Clinical Phenotypes from eMERGE reveals novel disease biology underlying cardiovascular disease. Int J Cardiol. 2019 Jul 19. pii: S0167-5273(19)30191-3. doi: 10.1016/j.ijcard.2019.07.058. [Epub ahead of print] PMID: 31447229
7. Roberts JD, Asaki SY, Mazzanti A, Bos JM, Tuleta I, Muir AR, Crotti L, Krahn AD, Kutyifa V, Shoemaker MB, Johnsrude CL, Aiba T, Marcondes L, Baban A, Udupa S, Dechert B, Fischbach P, Knight LM, Vittinghoff E, Kukavica D, Stallmeyer B, Giudicessi JR, Spazzolini C, Shimamoto K, Tadros R, Cadrin-Tourigny J, Duff HJ, Simpson CS, Roston TM, Wijeyeratne YD, El Hajjaji I, Yousif MD, Gula LJ, Leong-Sit P, Chavali N, Landstrom AP, Marcus GM, Dittmann S, Wilde AAM, Behr ER, Tfelt-Hansen J, Scheinman MM, Perez MV, Kaski JP, Gow RM, Drago F, Aziz PF, Abrams DJ, Gollob MH, Skinner JR, Shimizu W, Kaufman ES, **Roden DM**, Zareba W, Schwartz PJ, Schulze-Bahr E, Etheridge SP, Priori SG, Ackerman MJ. An International Multi-Center Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. Circulation. 2020 Jan 16. doi: 10.1161/CIRCULATIONAHA.119.043114. [Epub ahead of print] PMID: 31941373
8. Cadar AG, Feaster TK, Bersell KR, Wang L, Hong T, Balsamo JA, Zhang Z, Chun YW, Nam YJ, Gotthardt M, Knollmann BC, **Roden DM**, Lim CC, Hong CC. Real-time visualization of titin dynamics reveals extensive reversible photobleaching in human induced pluripotent stem cell-derived cardiomyocytes. Am J Physiol Cell Physiol. 2019 Nov 20. doi: 10.1152/ajpcell.00107.2019. [Epub ahead of print] PMID: 31747312
9. Mosley JD, Gupta DK, Tan J, Yao J, Wells QS, Shaffer CM, Kundu S, Robinson-Cohen C, Psaty BM, Rich SS, Post WS, Guo X, Rotter JI, **Roden DM**, Gerszten RE, Wang TJ: Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease. Accepted for publication, JAMA
10. Glazer AM, Kroncke BM, Matreyek KA, Yang T, Wada Y, Shields T, Salem, JE, Fowler DM, **Roden DM**: Deep Mutational Scan of a cardiac sodium channel voltage sensor. Circ Genom Precis Med. 2020 Jan 12. doi: 10.1161/CIRCGEN.119.002786. [Epub ahead of print] PMID:31928070 <http://biorxiv.org/cgi/content/short/773887v1>.
11. Choi L, Beck C, McNeer E, Weeks HL, Williams ML, James NT, Niu X, Abou-Khalil BW, Birdwell KA, **Roden DM**, Stein CM, Bejan CA, Denny JC, Van Driest SL: Development of a System for Post-marketing Population Pharmacokinetic and Pharmacodynamic Studies using Real-World Data from Electronic Health Records. Accepted for publication Clin Pharmacol Ther
12. Kannankeril PJ, Shoemaker MB, Gayle KA, Fountain D, Roden DM, Knollmann BC: Atropine-Induced Sinus Tachycardia Protects Against Exercise-Induced Ventricular Arrhythmias in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia. Accepted for publication, Europace

# B. ORIGINAL MANUSCRIPTS SUBMITTED/IN PREPARATION

1. Mautz BS, Hellwege J, Li C, Xu Y, Zhang S, Denny JC, **Roden DM**, McGregor TL, Velez Edwards DR, Edwards TL: Temporal changes in genetic admixture are linked to heterozygosity and health diagnoses in humans.

https://www.biorxiv.org/content/10.1101/697581v1

1. Carroll RJ, Eyler AE, Doss J, Bastarache L, Liao K, Williams M, Hebbring S, Carrell D, Jarvik G, Peissig P, Pathak J, Chute C, Kho A, Ritchie M, Li R, Plenge R, Carey D, Larson E, McCarty C, Kullo I, Böttinger E, Chisolm R, **Roden D**, Denny J: Phenome Wide Association Studies and Genetic Risk Scores to Identify Pleiotropy and Comorbidity in Rheumatoid Arthritis
2. Bersell KR, Yang T, Mosley JD, Glazer AM, Hale AT, Kryshtal DO, Kim K, Steimle JD, Brown JD, Salem JE, Campbell CC, Hong CC, Well QS, Johnson AN, Short L, Blair MA, Behr ER, Petropoulou E, Jamshidi Y, Benson MD, Vasan RS, Yang Q, Gerszten RE, Jarvik GP, Namjou B, Murray MF, Shaffer C, Parikh S, Sheng Q, Kannankeril PJ, eMERGE network investigators, Moskowitz IP, York JD, Wang TJ, Knollmann BC, **Roden DM**: Integrating patient cardiomyocyte function with population multi-omics identifies a novel arrhythmia pathway (Dr. Bersell was an AHA Katz Prize finalist for this work, AHA, 2017).
3. Robinson JR, Carroll RJ, Bastarache L, Chen Q, Mou Z, Wei WQ, Connolly J, Mentch F, Crane PK, Hebbring SJ, Crosslin DR, Gordon AS, Rosenthal EA, Stanaway IB, Hayes MG, Wei W, Petukhova L, Namjou B, Zhang G, Safarova MS, Walton NA, Still C, Bottinger EP, Loos RJF, Murphy SN, Jackson GP, Kullo IJ, Jarvik GP, Larson EB, Weng C, **Roden DM**, Denny JC: Association of Obesity with Postoperative Complications Using Electronic Health Records and Mendelian Randomization.
4. Glazer A, Wada Y, Li B, Muhammad A, Kalash O, O’Neill M, Shields T, Hall L, Short L, Blair MA, Kroncke BM, Capra AJ, **Roden DM**: High-throughput reclassification of SCN5A variants. https://www.biorxiv.org/content/10.1101/858175v1.article-info
5. Glazer AM, Bastarache L, Hall L, Short L, Kroncke BM, Shields T, Denny JC, **Roden DM**: A rare variant on a common risk haplotype of HFE causes increased risk of hereditary hemochromatosis. https://www.biorxiv.org/content/10.1101/547471v1
6. Van Driest SL, Sleeper LA, Gelb BD, Morris SA, Dietz HC, Forbus GA, Goldmuntz E, Hoskoppal A, James J, Lee TM, Levine JC, Li JS, Loeys BL, Markham LW, N. Meester JA, Mital S, Mosley JD, Olson AK, Renard M, Shaffer CM, Sharkey A, Young L, Lacro RV, **Roden DM**: Variants in ADRB1 and CYP2C9: Association with response to atenolol and losartan in Marfan syndrome.
7. Chakrabarti S, Yu G, Wang Z, Chen AL, Wang F, French BA, Prasad SVN, **Roden DM**, Chen Q, Wang QK: AAV9-MOG1 gene therapy in SCN5A D1275N knockin mice with cardiac arrhythmias and dilated cardiomyopathy by promoting NaV1.5 trafficking.

# C. REVIEWS, BOOKS AND CHAPTERS, INVITED MANUSCRIPTS

1. Woosley RL, **Roden DM**: **Chapter** - Pharmacokinetics of antiarrhythmic drugs, in Proceedings of the Second USA-USSR Joint Symposium on Sudden Cardiac Death (December 6-8, 1979), NIH Publication 81-2101, 1980, pp 291–307.
2. Woosley RL, **Roden DM**: **Chapter** - Antiarrhythmic drugs, in Baer DM, Dito WR (eds): Inter­pretations in Therapeutic Drug Monitoring, American Society of Clinical Pathologists, 1981, pp 37–60.
3. **Roden DM**, Woosley RL: Active drug metabolites: Monitoring and interpretation, in American Associa­tion for Clinical Chemistry, Therapeutic Drug Monitoring, January 1981, pp 1–3.
4. **Roden DM**, Woosley RL: **Chapter** - Antiarrhythmic drugs, in Wood M, Wood AJJ (eds): Drugs and Anesthesia: Pharm­a­cology for Anesthesiologists, Williams and Wilkins, Baltimore MD, 1982, pp 501–542.
5. Woosley RL, **Roden DM**, Duff HJ, Oates JA: Selection of an antiarrhythmic drug for a sudden-death-prevention trial. Am Heart J 1982;103:737–745. PMID:6175198
6. **Roden DM**, Woosley RL: Clinical evaluation of antiarrhythmic drug therapy. American Association for Clinical Chemistry, Therapeutic Drug Monitoring, May 1982, pp 1–6.
7. **Roden DM**, Woosley RL: **Chapter** - Application of pharmacologic principles in the evaluation of new antiarrhythmic agents, in Morganroth J, Moore EN (eds): Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment, Martinius Nijhoff, 1983, pp 13–30.
8. **Roden DM**, Woosley RL: **Chapter** - Tocainide, in Gould L (ed): Antiarrhythmic Drugs, Futura Publishing, Mt. Kisco, NY, 1983, pp 183–191.
9. Siddoway LA, McAllister CB, Wilkinson GR, **Roden DM**, Woosley RL: Amiodarone dosing: A proposal based on its pharmacokinetics. Am Heart J 1983;106:951–956. PMID:6613842
10. Woosley RL, **Roden DM**: Importance of metabolites in anti­arrhythmic therapy. Am J Cardiol 1983;52:3C–7C. PMID:6194679
11. **Roden DM**, Woosley RL: Multiple therapy with cardiac drugs, American Associa­tion for Clinical Chemistry, Therapeutic Drug Monitoring, March 1983, pp 1–2.
12. **Roden DM**, Woosley RL: Class I antiarrhythmic agents: Quinidine, procainamide, and N-acetylprocainamide, disopyramide. Pharmacol Ther 1984;23:179–191. PMID: 6199801
13. **Roden DM**, Wang T, Woosley RL: **Chapter** - Antiarrhythmic effects of beta-blocking drugs, in Lucchesi BR, Dingell JV, Schwartz RP Jr (eds:) Clinical Pharmacology of Antiarrhythmic Therapy, Raven Press, New York NY, 1984, pp 95–103.
14. Oates JA, **Roden DM**, Wilkinson GR, Woosley RL: **Chapter** - The clinical pharmacology of new antiarrhythmic drugs: An overview, in Lucchesi BR, Dingell JV, Schwartz RP Jr (eds): Clinical Pharmacology of Antiarrhythmic Therapy, Raven Press, New York NY, 1984, pp 156–165.
15. Woosley RL, Siddoway LA, Thompson K, Cerskus I, **Roden DM**: Potential applications of free drug level monitoring in cardiovascular therapy. Clin Pharmacokin 1984;9:79–83. PMID:6705429
16. Woosley RL, Siddoway LA, Duff HJ, **Roden DM**: Flecainide dose-response relations in stable ventricular arrhythmias. Am J Cardiol 1984;53:59B–65B. PMID:6695819
17. Woosley RL, Wang T, Stone W, Siddoway LA, Thompson K, Duff HJ, Cerskus I, **Roden DM**: Pharmacology, electrophysiology and pharmacokinetics of mexiletine. Am Heart J 1984;107:1058-1065. PMID:6326558
18. **Roden DM**, Woosley RL: Clinical pharmacology of the new antiarrhyth­mic encainide. Clin Prog Pacing and Electrophysiol 1984;2:112–119.
19. **Roden DM**, Wang T, Woosley RL, Wood AJJ, Branch RA, Küpfer A, Wilkinson GR: **Chapter** - Pharmacokinetic and pharmacological aspects of poly­morphic drug oxidation in man, in Benet LZ, Levy G (eds): Pharmacokinetics: A Modern View, Plenum Press, New York NY, 1984, pp 217–234.
20. Oates JA, **Roden DM**, Woosley RL: **Chapter** - Malignant cardiac arrhythmias: Pharmacologic considerations, in Hegyeli RJ (ed): Endpoints for Cardiovascular Drug Studies (Atherosclerosis Review, Vol 12), Raven Press, New York NY, 1984, pp 79–85.
21. Woosley RL, Cerskus I, **Roden DM**: **Chapter** - Pharmacokinetics of antiarrhythmic agents in acute myocardial infarction, in Morganroth J, Moore EN (eds): Interventions in the Acute Phase of Myocardial Infarction, Martinius Nijhoff, Boston MA, 1984, pp 20–36.
22. Siddoway LA, **Roden DM**, Woosley RL: Clinical pharmacology of propafenone: Pharmacokinetics, metabolism, and concentration-response relations. Am J Cardiol 1984;54:9D–12D. PMID:6496371
23. Woosley RL, Cerskus I, **Roden DM**: Antiarrhythmic therapy: Clinical pharmacology update. J Clin Pharmacol 1984;24:295–305. PMID:6384277
24. Siddoway LA, **Roden DM**, Woosley RL: **Chapter** - Clinical pharm­acology of old and new antiarrhythmic drugs, in Brest A (ed): Sudden Death Syn­drome, Cardiovascular Clinics, 1985, pp 199–248.
25. **Roden DM**: Editorial: Tocainide and mexiletine: Orally effective lidocaine analogues. Arch Intern Med 1985;145:417–418. PMID:3919665
26. **Roden DM**, Woosley RL: QT prolongation and arrhythmia suppression. Am Heart J 1985;109:411–415. PMID:2578242
27. **Roden DM**, Woosley RL: **Chapter** - Electropharmacology and pharma­codynamics of antiarrhythmic drugs, in Horowitz LN, Morganroth J (eds): Sudden Cardiac Death, Grune and Stratton, 1985, pp 155–168.
28. **Roden DM**: Antiarrhythmic drugs: Clinical pharmacology of the old and the new agents. Postgrad Med 1985;78:28–37. PMID:2412217
29. Woosley RL, Echt DS, **Roden DM**: Treatment of ventricular arrhythmias in the failing heart: Pharmacologic and clinical considerations. Ration Drug Ther 1985;19:1–7. PMID:4070623

1. **Roden DM**: Pharmacologic information required for design of programmed electrical stimulation. Circulation 1986;73:SII39–44. PMID:3080263
2. Woosley RL, Echt DS, **Roden DM**: Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Am J Cardiol 1986;57:25B–33B. PMID:3080860
3. **Roden DM**, Woosley RL: Flecainide. N Eng J Med 1986;315:36–41. PMID:3520324
4. **Roden DM**, Woosley RL: Tocainide. N Eng J Med 1986;315:41–45. PMID:3086724
5. **Roden DM**, Thompson KA, Hoffman BF, Woosley RL: Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 1986;8:73A–78A. PMID:2423573
6. **Roden DM**, Wood AJJ, Wilkinson GR, Woosley RL: Disposition kinetics of encainide and metabolites. Am J Cardiol 1986;58:4C–9C. PMID:3092618
7. **Roden DM**: Use of mexiletine in combination with other antiarrhythmic drugs. Clin Prog Pacing and Electrophys 1986;4:561–567.
8. Siddoway LA, Barbey JT, **Roden DM**, Woosley RL: Pharmacologic evaluation of standard and controlled-release disopyramide. Angiology 1987;38(2 Pt 2):184–7. PMID:3103492

1. **Roden DM**, Iansmith DHS: Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med 1987;82:18–23. PMID:3565423
2. **Roden DM**, Woosley RL: Pharmacology and clinical use of encainide. IM 1987;8:83–90.
3. Woosley RL, **Roden DM**: Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol 1987;59:19E–25E. PMID:3554949
4. **Roden DM**, Woosley RL, Primm RK: Quinidine-associated long QT syndrome. Cardiology Board Review 1987;4:89–93.
5. **Roden DM**: **Chapter** - New concepts in antiarrhythmic drug pharmaco­kinetics, in Zipes D, Lee, Febiger (eds): Symposium on New Therapeutic Approaches to Cardiac Arrhythmias, Philadelphia PA, 1987, pp 19–36.
6. **Roden DM**: **Chapter** - Ventricular tachycardia - drug therapy, in Fortuin N (ed): Current Therapy in Cardiovascular Disease, BC Decker, Toronto, 1986–1987, pp 206–212. Also in: Current Therapy in Internal Medicine, BC Decker, Toronto, pp 992–998.
7. Woosley RL, **Roden DM**: **Chapter** - Basic principles of clinical pharmacology, in Parmley WW, Chatterjee K (eds): Cardiology, JB Lippincott Co, Philadelphia PA, 1988, pp 1–19.
8. **Roden DM**, Woosley RL: **Chapter** - Electrophysiology and pharmaco­kinetics of mexiletine, in Podrid P (ed): A Comprehensive Guide to the Therapeutic Use of Mexiletine, Pharmalibri, Chicago IL, 1987, pp 93–104.
9. **Roden DM**: **Chapter** - How does congestive heart failure alter response to drugs?, in Morganroth J, Moore EN (eds): Proceedings of the 7th Annual Symposium on New Drugs, Martinius Nijhoff, Boston MA, 1987, pp 177–186.
10. **Roden DM**: **Chapter** - Arrhythmogenic potential of class III antiarrhythmic agents: Comparison with class I agent, in Singh BN (ed): Control of Cardiac Arrhythmias by Lengthening Repolarization, 1988, pp 559–576.
11. Oates JA, Woosley RL, Wood AJJ, **Roden DM**: Encainide. N Eng J Med 1988;318:1107–1115. PMID:3127714
12. **Roden DM**, Woosley RL: Clinical pharmacokinetics of encainide. Clin Pharmacokinet 1988;14:141–147. PMID:3131058
13. **Roden DM**: Role of the electrocardiogram in determining electrophysio­logic endpoints of drug therapy. Am J Cardiol 1988;62:34H–38H. PMID:3052007
14. **Roden DM**: Encainide and related new antiarrhythmic drugs. ISI Atlas of Science 1988, pp 374–380.
15. Woosley RL, **Roden DM**: **Chapter** - Treatment of ventricular arrhythmias in acute myocardial infarction, in Alpert J et al (eds): Modern Coronary Care, 1990, pp 195–219.
16. Turgeon J, **Roden DM**: Pharmacokinetic values of a drug pharmacokinetic profile of encainide. Clin Pharmacol Ther 1989;45:692–694. PMID:2499439
17. Fish F, **Roden DM**: A prolonged QTc interval: Is it an important effect of antiarrhythmic drugs? Med Toxicol Adverse Drug Exp 1989;4:400–411. PMID:2689835
18. **Roden DM**, Balser JR, Bennett PB: **Chapter** - Modulation of cardiac potassium currents by antiarrhythmic drugs: Present status and future directions, in Hondeghem L (ed): Molecular and Cellular Mechanisms of Antiarrhythmic Agents, Futura Press, Mt. Kisco NY, 1989, pp 133–154.
19. **Roden DM**: Magnesium treatment of ventricular arrhythmias. Am J Cardiol 1989;63:43G. PMID:2650516
20. **Roden DM**, Woosley RL: **Chapter** - Antiarrhythmic drugs, in Wood M, Wood AJJ (eds): Pharmacology for Anesthetists, Williams and Wilkins, Second Edition, 1989, pp 461–491.
21. Barbey JT, **Roden D**: Treatment of ventricular arrhythmias with combination tocainide and quinidine. Cardiology Board Review 1989;6:35–44.
22. **Roden DM**: Clinical features of arrhythmia aggravation by antiarrhythmic drugs and their implications for basic mechanisms. Drug Dev Res 1990;19:153–172.
23. Funck-Brentano C, Kroemer HK, Lee JT, **Roden DM**: Propafenone. N Eng J Med 1990;322:518–525. PMID:2405273
24. **Roden DM**: **Chapter** - Clinical pharmacological requisites to ensure the adequacy of antiarrhythmic therapy, in Rosen MR, Janse MJ, Wit AL (eds): Cardiac Electrophysiology: A Textbook, Futura Publishing, Mt. Kisco NY, 1990, pp 1095–1116.
25. Turgeon J, Murray KT, **Roden DM**: Effects of drug metabolism, metabolites and stereoselectivity on antiarrhythmic drug action. J Cardiovasc Electrophysiol 1990;1:238–260.
26. **Roden DM**: **Chapter** – The Long QT syndrome and Torsades de Pointes: Basic and clinical aspects, in El-Sherif N, Samet P (eds): Cardiac Pacing and Electrophysiology, WB Saunders, Philadelphia PA, 1991, pp 265–284.
27. **Roden DM**: **Chapter** - Quinidine, in Dangman KH, Miura DS (eds): Electrophysiology and Pharmacology of the Heart, Marcel Dekker, New York NY, 1991, pp 493–516.
28. **Roden DM**: **Chapter** – Tocainide, in Horowitz LN (ed): Current Management of Arrhythmias, BC Decker, 1991, p 372.
29. **Roden DM**, Funck-Brentano C, Lee JT, Kroemer HK: Properties of propafenone. Cardiology Board Review 1991;8:83–87.
30. **Roden DM**: Are pharmacokinetics helpful for the clinician? J Cardiovasc Electrophysiol 1991;2:S178–S191.
31. **Roden DM**: CAST: Implications for the use of antiarrhythmic agents in the setting of ischemic heart disease. Coronary Artery Disease 1991;2:723–729.
32. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-1851. Eur Heart J 1991;12:1112–1131.
33. Wiggins SS, **Roden DM**: Drug-induced Torsades de Pointes: Current concepts. Cardio 1992;9:36–45.
34. **Roden DM**: **Chapter** - Treatment of cardiovascular disorders: Arrhythmias, in Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW (eds): Clinical Pharmacology: Basic Principles in Therapeutics, McGraw-Hill Inc., 1992, pp 151–185.
35. Greene HL, **Roden DM**, Katz RJ, Woosley RL, Salerno DM, Henthorn RW, the CAST Investigators: The Cardiac Arrhythmia Suppression Trial: First CAST...Then CAST-II. J Am Coll Cardiol 1992;19:894–898. PMID:1552108
36. **Roden DM**: **Chapter** – Clinical pharmacodynamics of cardiovascular agents: Focus on sudden cardiac death, in Yacobi A, Skelly JP, Shah VP, Benet LZ (eds): Integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development, Plenum Press, New York NY, 1993, pp 207–215.
37. **Roden DM**: **Chapter** – Polymorphic ventricular tachycardia: Mechanisms and therapeutic implications, in Josephson ME, Wellens HJJ (eds): Tachycardias: Mechanisms and Management, Futura Publishing Co., Mt. Kisco NY, 1993, pp 273–282.
38. **Roden DM**, Echt DS, Lee JT, Murray KT: **Chapter** - Clinical pharmacology of antiarrhythmic agents, in Josephson ME (ed): Sudden Cardiac Death, Blackwell Scientific, 1993, pp 163–210.
39. **Roden DM**: Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol 1993;72:51A–55A. PMID:8346727
40. **Roden DM**: Current status of class III antiarrhythmic drug therapy. Am J Cardiol 1993;72:44B–49B. PMID:8256755
41. **Roden DM**: Early afterdepolarizations and torsade de pointes: Implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J 1993;14H:56–61.
42. **Roden DM**: Pharmacokinetics of amiodarone: Implications for drug therapy. Am J Cardiol 1993,72:45F–50F. PMID:8237829
43. **Roden DM**: Torsades de Pointes. Clin Cardiol 1993;16:683–686. PMID:7902224
44. **Roden DM**: **Chapter** - Plasma concentration response relations for class III antiarrhythmic drugs: Are pharmacokinetics important?, in Singh BN, Wellens HJJ, Hiraoka M (eds): Electropharmacologic control of cardiac arrhythmias: To delay conduction or to prolong refractoriness?, Futura Publishing, Mt. Kisco NY, 1994, pp 457–464.
45. **Roden DM**: Drug interactions: Focus on antihistamines. Monograph Series on Antihistamines and Drug Safety, Cahners Healthcare Communications, New York NY, Monograph #2, 1994, pp 10–14.
46. **Roden DM**: **Editorial:** Mirror, mirror on the wall… Stereochemistry in therapeutics. Circulation 1994;89:2451–2453. PMID:7910122
47. Members of the Sicilian Gambit: **Contributor** - Antiarrhythmic Therapy: A Pathophysiologic Approach, Futura Publishing Company, Inc., Armonk NY, 1994.
48. **Roden DM**: Risks and benefits of antiarrhythmic therapy. Invited review. N Engl J Med 1994;331:785–791. PMID:8065408
49. **Roden DM**: **Book Review** - Cardiovascular Pharmacology and Therapeutics, Singh BN, Dzau VJ, VanHoutte PM, Woosley RL (eds), Churchill Livingstone Inc, New York NY, 1994. J Cardiovasc Electrophys 1994;5:803–804.
50. **Roden DM**, Murray KT: **Chapter** - Pharmacokinetics, pharmacodynamics and pharmacogenetics, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology: From Cell to Bedside, 2nd edition, W.B. Saunders, 1994, pp 1287–1296.
51. Hondeghem LM, **Roden DM**: **Chapter** - Agents used in cardiac arrhythmias, in Katzung BG (ed): Basic and Clinical Pharmacology, 6th Edition, Appleton and Lange, Norwalk CT, 1994, pp 205–229.
52. **Roden DM**, Tamkun MM: Toward a molecular view of cardiac arrhythmogenesis. Trends Cardiovasc Med 1994;4:278–285. PMID:21244879
53. **Roden DM**: **Editorial Comment** - Role of sodium and potassium channels in atrial electrogenesis and their blockade by antiarrhythmic drugs, in DiMarco JP, Prystowsky EN (eds): Atrial Arrhythmias: State of the Art, Futura Publishing Company, Inc., Armonk, NY, 1995, pp 201–212.
54. **Roden DM**: **Chapter** - The study of pharmacokinetics and pharmacodynamics as a tool for understanding mechanisms of antiarrhythmic drug action, in Breithardt G, Borggrefe M, Camm J, Shenasa M (eds): Antiarrhythmic Drugs: Mechanisms of Antiarrhythmic and Proarrhythmic Actions, Springer-Verlag Berlin, Heidelberg, Germany, 1995, pp. 290–299.
55. **Roden DM**, George AL Jr, Bennett PB: Recent advances in understanding the molecular mechanisms of the long QT syndrome. Invited review. J Cardiovasc Electrophysiol 1995;6:1023–1031. PMID:8589871
56. **Roden DM**: **Chapter** - Antiarrhythmic drugs, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Hardman JL, Limbird LE, Molinoff PB, Ruddon RW, and Gilman AG (eds.), 9th ed., New York: McGraw-Hill, 1995, pp 839–874.
57. **Roden DM**, George AL Jr: The cardiac ion channels: Relevance to management of arrhythmias. Annu Rev Med 1996;47;135–148. PMID:8712768
58. **Roden DM**: Is there a need for new antiarrhythmic drugs? Archives des Maladies du Coeur et des Vaisseaux 1996;89(I):13-18.
59. Friedrich T, Nichols DJ, Alabaster CT, **Roden DM**: **Chapter** - Dofetilide, in Messerli FH (ed): *Cardiovascular Drug Therapy*, 2nd edition, WB Saunders Co., 1996, pp 1296–1303.
60. Murray KT, **Roden DM**: **Chapter** - Cardiac arrhythmias and sudden death, in Robertson D, Low PA, Polinsky RJ (eds): *Primer on the Autonomic Nervous System*, Academic Press, 1996, pp 149–152.
61. **Roden DM**, Lazzara R, Rosen MR, Schwartz PJ, Towbin J, Vincent GM, for the SADS Foundation Task Force on LQTS: Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996;94:1996–2012. PMID:8873679
62. **Roden DM**: Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Am J Cardiol 1996;78(4A):12–16. PMID:8780324
63. **Roden DM**: **Editorial:** Ibutilide and the treatment of atrial arrhythmias: A new drug -- almost unheralded -- is now available to U.S. physician. Circulation 1996;94:1499–1502. PMID:8840835
64. **Roden DM**: A practical approach to Torsade de Pointes. Clin Cardiol 1997;20:285–290. PMID:9068917
65. **Roden DM**: Recent advances in the long QT syndrome. Cardiac Electrophysiology Review 1997;1(1/2):262–263.
66. **Roden DM**: **Chapter** - New antiarrhythmic drug development: Rationale and approach, in El-Sherif N, LeKieffre J (eds): *Practical Management of Cardiac Arrhythmias*, Futura Publishing Co., Armonk NY, 1997, pp 3–16.
67. **Roden DM**: Cardiovascular and Renal Advisory Panel of the US Food and Drug Administration considers four drugs. Circulation 1997;95:2335–2337.
68. **Roden DM**, George AL Jr: Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997;273:H511–H525. PMID:9277464
69. Hondeghem LM, **Roden DM**: **Chapter** - Agents used in cardiac arrhythmias in Katzung BG (ed): Basic and Clinical Pharmacology, 7th edition, Appleton and Lange, 1998, pp 216–241.
70. **Roden DM**: **Chapter** - Antiarrhythmic drugs, in Topol (ed): Comprehensive Cardiovascular Medicine, Lippincott-Raven, Philadelphia PA, 1998, pp 2053–2069.
71. **Roden DM**: **Editorial:** Taking the “idio out of “idiosyncratic”: predicting Torsades de Pointes. PACE 1998;21:1029–1034. PMID:9604234
72. **Roden DM**, Willerson JT: Cardiovascular drugs: review of mechanisms and clinical applications. Circulation 1998;97:415.
73. Members of the Sicilian Gambit: **Contributor** - The search for novel antiarrhythmic strategies. Eur Heart J 1998;19:1178–1196. *PMID:9740340* Japanese Circulation J 1998;62(9):633–648. *PMID:9766701*
74. **Roden DM**: **Chapter -** Molecular and electrophysiological mechanisms of arrhythmias in hypertrophic cardiomyopathy in Vardas (ed): Cardiac Arrhythmias, Pacing, and Electrophysiology, 1998, pp 77–82.
75. **Roden DM**: **Chapter** - Antiarrhythmic therapy. In Melmon K, Hoffman BB, Carruthers G, Nierenberg D (eds) Melmon and Morelli’s Clinical Pharmacology 4th edition,1998. pp 183-206.
76. **Roden DM**: Cardiovascular and Renal Advisory Panel of the US Food and Drug Administration. Circulation 1998;97:1107. PMID:9537333
77. Thadani U, **Roden DM**: FDA Panel Report: January 1998. Circulation 1998;97:2295–2296. PMID:9639370
78. **Roden DM**: Mechanisms and management of proarrhythmia. Am J Cardiol 1998;82:49I–57I. PMID:9737654
79. **Roden DM**, Kupershmidt S: From genes to channels: normal mechanisms. Cardiovasc Res, 1999;42:318–326. PMID:10533570
80. Priori SG, Barhanin J, Hauer RNW, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, **Roden DM**, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, and Wilde AM: Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management. Circulation 1999;99:518–528 (parts I and II) *PMID: 9927398*, 1999;99:674–681 (part III) *PMID:9950666*; Eur Heart Journal 1999;20:174–195 *PMID:10082151*.
81. **Roden DM**, Wilde AAM: **Editorial:** Drug-induced J point elevation: a marker for genetic risk of sudden death or ECG curiosity. J Cardiovasc Electrophysiol 1999;10:219–223. PMID:10090225
82. **Roden DM**, Spooner PJ: Inherited Long QT Syndromes: A Paradigm for Understanding Arrhythmogenesis. J Cardiovasc Electrophysiol 1999;10:1664–1683. PMID:10636197
83. **Roden DM**: An Overview of Contemporary Approaches to Antiarrhythmic Therapy. Jpn Circulation J 1999;63:655–658. PMID:10496478
84. **Roden DM**: **Chapter** – IMPACT: Critique. In Woosley RL and Singh SN, (eds). Arrhythmia Treatment and Therapy. Evaluation of Clinical Trial Evidence. Marcel Dekker, 2000, pp 15–18.
85. **Roden DM**: **Chapter -** Molecular Genetics of the Acquired Long QT Syndrome. In Berul C and Towbin J (eds): Molecular Genetics of Cardiac Arrhythmias. Kluwer Academic Publishers, 2000, pp 137–146.
86. **Roden DM**: **Chapter** - Cardiac membrane and action potentials, in Spooner PJ, Rosen MR (eds): Review of Cardiac Electrophysiology, 2000, pp 21–41.
87. **Roden DM** and Balser JR: **Editorial**:A Plethora of Mechanisms in the *HERG*-related Long QT Syndrome: Genetics Meets Electrophysiology. Cardiovasc Res 1999;44:242–246. PMID:10690299
88. **Roden DM**: Mechanisms Underlying Variability in Response to Drug Therapy: Implications for Amiodarone Use. Am J Cardiol 1999;84:29R–36R. PMID:10568657
89. Nattel S, Roden DM, Escande D: **Editorial:** A spotlight on electrophysiological remodeling and the molecular biology of ion channels. Cardiovasc Res 1999;42:267–269. PMID:10533565
90. **Roden DM** and Kim RB: **Chapter** - Pharmacokinetics, pharmacodynamics, pharmacogenetics, and drug interactions, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology: From Cell to Bedside, 3rd edition, W.B. Saunders, Philadelphia PA, 2000, pp 882–890.
91. Oates JA, **Roden DM**, Wilkinson GR: **Chapter** - Principles of Drug Therapy. In Fifteenth Edition of Harrison’s Principles of Internal Medicine, McGraw-Hill, 2001, pp 419–430.
92. Chiang C, **Roden DM**: The Long QT Syndromes: Genetic Basis and Clinical Implications. J Am Coll Card 2000;36:1–12. PMID:10898405
93. **Roden DM**: Point of View: Acquired Long QT Syndromes and the Risk of Proarrhythmia. Journal of Cardiovascular Electrophysiology 2000;11:938–940. PMID:10969760
94. **Roden DM**: **Chapter -** Antiarrhythmic drugs, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Hardman JL, Limbird LE, and Gilman AG (eds.), 10th ed., New York: McGraw-Hill, 2001, pp 933–970.
95. **Roden DM**: **Chapter -** Ion channel clones to predict clinical actions in Prediction of Clinical Drug Actions From In-Vitro Approaches - Fact or Fiction? Clinical Pharmacology 1999;19:17–24, Kuhmann J and Roden DM (eds).
96. **Roden DM**: Impact of Recent Molecular Studies on Evaluation of Ventricular Arrhythmias. J Interventional Cardiac Electrophysiology 2000;4(Suppl 1):7–16. PMID:10590483
97. **Roden DM:** **Chapter -** Arrhythmias. In Melmon and Morrelli’s Clinical Pharmacology, Fourth Edition. Carruthers, Hoffman, Melmon and Nierenberg (eds) McGraw-Hill, 2000, pp 183-206.
98. **Roden DM**: Atrial Fibrillation. In: EBM Solutions Guidelines for Health Care Providers and Consumers (online database). Issue 1 Nashville TN, EBM Solutions; 2000.
99. **Roden DM:** **Chapter -** Sudden death risk assessment: The long QT syndromes, in Oto A and Breithardt G (eds): Risk Stratification, 2000.
100. **Roden DM:** Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000; 84:339–446. PMID:10956304 PMCID:PMC1760959
101. **Roden DM** and Anderson ME: **Editorial:** The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart 2000;84:235–237. PMID:10956280 PMCID:PMC1760962
102. **Roden DM**: **Chapter -** Cardiovascular Pharmacogenetics, with a focus on arrhythmias, in Eichelbaum M et al (eds): Pharmacogenetics, Springer Verlag, 2000.
103. Anderson ME and **Roden DM**: **Chapter -** Basic Cardiac Electrophysiology and Anatomy, in Dimarco J and Crawford M (eds): A Textbook of Cardiology, Mosby, 2001. pp. 1.1-1.12.
104. Murray KT and **Roden DM**: **Chapter -** Disorders of Cardiac Repolarization:The Long QT Syndromes, in Dimarco J and Crawford M (eds): A Textbook of Cardiology, Mosby, 2001. pp 15.1-15.10.
105. **Roden DM**:How do we treat arrhythmias in heart failure? Dialogues in Cardiovascular Medicine 2000;5:225–232.
106. Camm AJ, Janse M, **Roden DM,** Rosen MR, Cinca J, Cobbe SM: Congenital and acquired long QT syndrome. Eur Heart J 2000;21:1232–1237. PMID:10924312
107. Wilde AAM and **Roden DM**: **Editorial:** Predicting the long QT genotype from clinical data. From sense to science. Circulation 2000;102:2796–2798. PMID:11104734
108. Hondeghem LM, **Roden DM**. **Chapter -** Agents used in cardiac arrhythmias. In Basic & Clinical Pharmacology Bertram G. Katzung (ed), 8th Edition, Lange Medical Books/McGraw-Hill, 2000, pp 219–245.
109. Viskin S, Fish R, **Roden DM**. Drug-Induced Torsades de Pointes. Harrison’s Online. McGraw Hill Publishing, 2000.
110. **Roden DM**. Section Editor, Section VI Pharmacology 2000, Cardiac Electrophysiology Review. December 2000.
111. **Roden DM** and Brown NB: **Editorial**:Pre-prescription genotyping: Not yet ready for prime time, but getting there. Circulation 2001;103:1608–1610. PMID:11273984
112. **Roden DM**: **Editorial**:Defective ion channel function in the Long QT syndrome: multiple unexpected mechanisms. J Mol Cell Cardiol 2001;33:185–187. PMID:11162124
113. **Roden DM**:Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001;50:224–231. PMID:11334826
114. Members of the Sicilian Gambit: **Contributor** – New approaches to antiarrhythmic therapy: Emerging therapeutic applications of the cell biology of cardiac arrhythmias. Part I: Circulation 2001;104:2865–2873. *PMID:11733408*; part II: Circulation 2001;104:2990–2994. *PMID:11739317*. Also published in Eur Heart J 2001;22:2148–2163. *PMID:11913477*.
115. **Roden DM**: Principles in Pharmacogenetics. Epilepsia 2001;42(Suppl 5):44–48. PMID:11887967
116. **Roden DM** and George AL Jr: The genetic basis of variability in drug responses. Nature Reviews Drug Discovery 2002;1:37–44. PMID:12119608
117. Anderson ME, Al-Khatib S, **Roden DM**, Califf RM: Proceedings of an expert panel conference on repolarization changes: Cardiac Repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002;144:769–81. PMID:12422144
118. **Roden DM**: **Editorial**:QT Bumps: Unraveling the mechanisms. J Cardiovasc Electrophysiol 2001;12:1379–80. PMID:11797995
119. **Roden DM**, Balser JR, George AL Jr, Anderson, ME: Cardiac Ion Channels. Ann Rev Physiol 2002;64:431–475. PMID:11826275
120. **Roden DM**: Genetics of the long QT syndrome. ACC Current Journal Review. March/April 2002, pp 70–73.
121. **Roden DM**: **Editorial** – The problem, challenge, and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death. J Am Coll Cardiol 2002;40:357–359. PMID: 12106944
122. Anderson ME and **Roden DM**: **Chapter -** Basic Cardiac Electrophysiology and Anatomy, in Dimarco J and Crawford M (eds): A Textbook of Cardiology, 2nd ed., Mosby, 2003, pp 581–592.
123. Murray KT and **Roden DM**: **Chapter -** Disorders of Cardiac Repolarization:The Long QT Syndromes in Dimarco J and Crawford M (eds): A Textbook of Cardiology, 2nd ed., Mosby, 2003, pp 765–774.
124. **Roden DM**: Genetic Polymorphisms, Drugs, and Proarrhythmia. Journal of Interventional Cardiovascular Electrophysiology 2003;9:131–5. PMID:14574023
125. **Roden DM**: **Chapter** – The Autonomic Nervous system and Sudden Cardiac Death, in Robertson D, et al. (eds): *Primer on the Autonomic Nervous System*, 2nd Edition, Academic Press, 2003, pp 245–246.
126. **Roden DM**: **Chapter** – The Genetics of Cardiac Channelopathies: Implications for Therapeutics, in Wilkins M (eds): Cardiovascular Pharmacogenetics; Handbook of Experimental Pharmacology, vol. 160. Springer, Berlin, 2003, pp. 223–241.
127. **Roden DM**: **Chapter** – Pharmacogenomics of Cardiac Arrhythmias and Impact on Drug Therapy, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology: From Cell to Bedside, 4th edition, W.B. Saunders, Philadelphia PA, 2003, pp 471–7.
128. **Roden DM**: **Editorial** - A surprising new arrhythmia mechanism in heart failure. Circ Res 2003;93:589–591. PMID:14525920
129. **Roden DM**: *Circulation* Clinician Update: Cardiovascular Pharmacogenomics. Circulation 2003;108:3071–3074. PMID:14691022
130. **Roden DM**:Antiarrhythmic Drugs: Past, Present, and Future. Special NASPE 25th anniversary issue. J Cardiovasc Electrophysiol. 2003;14:1389–1396. *PMID:14678124* PACE (Pacing And Cardiac Electrophysiology) 2003;26:2340–9. *PMID:14675028*
131. **Roden DM**: Drug-induced Prolongation of the QT interval. New Engl J Med 2004;350:1013–1022. [Response-Letter to the Editor 2004; 350; 25; 2618-2621] PMID:14999113
132. **Roden DM:** Human Genomics and its Impact on Arrhythmias. Trends in Cardiovascular Medicine 2004;[14](http://www.sciencedirect.com/science?_ob=IssueURL&_tockey=%23TOC%234888%232004%23999859996%23499804%23FLA%23display%23Volume_14,_Issue_3,_Pages_83-125_(April_2004)%23tagged%23Volume%23first%3D14%23Issue%23first%3D3%23Pages%23first%3D83%23last%3D125%23date%23(April_2004)%23&_auth=y&view=c&_acct=C000006878&_version=1&_urlVersion=0&_userid=86629&md5=771952ffa1e1c3d968c8491459da0588):112–116. PMID:15121159
133. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, **Roden DM**, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR: Drug-Induced Torsade de Pointes and Implications for Drug Development. J Cardiovasc Electrophysiology 2004;15:475–495. PMID:15090000 PMCID:PMC1544371
134. **Roden DM**: **Guest Editorial** *–*Issues expanding in the field of pacing arrhythmia.Today in Cardiology 2004;7:4.
135. **Roden DM**: **Chapter** - The Principles of Drug Therapy, in Zipes D, Libby P, Bonow R, Braunwald E (eds): Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 7th Edition, Elsevier, Philadelphia PA, 2005, pp 43–52.
136. **Roden DM**:An under-recognized challenge in evaluating post-marketing drug safety. Circulation 2005;111:246–8. PMID:15668350
137. **Roden DM** and Temple R: The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. Circulation 2005;111:1697–702. PMID:15811869
138. Darbar D, **Roden DM**: Symptomatic Burden as an Endpoint to Evaluate Interventions in Patients with Atrial Fibrillation. Heart Rhythm 2005;2:544–9. PMID:15840484
139. **Roden DM**: **Chapter** - Principles of Clinical Pharmacology. In Sixteenth Edition of Harrison’s Principles of Internal Medicine, McGraw-Hill, 2005, pp 13–25.
140. **Roden DM,** Anderson ME: **Chapter** – Proarrhythmia, in Kass RS and Clancy CE (eds): Basis and Treatment of Cardiac Arrhythmias, Handbook of Experimental Pharmacology, vol. 171. Springer Verlag, 2006, Berlin. pp 73–97.
141. **Roden DM**: Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res 2005;67:419–425. PMID:15936006
142. **Roden DM** and Viswanathan PC: Genetics of acquired long QT syndrome. J Clin Invest 2005;115:2025–2032. PMID:16075043 PMCID:PMC1180553
143. **Roden DM**, Yang T: **Editorial** - Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation 2005;112:1376–1378. PMID:16145010
144. Bezzina CR, Wilde AAM, **Roden DM**: Editorial – The molecular genetics of arrhythmias. Cardiovasc Res 2005;67;343-346. PMID:16005449
145. **Roden DM**, Drici MD: **Chapter** - Drug-Induced Sudden Death, in Priori S and Zipes DP (eds): Sudden Cardiac Death: A Handbook for Clinical Practice, Blackwell Scientific 2005, pp 177–188.
146. Tomaselli G, **Roden DM**: **Chapter** – Molecular and cellular basis of cardiac electrophysiology, in Saksena S, Camm AJ (eds): Electrophysiological Disorders of the Heart, Elsevier, Philadelphia PA, 2005, pp 1–31.
147. **Roden DM**: **Chapter -** Antiarrhythmic drugs, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Brunton LL, Laso JS, Parker KL (eds.), 11th ed., New York: McGraw-Hill, 2005, pp 899–932.
148. **Roden DM**: **Chapter** – Principles of pharmacogenetics: focus on arrhythmias. In New Arrhythmia Technologies, Wang P.J., ed. Blackwell Futura, Malden MA. 2005. pp. 31–35.
149. Page RL, **Roden DM**: Drug therapy for atrial fibrillation: Where do we go from here? Nature Drug Discovery 2005; 4:899–910. PMID:16264433
150. **Roden DM**: **Chapter 7** - Pharmacogenetics and Cardiac Ion Channels, in Kalow W, Meyer UA, and Tyndale RF (eds): Pharmacogenomics, Taylor and Francis, Boca Raton, FL. 2006. pp. 207–220.
151. **Roden DM**: Long QT syndrome: reduced repolarization reserve and the genetic link. Journal of Internal Medicine 2006;259:59–69. PMID:16336514
152. Motsinger AA, Donahue BS, Brown NJ, **Roden DM**, Ritchie MD: Risk factor interactions and genetic effects associated with post-operative effects associated with post-operative atrial fibrillation. Pac Symp Biocomput 2006;584–95. PMID:17094271
153. **Roden DM**: Intracellular sodium overload: A system biology problem with implications for drug target identification. J Cardiovasc Electrophysiol 2006;17:S149–S150. PMID:16686670
154. **Roden DM**, Darbar D, Kannankeril PJ: **Chapter 99 -** Antiarrhythmic drugs, in Willerson JT, Cohn JN, Wellens HJJ, Holmes DR (eds): Cardiovascular Medicine, 3rd ed, Springer Verlag, London, 2006, pp 2085–2102.
155. **Roden DM**: **Chapter** - Antiarrhythmic drugs, in Topol E (ed): Comprehensive Cardiovascular Medicine, Lippincott-Raven, Philadelphia PA, 3rd edition, 2006, pp 1151–1165.
156. **Roden DM**, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring H, Shuldiner AR, Weinshilboum RM, Weiss ST, for the Pharmacogenetics Research Network: Pharmacogenomics: challenges and opportunities. Ann Int Med 2006;149:749–757. PMID:17116919
157. **Roden DM**: **Editorial** – A new role for calmodulin in ion channel biology. Circ Res 2006;98:979–981. PMID:16645144
158. **Roden DM**: **Editorial –** Probing the arrhythmogenic substrate. Heart Rhythm 2006; 3:779–780. PMID:16818205
159. Darbar D, **Roden DM**: Future of antiarrhythmic drugs. Curr Opin Cardiol 2006;21:361–7. PMID:16755206
160. Darbar D, **Roden DM**: Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother 2006;7:1583–1590. PMID:16872261
161. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, **Roden DM**, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Full text published at J Am Coll Cardiol 2006;48:e247-e346; Circulation; Heart Rhythm; Europace; European Heart Journal. Executive summary at J Am Coll Cardiol 2006;48:1064-1108; Circulation; Heart Rhythm; Europace; European Heart Journal. Rev Esp Cardiol 2006;59:1328. PMID:16949478
162. **Roden DM**: **Chapter** - Principles of Clinical Pharmacology. In Seventeenth Edition of Harrison’s Principles of Internal Medicine, McGraw-Hill, 2007, pp 27–39.
163. Kannankeril PJ, **Roden DM**: When should QT be measured? Summer solstice or Christmas Eve? Heart Rhythm 2007;4:282–3. PMID:17341388
164. Kannankeril PJ, **Roden DM**: Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007;22:39–43. PMID:17143043
165. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, **Roden DM**, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I: The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007;81:328–45. PMID:17339863
166. Giacomini KM, Krauss RM, **Roden DM**, Eichelbaum M, Hayden MR, Nakamura Y: When good drugs go bad. Nature 2007;446:975–7. PMID:17460642
167. Wilke RA, Lin DW, **Roden DM**, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss R: Identifying genetic risk factors for serious adverse drug reactions: current progress and future challenges. Nature Reviews Drug Discovery 2007;6:904–916. PMID:17971785 PMCID:PMC2763923
168. **Roden DM**, Kannankeril PJ, Darbar D: On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace 2007; 9(Supplement 4):iv1-iv3. Supplement 4: A re-examination of the relationship between drug-induced QT-interval prolongation and proarrhythmic risk; **Roden DM, guest editor**. PMID:17766319PMCID:PMC2599908
169. Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, **Roden D**, Krauss RM, Ratain M: Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics 2007;8:519. PMID:17465717

1. **Roden DM**: Long-QT Syndrome (Clinical Practice Series). N Engl J Med 2008;358:169-176. PMID:18184962 *Correspondence:* N Engl J Med 2008;358:1967–1968.

1. Knollmann BC, **Roden DM**: A genetic framework for improving arrhythmia therapy (Cardiovascular Insight Series). Nature 2008;451:929–936. PMID:18288182
2. **Roden DM**: Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm 2008;5:1213–1215. Epub 2008 May 15 PMID:18675237 PMCID:PMC3212752
3. **Roden DM**: Cellular basis of drug-induced torsades de pointes. Br J Pharm 2008;154:1502–1507. PMID:18552874 PMCID:PMC2492095
4. **Roden DM**: **Editorial -** Repolarization Reserve: A Moving Target. Circulation 2008;118:981–982. PMID:18765386

1. Watanabe H, **Roden DM**: Cardiac Arrest. Encyclopedia of Molecular Mechanisms of Disease, SPi-BPO, 2008. pp 271-272.
2. **Roden DM**, **Book Editor**: Cardiovascular Genetics and Genomics. AHA Clinical Series, Wiley-Blackwell, Chichester, West Sussex. 2009.
3. **Roden DM**: ASCPT remembers Jason Morrow. Clin Pharmacol Ther 2009;85:121–122.
4. **Roden DM**, Stein CM: **Editorial statement** – Clopidogrel and the concept of high risk pharmacokinetics. Circulation 2009;119:2127–2130. PMID:19398674
5. Darbar D, **Roden DM**: Therapy of Rhythm Disorders, Pharmacology and Therapeutics, Principles to Practice, Waldman S and Terzic A, eds., Elsevier, Philadelphia PA 2009, pp 367-87.
6. **Roden DM**: **Chapter** – Pharmacogenomics of Cardiac Arrhythmias and Impact on Drug Therapy, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology: From Cell to Bedside, 5th edition, W.B. Saunders, Philadelphia PA, 2009, pp 547–53.
7. **Roden DM**: **Chapter** - The Principles of Drug Therapy, in Libby P, Bonow R, Mann D, Zipes D (eds): Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8th Edition, Elsevier, Philadelphia PA, 2008, pp 57–66.
8. **Roden DM**: **Chapter** – Toxicology and Genetics of Adverse Events, in Robertson D, Williams G (eds): Clinical and Translational Science, Principles of Human Research, Elsevier, San Diego CA, 2009, pp 339-44.
9. **Roden DM**, Kannankeril P, Darbar D: Arrhythmia Pharmacogenomics: Methodological Considerations. Current Pharmaceutical Design 2009;15:3734–3741. PMID:19925424 PMCID:PMC2788624
10. Raj S, Stein CM, Saavedra P, **Roden DM**: Cardiovascular effects of non-cardiovascular drugs. Circulation 2009;120:1123–32. PMID:19770411 PMCID: PMC2773827
11. Anderson ME and **Roden DM**: **Chapter -** Basic Cardiac Electrophysiology and Anatomy, in Dimarco J and Crawford M (eds): A Textbook of Cardiology, 3rd ed., Mosby, 2010, pp 653–665.
12. **Roden DM**: Editorial - Brugada syndrome: lots of questions, some answers. Heart Rhythm. 2010 Jan;7(1):47-9. doi: 10.1016/j.hrthm.2009.10.016. PMID:20129284
13. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, **Roden DM**, Zareba W: Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College Of Cardiology Foundation. Circulation. 2010 Mar 2;121(8):1047-60. doi: 10.1161/CIRCULATIONAHA.109.192704. Epub 2010 Feb 8. J Am Coll Cardiol. 2010 Mar 2;55(9):934-47. doi: 10.1016/j.jacc.2010.01.001. PMID:20185054 PMCID:PMC3057430
14. Oshiro C, Thorn CF, **Roden DM**, Klein TE, Altman RB: *KCNH2* pharmacogenomics summary. Pharmacogenet Genomics 2010,20:775–777. Epub 2010 Feb 10. PMID:20150828 PMCID:PMC3086352
15. **Roden DM**, Wilke RA, Kroemer HK, Stein CM: Pharmacogenomics: The genetics of variable drug responses. Circulation. 2011 Apr 19;123(15):1661-70. doi: 10.1161/CIRCULATIONAHA.109.914820. PMID:21502584 PMCID:PMC3093198
16. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, **Roden DM**: Genome-Wide Association Studies in Pharmacogenomics: Successes and Lessons. Pharmacogenet Genomics. 2013 Aug;23(8):383-94. doi: 10.1097/FPC.0b013e32833d7b45. PMID:20639796 PMCID:PMC3003940
17. **Roden DM**, Shuldiner AR: **Editorial**: Responding to the Clopidogrel Warning by the US Food and Drug Administration: Real Life Is Complicated. Circulation. 2010 Aug 3;122(5):445-8. doi: 10.1161/CIRCULATIONAHA.110.973362. Epub 2010 Jun 28. PMID:20585014 PMCID:PMC2921991
18. **Roden DM**: **Editorial**: Genetic testing in subjects with no clinical abnormality: the tip of a huge iceberg. J Am Coll Cardiol. 2011 Jan 4;57(1):60-2. doi: 10.1016/j.jacc.2010.08.622. PMID:21185502
19. Fishman GI, Chugh S, DiMarco J, Albert C, Anderson ME, Bonow RO, Buxton A, Chen PS, Estes M, Jouven X, Kwong R, Lathrop D, Mascette A, Nerbonne J, O’Rourke B, Page R, **Roden DM**, Rosenbaum DS, Sotoodehnia N, Trayanova N, Zheng ZJ: Sudden Cardiac Death Prediction and Prevention: a Report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation. 2010 Nov 30;122(22):2335-48. doi: 10.1161/CIRCULATIONAHA.110.976092. PMID:21147730 PMCID:PMC3016224
20. Kannankeril P, **Roden DM**, Darbar D: Drug-induced long QT syndrome. Pharmacol Rev 2010 Dec;62:760–81. PMID:21079043 PMCID:PMC2993258
21. **Roden DM**: **Chapter** - Principles of Clinical Pharmacology. In 18th Edition of Harrison’s Principles of Internal Medicine, McGraw-Hill, 2011, pp 13-25.
22. Altman RB, Kroemer HK, McCarty CA, Ratain MJ, **Roden D**: Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet 2011 Jan;12:69–73. Epub 2010 Nov 30. PMID:21116304 PMCID:PMC3098748
23. McCarty CA, Chisholm RL, Chute CG, Kullo I, Jarvik G, Larson EB, Li R, Masys DR, Ritchie MD, **Roden DM**, Struewing JP, Wolf WA and the eMERGE team: The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Medical Genomics 2011;4:13 [published on-line Jan 26, 2011]. PMID:21269473 PMCID:PMC3038887
24. **Roden DM**: Personalized medicine and the genotype-phenotype dilemma. J Interv Card Electrophysiol 2011;31:17–23. PMID:21476088 PMCID:PMC3123434
25. **Roden DM** and Tyndale RF: Pharmacogenomics at the Tipping Point: Challenges and Opportunities. Clin Pharmacol Ther 2011;89:323–7. PMID:21326256
26. Wilke RA, Xu H, Denny JC, **Roden DM**, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G: The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 2011;89:379–86. PMID:21248726 PMCID:PMC3204342
27. Ashley E, Hershberger RE, Caleshu C, Ellinor PT, Garcia JGN, Herrington DM, Ho YC, Johnson JA, Kittner SJ, MacRae CA, Mudd-Martin G, Rader DJ, **Roden DM**, Scholes D, Sellke F, Towbin JA, VanEyk J, Worrall BB: Genetics and cardiovascular disease: A policy statement from the American Heart Association. Circulation 2012;126:142–157. PMID:22645291 PMCID:PMC3721666

1. **Roden DM**, Johnson JA, Kimmel S, Krauss RA, Medina MW, Shuldiner A, Wilke RB: Cardiovascular Pharmacogenomics. Circ Res 2011;109:807–820. PMID:21921273 PMCID:PMC3201825
2. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, **Roden DM**, Klein TE, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (*CYP2C19*) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011 Aug;90):328-32. PMID:21716271 PMCID:PMC3234301
3. **Roden DM**, Abraham RL: Refining Repolarization Reserve. Heart Rhythm 2011;11:1756-7. PMID:21708111 PMCID:PMC3923504

1. Pirmohamed M, Aithal GP, Behr E, Daly A, **Roden D**: The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 2011;89:784-5. PMID:21593754
2. **Roden DM**: **Chapter** - The Principles of Drug Therapy, in Bonow R, Mann D, Zipes D, Libby P (eds): Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 9th Edition, Elsevier, Philadelphia PA, 2011, pp 91-98.
3. Wells QS, Delaney JT, **Roden DM**: Genetic determinants of response to cardiovascular drugs. Current Opinion in Cardiology 2012;27:253-61. [Epub ahead of print Feb 29] PMID:22382501 PMCID:PMC3874723

1. **Roden DM**, Xu H, Denny JC, Wilke RA: Electronic Medical Records as a tool in Clinical Pharmacology: Opportunities and Challenges. Clin Pharmacol Ther 2012;6:1083-1086. PMID:22534870 PMCID:PMC3819803
2. Musunuru K, **Roden DM**, Boineau R, Bristow MR, McCaffrey TA, Newton-Cheh C, Paltoo D, Rosenberg Y, Wohlgemuth JG, Zineh I, Hasan AAK: Cardiovascular Pharmacogenomics: Current Status and Future Directions—Report of a National Heart, Lung, and Blood Institute Working Group. J Am Heart Assoc 2012;1:e000554. PMID:23130127 PMCID:PMC3487365
3. Johnson JA, **Roden DM**, Lesko LJ, Ashley E, Klein TE, Shuldiner AR: Clopidogrel: A case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012;91:774-6. PMID:22513313 PMCID:PMC3382015
4. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, **Roden DM**, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M: The Clinical Pharmacogenomics Implementation Consortium: CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012;92:112–117. PMID:22617227 PMCID:PMC3384438
5. **Roden DM: Chapter** – Pharmacogenomics of Cardiac Arrhythmias and Impact on Drug Therapy, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology: From Cell to Bedside, 5th edition, W.B. Saunders, Philadelphia PA, 2009, pp 547–53.
6. Manolio TA, Chisholm R, Ozenberger B, **Roden DM**, Williams M, Wilson R, Bick D, Bottinger E, Brilliant M, Eng C, Frazer K, Korf B, Ledbetter D, Lupski J, Marsh C, Mrazek D, Murray M, O’Donnell P, Rader D, Relling M, Shuldiner A, Valle D, Weinshilboum R, Green E, Ginsburg GS: Implementing genomic medicine in the clinic: the future is here. Genet Med 2013;15:258–267. 2013 Jan 10. doi: 10.1038/gim.2012.157. [Epub ahead of print] PMID:23306799 PMCID:PMC3835144
7. Behr ER, **Roden DM**: Drug-induced arrhythmia: pharmacogenomic prescribing. Invited review. European Heart Journal 2013;34:89–95. PMID:23091201 PMCID:PMC3538275
8. Lieb W, Völzke H, Pulley JM, **Roden DM**, Kroemer HK: Strategies for personalized medicine-based research and implementation in the clinical workflow. Clinical Pharmacology & Therapeutics 2012;92;443–445. PMID:22910438
9. Grace AA, **Roden DM**: Systems biology and cardiac arrhythmias. The Lancet 2012;380:1498–1508. PMID:23101717 PMCID:PMC3745651
10. Kullo IJ, Jarvik GP, Manolio TA, Williams MS, **Roden DM**: Leveraging the electronic health record to implement genomic medicine. Genet Med 2013 Apr;15(4):270–1. 2012 Sep 27. doi: 10.1038/gim.2012.131. [Epub ahead of print] PMID:23018749 PMCID:PMC4206937
11. **Roden DM**: Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics? Can J Cardiol. 2013;29:58–66. PMID:23200096 PMCID:PMC3529768
12. **Roden DM**, Hong CC: Stem Cell-Derived Cardiomyocytes as a Tool for Studying Proarrhythmia: A Better Canary in the Coal Mine? Circulation 2013 Apr 23;127(16):1641–3. 2013 Mar 21 [Epub ahead of print]. PMID:23519759 PMCID:PMC3954984
13. Curtis MJ, Hancox JC, Farkas A, Wainwright CL, Stables CL, Saint DA, Clements-Jewery H, Lambiase PD, Billman GE, Janse MJ, Pugsley MK, Ng GA, **Roden DM**, Camm AJ, Walker MJA: The Lambeth Conventions (II): Guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacology and Therapeutics 2013;139:213–248. Available online 12 April 2013 doi: 10.1016/j.pharmthera.2013.04.008. PMID:23588158
14. Darbar D, **Roden DM**: Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nat Rev Cardiol 2013 June;10(6):317–29. doi: 10.1038/nrcardio.2013.53. Epub 2013 April 16. PMID:23591267 PMCID:PMC3664212
15. Shuldiner AR, Relling MV, Peterson JF, Hicks K, Freimuth RR, Sadee W, Pereira NL, **Roden DM**, Johnson JA, Klein TE: The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clin Pharmacol Ther 2013;94(2):207–210. Mar 19. doi: 10.1038/clpt.2013.59. [Epub ahead of print] PMID:23588301 PMCID:PMC3720847
16. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, **Roden DM**, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 Update. Clin Pharmacol Ther 2013;94(2):317–323. May 22. doi: 10.1038/clpt.2013.105. [Epub ahead of print] PMID:23698643 PMCID:PMC3234301
17. **Roden DM**, Tyndale RF: Genomic Medicine, Precision Medicine, Personalized Medicine: What's in a Name? Clin Pharmacol Ther 2013 Aug;94(2):169–72. PMID:23872826 PMCID:PMC3965175
18. Weeke P, **Roden DM**: Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep 2013;15:376. PMID:23689943 PMCID:PMC3941471
19. Weeke P, **Roden DM**: Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med 2014;65:81-94. doi: 10.1146/annurev-med-101712-122545. Epub 2013 Oct 2. PMID:24111889 PMCID:PMC4081861
20. **Roden DM**: **Chapter** - Principles of Clinical Pharmacology. In 19th Edition of Harrison’s Principles of Internal Medicine, McGraw-Hill, 2015, pp 31-45.
21. **Roden DM:** **Editorial:** Atrial fibrillation genomics: Time to take the next step. J Am Coll Cardiol 2014 Jan 17. pii: S0735-1097(14)00172-7. doi: 10.1016/j.jacc.2013.12.016. [Epub ahead of print] PMID:24486270
22. **Roden DM**, Knollmann BC: **Editorial:** Dantrolene: from better bacon to a treatment for ventricular fibrillation. Circulation 2014;129:834-6. PMID:24403562 PMCID:PMC3959791
23. **Roden DM**: Personalized medicine to treat arrhythmias. Current Opinion in Pharmacology 2014, 15:61–67. PMID:24721655 PMCID:PMC3984450
24. Karnes JH, Van Driest S, Bowton EA, Weeke PE, Mosley JD, Peterson JF, Denny JC, **Roden DM**. Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med 2014 Mar-Apr;6(2):125-35. PMID:24319008 PMCID:PMC3944797
25. **Roden DM**: **Editorial:** The Brugada ECG and schizophrenia. Circ Arrhythm Electrophysiol 2014;7:365-367. PMID:24951569
26. Crawford DC, Crosslin DR, Tromp G, Kullo IJ, Kuivaniemi H, Hayes MG, Denny JC, Bush WS, Haines JL, **Roden DM**, McCarty CA, Jarvik GP, Ritchie MD: eMERGEing progress in genomics-the first seven years. Front Genet. 2014 Jun 17;5:184. doi: 10.3389/fgene.2014.00184. eCollection PMID:24987407 PMCID:PMC4060012
27. Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC, Chakravarti A, Chantratita W, Chisholm RL, Dissanayake VHW, Dzau VJ, Frebourg T, Han BG, Hubbard T, Kolbe A, Korf B, Kubo M, Leego E, Mahasirimongkol S, Majumdar PP, Matthijs G, McLeod H, Metspalu A, Meulien P, Miyano S, Moses K, Naparstek Y, Norstedt I, Okamura N, O’Rourke P, Patrinos G, Rehm HL, Relling MV, Rennert G, Lyman Rodriguez L, **Roden DM**, Shuldiner AR, Sinha S, Tan P, Ulfendahl M, Williams MS, Wong J, Li E, Green ED, Ginsburg GS: Implementing Genomic Medicine Globally: We Are Not Alone. Science Translational Medicine 03 Jun 2015: Vol. 7, Issue 290, pp. 290ps13. DOI: 10.1126/scitranslmed.aab0194.
28. **Roden DM**: **Chapter**: Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs. Cardiac Sodium Channel Disorders in Cardiac Electrophysiology Clinics, Elsevier. Abriel H, ed. 2014, pp 695-704.
29. **Roden DM**: **Chapter** - Drug Therapeutics and Personalized Medicine, in Bonow R, Mann D, Zipes D, Libby P (eds): Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 10th Edition, Elsevier, Philadelphia PA, 2014, pp 75-83.
30. Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, Califf RM, Calkins H, Chen PS, Chiamvimonvat N, Darbar D, Eckhardt L, Ellinor PT, Exner DV, Fogel RI, Gillis AM, Healey J, Hohnloser SH, Kamel H, Lathrop DA, Lip GY, Mehra R, Narayan SM, Olgin J, Packer D, Peters NS, **Roden DM**, Ross HM, Sheldon R, Wehrens XH: Progress towards the Prevention and Treatment of Atrial Fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, D.C., December 9-10, 2013. Heart Rhythm. 2014 Nov 18. pii: S1547-5271(14)01290-9. doi: 10.1016/j.hrthm.2014.11.011. [Epub ahead of print]. PMID:25460864 PMCID:PMC4425127
31. **Roden DM**: **Chapter** – Genomics of the Drug-Induced Long-QT Syndrome in Altman R, Flockhart D, Goldstein D, (eds): Principles of Pharmacogenetics and Pharmacogenomics, Cambridge University Press, New York NY, 2012, pp 136-144.
32. **Roden DM: Chapter** – Lidocaine Use in a Patient with Old Myocardial Infarction in Sra J, Akhtar M, Natale A, Wilbert D, (eds): Practical Electrophysiology the Drug-Induced Long, Cardiotext Publishing LLC, Minnneapolis MN, 2015, pp 458-460.
33. **Roden DM**. Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet. 2015 Jul 16. doi: 10.1038/jhg.2015.78. [Epub ahead of print] Review. PMID:26178435 PMCID:PMC4849475
34. Hall JL, Ryan JJ, Bray B, Brown C, Lanfear D, Newby K, Relling M, Risch NJ, **Roden DM**, Shaw SY, Tcheng JE, Tenenbaum J, Wang TN, Weintraub WS, on behalf of the American Heart Association Advocacy Coordinating Committee: Merging Electronic Health Record Data and Genomics for Cardiovascular Research: An Advisory Statement from the American Heart Association. Circ Cardiovasc Genet. 2016 Mar 14. pii: HCG.0000000000000029. [Epub ahead of print] PMID:26976545 PMCID:PMC5646218
35. Mital S, Musunuru K, Garg V, Russell MW, Lanfear DE, Gupta RM, Hickey KT, Ashley EA, Ackerman MJ, Perez MV, **Roden DM**, Woo D, Fox CS, Ware S, on behalf of the American Heart Association Council on Functional Genomics and Translational Biology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Stroke Council, Council on Lifestyle and Cardiometabolic Health, Council on Quality of Care and Outcomes Research: Cardiovascular Genetics Education: A Scientific Statement from the American Heart Association, submitted.
36. **Roden DM: Chapter** – Adverse Drug Events, in Robertson D, Williams G (eds): Clinical and Translational Science, Principles of Human Research, 2nd ed. Elsevier, 2017, pp 389-396.
37. **Roden DM: Chapter** – Arrhythmia Genomics, in Ginsburg G, Willard H (eds): Genomic and Precision Medicine, 3rd ed. Elsevier 2017, pp 179-196.
38. **Roden DM: Chapter** – Arrhythmia pharmacogenomics, in Zipes DP, Jalife J, Stevenson WS (eds): Cardiac electrophysiology: from cell to bedside, 7th ed. Elsevier.
39. **Roden DM: Chapter** – Pharmacogenetics of potassium channel blockers, in Shenasa M, Nattel S (eds): Cardiac Potassium Channel Disorders: From Basic to Clinics. EP Clinic June 2016. Elsevier.
40. **Roden DM:** Predicting drug-induced QT prolongation and torsades de Pointes. J Physiol. 2016 May 1;594(9):2459-68. doi: 10.1113/JP270526. Epub 2016 Jan 18. PMID:26660066 PMCID:PMC4850203
41. **Roden DM**, Denny JC: Integrating electronic health record genotype and phenotype datasets to transform patient care. Clin Pharmacol Ther. 2016 Mar;99(3):298-305. doi: 10.1002/cpt.321. PMID:26667791 PMCID:PMC4760864
42. Denny JC, Bastarache L, **Roden DM**: Phenome-wide association studies as a tool to advance precision medicine. Annu Rev Genomics Hum Genet. 2016;17:353-73. PMID: 27147087 PMCID:PMC5480096
43. **Roden DM**: Chapter - Antiarrhythmic drugs, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Brunton LL, Knollman KC, editors. 13th edition, New York: McGraw-Hill, 2017.
44. **Roden DM**: Chapter - Pharmacogenetics, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Brunton LL, Knollman KC, editors. 13th edition, New York: McGraw-Hill, 2017.
45. MacRae CA, **Roden DM**, Loscalzo J: The Future of Cardiovascular Therapeutics. Circulation. 2016;133:2610-2617. doi: 10.1161/CIRCULATIONAHA.116.023555. PMID:27324356
46. Schildcrout JS, Denny JC, **Roden DM**: On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database. Drug Saf. 2016 Nov 21. [Epub ahead of print] PMID:27873192 PMCID:PMC5225656
47. **Roden DM**: Editiorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. Trends Cardiovasc Med. 20 Sep 2016, 27(3):203-206. DOI: 10.1016/j.tcm.2016.09.004. PMID:27771237 Reprinted: 2017 Jul;27(5):360-362. doi: 10.1016/j.tcm.2017.05.008. Epub 2017 Jun 7. PMID:28601251
48. Mital S, Musunuru K, Garg V, Russell MW, Lanfear DE, Gupta RM, Hickey KT, Ackerman MJ, Perez MV, **Roden DM**, Woo D, Fox CS, Ware S; American Heart Association Council on Functional Genomics and Translational Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Stroke Council; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research: Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. Circ Cardiovasc Genet. 2016 Oct;9(5):448-467. PMID:27672144
49. **Roden DM**, Mosley JD, Denny JC: Finding a Needle in a QT Interval Big Data Haystack: The Role for Orthogonal Datasets. J Am Coll Cardiol. 2016 Oct 18;68(16):1765-1768. doi: 10.1016/j.jacc.2016.08.012. PMID:27737743
50. **Roden DM**: **Chapter** – Principles of Clinical Pharmacology. In 20th Edition of Harrison’s Principles of Internal Medicine, McGraw-Hill, 2017.
51. **Roden DM**: **Chapter** – Pharmacogenomics. In 20th Edition of Harrison’s Principles of Internal Medicine, McGraw-Hill, 2017.
52. **Roden DM**: **Chapter** - Drug Therapeutics and Personalized Medicine, in Bonow R, Mann D, Zipes D, Libby P (eds): Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 11th Edition, Elsevier, Philadelphia PA, 2017.
53. **Roden DM**: **Editorial** – Pharmacogenetic implementation lessons from the “real world”. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.584. [Epub ahead of print]. PMID:27981579 PMCID:PMC5474210
54. **Roden DM**: Phenome-wide association studies: A new method for functional genomics in humans. J Physiol. 2017 Feb 23. doi: 10.1113/JP273122. [Epub ahead of print] PubMed PMID:28229460 PMCID:PMC5471509
55. Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, Worthey E, Chisholm RL, Green ED, Jacob HJ, McLeod HL, **Roden DM**, Rodriguez LL, Williams MS, Cooper GM, Cox NJ, Herman GE, Kingsmore S, Lo C, Lutz C, MacRae CA, Nussbaum RL, Ordovas JM, Ramos EM, Robinson PN, Rubinstein WS, Seidman CE, Stranger BE, Wang H, Westerfield M, Bult C: Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research. Cell 2017 Mar 23;169(1):6-12. PMID:28340351 PMCID:PMC5511379
56. Relling M, Krauss R, Roden D, Klein T, Fowler D, Terada N, Lin L, Riel-Mehan M, Do T, Kubo M, Yee SW, Johnson G, Giacomini K: The New Pharmacogenomics Research Network (PGRN): An open community catalyzing research and translation in precision medicine. Clin Pharmacol Ther. 2017 Aug 10. doi: 10.1002/cpt.755. [Epub ahead of print] PMID:28795399 PMCID:PMC5706548
57. Hill JA, Ardehali R, Clarke KT, Del Zoppo GJ, Eckhardt LL, Griendling KK, Libby P, **Roden DM**, Sadek HA, Seidman CE, Vaughan DE; American Heart Association Council on Basic Cardiovascular Sciences; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Stroke Council: Fundamental Cardiovascular Research: Returns on Societal Investment: A Scientific Statement From the American Heart Association. Circ Res. 2017 Jul 21;121(3):e2-e8. doi: 10.1161/RES.0000000000000155. Epub 2017 Jun 26. PMID:28652256
58. **Roden DM: Chapter** – Genomics of Cardiac Arrhythmias in Cardiac Arrhythmias, Pacing and Sudden Death. Springer Verlag, 2017
59. Denny J, Van Driest S, Wei WQ, **Roden D**: The influence of big (clinical) data and genomics on precision medicine and drug development. Clin Pharmacol Ther. 2017 Nov 24. doi: 10.1002/cpt.951. [Epub ahead of print] PMID:29171014 PMCID:PMC5805632
60. **Roden DM**, Van Driest S, Mosley J, Wells QS, Denny JC, Peterson JF: Opportunities and challenges in cardiovascular pharmacogenomics: from discovery to implementation. Circ Res. 2018 Apr 27;122(9):1176-1190. doi: 10.1161/CIRCRESAHA.117.310965. Review. PMID:29700066 PMCID:PMC5926807
61. Robinson JR, Denny JC, **Roden DM**, Van Driest SL: Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. Clin Transl Sci. 2017 Nov 17. doi: 10.1111/cts.12522. [Epub ahead of print] PMID:29148204 PMCID:PMC5866959
62. **Roden DM**, Van Driest SL, Mosley JD, Wells QS, Robinson JR, Denny JC, Peterson JF: Benefit of pre-emptive pharmacogenetic information on clinical outcome. Clin Pharmacol Ther. 2018 Jan 29. doi: 10.1002/cpt.1035. PMID:29377064 PMCID: PMC6134843
63. Giudicessi JR, **Roden DM**, Wilde A, Ackerman MJ: Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. Circulation. 2018 Feb 6;137(6):619-630. doi: 10.1161/CIRCULATIONAHA.117.030142. PMID:29431662 PMCID:PMC6383807
64. Volpi S, Bult C, Chisholm R, Deverka P, Ginsburg G, Jacob H, Kasapi M, McLeod H, **Roden D**, Williams M, Green E, Rodriguez L, Aronson S, Cavallari L, Denny J, Dressler L, Johnson J, Klein T, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik L, Rehm H, Ritchie M, Skaar T, Wagle N, Weinshilboum R, Weitzel K, Wildin R, Wilson J, Manolio T, Relling M: Research directions in the clinical implementation of pharmacogenomics - An Overview of US programs and projects. Clin Pharmacol Ther. 2018 May;103(5):778-786. doi: 10.1002/cpt.1048. Epub 2018 Mar 30. PMID:29460415 PMCID:PMC5902434
65. Alexandre J, Moslehi J, Bersell KR, Funck-Brentano C, **Roden DM**, Salem JE: Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018 Apr 24. pii: S0163-7258(18)30072-X. doi: 10.1016/j.pharmthera.2018.04.009. [Epub ahead of print] PMID:29698683
66. **Roden DM**, Glazer AM, Kroncke B: **Editorial:** Arrhythmia genetics: Not dark and lite, but 50 shades of gray. Heart Rhythm. 2018 Apr 27. pii: S1547-5271(18)30393-X. doi: 10.1016/j.hrthm.2018.04.031. [Epub ahead of print] PMID:29709575 PMCID:PMC6590670
67. **Roden DM**: Pharmacogenetics of Potassium Channel Blockers. Card Electrophysiol Clin. 2016 Jun;8(2):385-93. doi: 10.1016/j.ccep.2016.02.003. PMID:27261829 PMCID:PMC4893809
68. **Roden DM: Editorial:** Growing pains in cardiovascular genetics. Circulation. 2018 Sep 18;138(12):1206-1209. doi: 10.1161/CIRCULATIONAHA.118.035933. No abstract available. PMID:30354441 PMCID:PMC6206881
69. **Roden DM**, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL: Pharmacogenomics. Lancet. 2019 Aug 10;394(10197):521-532. doi: 10.1016/S0140-6736(19)31276-0. Epub 2019 Aug 5. PMID:31395440 PMCID:PMC6707519
70. Wise AL, Manolio TA, Mensah GA, Peterson JF, **Roden DM**, Tamburro C, Williams MS, Green ED: Genomic Medicine for Undiagnosed Diseases. Lancet. 2019 Aug 10;394(10197):533-540. doi: 10.1016/S0140-6736(19)31274-7. Epub 2019 Aug 5. PMID:31395441 PMCID:PMC6709871
71. Manolio TA, Bult C, Chisholm RL, Deverka PA, Ginsburg GS, Green ED, McLeod HL, Mensah GA, Relling MV, **Roden DM**, Rodriguez LL, Rowley R, Tamburro C, Williams MS: Opportunities, Resources, and Techniques for Implementing Genomics in Clinical Care. Lancet. 2019 Aug 10;394(10197):511-520. doi: 10.1016/S0140-6736(19)31140-7. Epub 2019 Aug 5. PMID:31395439 PMCID:PMC6699751
72. Peterson JF, **Roden DM**, Orlando LA, Ramirez AH, Mensah G, Williams MS: Building Evidence and Measuring Clinical Outcomes for Genomic Medicine. Lancet. 2019 Aug 17;394(10198):604-610. doi: 10.1016/S0140-6736(19)31278-4. Epub 2019 Aug 5. PMID:31395443 PMCID:PMC6730663
73. **Roden DM**: A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019 Apr 15;115(5):895-903. doi: 10.1093/cvr/cvz013. PMID:30689740
74. **Roden DM**, Below JE: My Cousin Also Has Atrial Fibrillation: Family Relationships in a Genomic Era. JACC Clin Electrophysiol. 2019 Apr;5(4):501-503. doi: 10.1016/j.jacep.2019.03.002. PMID:31000105
75. Bowman L, Baras A, Bombien R, Califf RM, Chen Z, Gale CP, Gaziano JM, Grobbee DE, Maggioni AP, Muse ED, **Roden DM**, Schroeder S, Wallentin L, Casadei B: Understanding the Use of Observational and Randomized Data in Cardiovascular Medicine. Accepted for publication, European Heart Journal.
76. **DM Roden**: **Editorial**: Clopidogrel Pharmacogenetics — Why the Wait? N Engl J Med. 2019 Oct 24;381(17):1677-1678. doi: 10.1056/NEJMe1911496. PMID:31644850
77. **Roden DM**: John A. Oates: A Founding Father of Clinical Pharmacology. Clin Pharmacol Ther. 2019 Dec;106(6):1155-1157. doi: 10.1002/cpt.1614. Epub 2019 Sep 16. No abstract available. PMID: 31529489

# D. ABSTRACTS

1. **Roden DM**, Reele SB, Smith RF, Oates JA, Woosley RL: Tocainide therapy for refractory ventricular arrhythmias. Clin Res 1979;27:200A.
2. Reele SB, **Roden DM**, Woosley RL, Oates JA: High incidence of adverse reactions during chronic disopyramide therapy. Clin Res 1979;27:197A.
3. Woosley RL, **Roden DM**, Reele SB, Smith RF, Wilkinson GR, Oates JA: Comparative clinical pharmacology of procainamide and N-acetyl­pro­cainamide (acecainide). Circulation 1979;60:ll323.
4. **Roden DM**, Reele SB, Oates JA, Woosley RL: ECG interval prolongation during encainide therapy: A guide to drug effect. Clin Res 1979;27:733A.
5. **Roden DM**, Reele SB, Oates JA, Woosley RL: Abolition of ventricular arrhythmias during chronic oral therapy with encainide in man. Clin Res 1979;27:776A.
6. **Roden DM**, Reele SB, Oates JA, Woosley RL: ECG interval prolongation during encainide therapy. Am J Cardiol 1980;45:473.
7. **Roden DM**, Reele SB, Oates JA, Woosley RL: Abolition of ventricular arrhythmias during chronic oral therapy with encainide in man. Am J Cardiol 1980;45:451.
8. Duff HJ, **Roden DM**, Smith RF, Dawson A, Oates JA, Woosley RL: Time-dependent changes in the repetitive ventricular response (RVR) mimic drug effect. Clin Res 1980;28:167A.
9. Woosley RL, **Roden DM**, Duff HJ, Oates JA: Abolition of chronic ventricular arrhythmias with encainide therapy. Fed Proc 1980;39:746.
10. Woosley RL, **Roden DM**, Duff HJ, Oates JA: Abolition of chronic ventricular arrhythmias with encainide therapy. World Conference on Clinical Pharmacology, August 1980.
11. Duff HJ, **Roden DM**, Smith RF, Dawson AK, Wood AJJ, Oates JA, Woosley RL: Electrophysiologic actions of high dose propranolol independent of beta blockade. Circulation 1980;62:SIII-11.
12. **Roden DM**, Duff HJ, Wang T, Woosley RL: Contribution of a metabolite to the ECG and antiarrhythmic actions of encainide. Circulation 1980;62:SIII-141.
13. Duff HJ, **Roden DM**, Woosley RL: Abolition of resistant ventricular arrhythmias by twice daily dosing with flecainide. Circulation 1980;62:SIII-181.
14. Duff HJ, **Roden DM**, Primm RK, Carey EL, Oates JA, Woosley RL: Mexiletine for resistant ventricular tachycardia: Comparison with lidocaine and enhancement of efficacy by combination with quinidine. Clin Res 1980;28:878A.
15. Duff HJ, **Roden DM**, Carey EL, Woosley RL, Smith RF: Efficacy of radiofrequency ventricular burst-pacing for recurrent ventricular tachycardia. Clin Res 1980;28:808A.
16. Duff HJ, **Roden DM**, Primm RK, Carey EL, Oates JA, Woosley RL: Mexiletine for resistant ventricular tachycardia: Comparison with lidocaine and enhancement of efficacy by combination with quinidine. Am J Cardiol 1981;47:438.
17. Duff HJ, **Roden DM**, Carey EL, Hammon JW, Woosley RL, Smith RF: Benefits and risks of combined burst pacing and drug therapy for recurrent ventricular tachycardia. Am J Cardiol 1981;47:476.
18. Carey EL, Duff HJ, **Roden DM**, Smith RF, Primm RK, Oates JA, Woosley RL: Encainide: Lack of efficacy in drug-resistant sustained ventricular tachycardia. Clin Res 1981;29:1­80A.
19. Duff HJ, Dawson AK, Carey EL, **Roden DM**, Oates JA, Smith RF, Woosley RL: The electrophysiologic actions of O-demethyl encainide: An active metabolite. Clin Res 1981;29:270A.
20. Woosley RL, **Roden DM**, Duff HJ, Carey EL, Wood AJJ, Wilkinson GR (intr by Oates JA): Co-inheritance of deficient oxidative metabolism of encainide and debrisoquine. Clin Res 1981;29:501A.
21. Carey EL, Duff HJ, **Roden DM**, Primm RK, Oates JA, Woosley RL: Relative electrocardiographic and antiarrhythmic effects of encainide and its metabolites in man. Circulation 1981;64:SIV-264.
22. Dawson AK, Duff HJ, Woosley RL, **Roden DM**, Smith RF: Paradoxical responses to O-demethyl encainide in a canine infarction model. Circulation 1981;64:SIV-273.
23. Wang T, **Roden DM**, Wolfenden HT, Woosley RL, Wood AJJ: Pharmacokinetics of encainide and it metabolites in man. Clin Pharmacol Ther 1982;31:278.
24. Wang T, Duff HJ, Hopkins JT, **Roden DM**, Primm RK, Smith RF, Oates JA, Woosley RL: Suppression of complex ventricular arrhythmias by timolol. Am J Cardiol 1982;49:1018.
25. Duff HJ, **Roden DM**, Oates JA, Robertson DH, Woosley RL: Bretylium: Relationships among plasma norepinephrine, arrhythmogenicity, blood pressure responses, and adrenergic blockade. Clin Res 1982;30:251A.
26. Wang T, Duff HJ, **Roden DM**, Primm RK, Woosley RL: Suppression of refractory arrhythmias with flecainide. Circulation 1982;66:SII-69.
27. Duff HJ, Wood AJJ, Dawson AK, **Roden DM**, Primm RK, Smith RF, Woosley RL: d-Propranolol: Non-adrenergically mediated electrophysio­logic actions in man. Circulation 1982;66:SII-372.
28. **Roden DM**, Dawson AK, Duff HJ, Woosley RL, Smith RF: Effects of O-demethyl encainide in a canine model in inducible ventricular tachycardia. Clin Res 1982;30:868A.
29. Riddell JG, McAllister CB, Wilkinson GR, Wood AJJ, **Roden DM**: A new simple method for rapidly achieving constant plasma drug concentrations: Application to lidocaine. Clin Pharmacol Ther 1983;33:260.
30. Forman MB, Siddoway LA, Cain MA, Wang T, Bergstrand RH, Wilkinson GR, Woosley RL, **Roden DM**: Effects of enzyme induction on quinidine pharmacodynamics. Clin Res 1983;31:247A.
31. Duff HJ, **Roden DM**, Kolodgie F, Wang T, Woosley RL: Synergistic electrophysiologic actions of mexiletine and quinidine. Clin Res 1983;31:180A.
32. Wang T, Bergstrand RH, Siddoway LA, Duff HJ, Woosley RL, **Roden DM**: Dissociation of antiarrhythmic and beta-blocking actions of sotalol in man. Clin Res 1983;31:255A.
33. **Roden DM**, Wang T, Bergstrand RH, Siddoway LA, Duff HJ, Woosley RL: Dissociation of antiarrhythmic and beta-blocking actions of sotalol in man. II World Conference in Clinical Pharmacology, Washington DC, 1983, p 105.
34. Bergstrand RH, Wang T, **Roden DM**, Avant GR, Sutton WW, Siddoway LA, Wolfenden H, Woosley RL, Wilkinson GR, Wood AJJ: Effects of liver disease on encainide disposition. II World Conference in Clinical Pharmacology, Washington DC, 1983, p 11.
35. Wang T, Siddoway LA, Duff HJ, Bergstrand RH, **Roden DM**, Woosley RL: Use of individualized pharmacokinetic data to design safe and effective intravenous flecainide dosing regimens. II World Conference in Clinical Pharmacology, Washington DC, 1983, p 45.
36. Siddoway LA, Forman MB, Cain MA, Wang T, Bergstrand RH, Woosley RL, **Roden DM**: Effects of enzyme induction on quinidine pharmacodynamics. II World Conference in Clinical Pharmacology, Washington DC, 1983, p 136.
37. Siddoway LA, Bergstrand RH, Primm RK, **Roden DM**, Woosley RL: Antiarrhythmic efficacy, safety and pharmacokinetics of indecainide. Circulation 1983;68:SIII-311.
38. Wang T, Bergstrand RH, Siddoway LA, Duff HJ, Woosley RL, **Roden DM**: Dissociation of antiarrhythmic and beta-blocking actions of sotalol. Circula­tion 1983;68:SIII-270.
39. Wang T, Siddoway LA, Bergstrand RH, Duff HJ, **Roden DM**, Woosley RL: Treatment of ventricular arrhythmias with individualized intravenous flecainide dosing regimens. Circulation 1983;68:SIII-416.
40. **Roden DM**, Woosley RL, Bostick D, Bernard Y, Primm RK: Quinidine-induced long QT syndrome: Incidence and presenting features. Circulation 1983;68:SIII-276.
41. Siddoway LA, Wang T, Bergstrand RH, **Roden DM**, Woosley RL: Polymorphic oxidative metabolism of propafenone in man. Circulation 1983;68:SIII-64.
42. **Roden DM**, Hoffman BF: Determinants of action potential prolongation by quinidine. J Am Coll Cardiol 1984;3:617.
43. **Roden DM**, Hoffman BF: Induction of early afterdepolarizations by low concentrations of quinidine *in vitro*: Relation to cycle length and potassium. J Am Coll Cardiol 1984;3:617.
44. Siddoway LA, Thompson KA, Bergstrand RH, Wang T, **Roden DM**, Woosley RL: Safety and efficacy of propafenone in treatment of refractory ventricular arrhythmias. J Am Coll Cardiol 1984;3:474.
45. Kolodgie FD, Dawson AK, **Roden DM**, Smith RF, Woosley RL, Virmani R: Effect of fluosol-DA on infarct arrhythmias. Clin Res 1984;32:180A.
46. Thompson KA, **Roden DM**, Wood AJJ, Siddoway LA, Barbey JT, and Woosley RL: Suppression of ventricular arrhythmias by dextropropranolol in man. Circulation 1984;70:SII-441.
47. **Roden DM**, Woosley RL: Cycle length dependent interactions of quinidine and mexiletine. J Am Coll Cardiol 1985;5:493.
48. **Roden DM**, Arthur M, Woosley RL: Bradycardia-dependent triggered activity in the intact heart. J Am Coll Cardiol 1985;5:390.
49. Bergstrand RH, Wang T, Stone WJ, Wilkinson GR, Wolfenden HT, **Roden DM**, Woosley RL, Wood AJJ: Encainide disposition in renal failure. Clin Pharmacol Ther 1985;37:182.
50. Barbey JT, Thompson KA, **Roden DM**, Echt DS, Woosley RL: Limited effect of bepridil on chronic ventricular arrhythmias in man. Clin Res 1985;33:168A.
51. Thompson KA, Blair I, Woosley RL, **Roden DM**: Comparative *in vitro* electrophysiology of quinidine, its metabolites and dihydroquinidine. Clin Res 1985;33:298A.
52. Thompson KA, Barbey JT, Kopelman HA, Siddoway LA, Echt DS, Woosley RL, **Roden DM**: Comparison of the antiarrhythmic and adverse effects of mexiletine and tocainide in man. Clin Res 1985;33:168A.
53. Primm RK, Nadeau JH, **Roden DM**: Electrophysiologic and hemodynamic effects of alpha-2 agonists in hypertensive patients. Clin Res 1985;33:367A.
54. Siddoway LA, McAllister CB, Thompson KA, Barbey JT, Wilkinson GR, **Roden DM**, Woosley RL: Inhibition of propafenone metabolism by debrisoquine in man. Clin Res 1985;33:288A.
55. Wikswo JP Jr, Kopelman HA, **Roden DM**: Cardiac excitability and space constants measured *in vivo* using the virtual cathode effect. Circulation 1985;72:SIII-3.
56. Barbey JT, Chaffin PL, Rigby S, Thompson KA, Echt DS, Woosley RL, **Roden DM**: Pharmacology of encainide metabolites in man. Circulation 1985;72:SIII-165.
57. Barbey JT, Echt DS, Thompson KA, **Roden DM**, Woosley RL: Effect of d-sotalol on ventricular arrhythmias in man. Circulation 1985;72:SIII-170.
58. Thompson KA, Siddoway LA, Woosley RL, **Roden DM**: Potent dose-dependent electrophysiologic effects of the major metabolite of propafenone. Circulation 1985;72:SIII-233.
59. Campbell RM, Woosley RL, **Roden DM**: Lack of early afterdepolarizations despite phase 3 repolarization abnormalities due to bepridil and lidoflazine. Circulation 1985;72:SIII-381.
60. **Roden DM**, Bennett PB, Hondeghem LM: Quinidine blocks cardiac potassium channels in a time- and voltage-dependent fashion. Biophys J 1986;49:352a.
61. Kopelman HA, Bajaj AK, Wikswo JP Jr, Hondeghem LM, Woosley RL, **Roden DM**: Frequency- and direction-dependent effects of single and combination antiarrhythmic drugs on conduction velocity *in vivo*. J Am Coll Cardiol 1986;7:82A.
62. Barbey JT, Thompson KA, Echt DS, Woosley RL, **Roden DM**: Combination of low dose quinidine and tocainide in the treatment of ventricular arrhythmias in man. J Am Coll Cardiol 1986;7:108A.
63. Woosley RL, Branch RA, Weinshilboum R, Garcia KC, Martin C, **Roden DM**, Wilkinson GR: Influence of multiple metabolic polymorphisms on the generation of active metabolites of encainide in man. Clin Res 1986;34:409A.
64. Thompson KA, Murray JJ, Blair IA, Woosley RL, **Roden DM**: Plasma concentrations of quinidine, its major active metabolites, and dihydroquinidine in patients with Torsades de Pointes. Clin Res 1986;34:408A.
65. Bajaj AK, Woosley RL, **Roden DM**: Reversal of the QRS prolonging effects of O-desmethyl encainide by hypertonic saline. Clin Res 1986;34:281A.
66. Davies RF, Siddoway LA, Shaw L, Barbey JT, Lineberry MD, **Roden DM**, Woosley RL: An assessment of the pharmacokinetic and pharmacodynamic consequences of concentration dependent plasma binding of disopyramide: A comparison of regular with sustained release disopyramide. Clin Res 1986;34:396A.
67. Barbey JT, Thompson KA, Echt DS, Woosley RL, **Roden DM**: Plasma concentration-response relations and disposition of encainide metabolites in man. Clin Res 1986;34:394A.
68. **Roden DM**, Bennett PB, Snyders DJ, Hondeghem LM: Quinidine reduces IK and delays its activation. Circulation 1986;74:SII-255.
69. Davies RF, Lineberry MD, Echt DS, Lee JT, Capuzzi D, **Roden DM**, Woosley RL: Dose titration and pharmacokinetics of recainam, a new antiarrhythmic drug. Circulation 1986;74:SII-103.
70. Echt DS, Kopelman HA, Lee JT, Crawford D, Woosley RL, **Roden DM**: Control mechanisms for QT interval in man. Circulation 1986;74:SII-401.
71. Kopelman HA, Woosley RL, Lee JT, **Roden DM**, Echt DS: A comparison of the clinical electrophysiology of intravenous and oral sotalol. J Am Coll Cardiol 1987;9:49A.
72. Woosley RL, Giardina EG, **Roden DM**, Henthorn RW, Hallstrom A, the CAPS Investigators: Value of dose-titration in the cardiac arrhythmia pilot study (CAPS). J Am Coll Cardiol 1987;9:70A.
73. Bigger T, Woosley R, **Roden D**, Hallstrom A, Echt D, Greene L, Butler L, the CAPS Investigators: A placebo-controlled study of the proarrhythmic effects of Class I antiarrhythmic drugs. J Am Coll Cardiol 1987;9:245A.
74. Balser JR, **Roden DM**: Inhibitory effect of ventricular muscle on induction of early afterdepolarizations in canine false tendons. Clin Res 1987;35:260A.
75. Balser JR, Hondeghem LM, **Roden DM**: Quinidine block of IK accumulates at negative potentials. Circulation 1987;76:SIV-149.
76. Balser JR, Hondeghem LM, **Roden DM**: Amiodarone reduces time dependent IK activation. Circulation 1987;76:SIV-150.
77. Lineberry MD, Davies RF, Chaffin PL, Lee JT, Echt DS, **Roden DM**, Woosley RL: Safety and efficacy of combining encainide and lidocaine. Circulation 1987;76:SIV-511.
78. Funck-Brentano C, Jared LL, **Roden DM**, Woosley RL: Interaction of procainamide and N-acetyl-procainamide in man. Circulation 1987;76:SIV-520.
79. Balser JR, **Roden DM**: Lanthanum-sensitive current contaminates IK in guinea pig ventricular myocytes. Biophys J 1988;53:642a.
80. Balser JR, **Roden DM**, Bennett PB: A method for determining microscopic rate constants from whole cell currents. Biophys J 1988;53:543a.
81. Kroemer H, Funck-Brentano C, **Roden DM**, Wright GM, Wilkinson GR, Eichelbaum M, Woosley RL: Stereoselective disposition of propafenone during chronic oral therapy in man. FASEB J 1988;2:A608.
82. **Roden DM**, Lee JT, Woosley RL, Echt DS: A dose-ranging evaluation of antiarrhythmic drug efficacy in patients with inducible sustained ventricular tachycardia. Clin Res 1988;36:368A.
83. Balser JR, Hondeghem LM, **Roden DM**: Drug block of the delayed rectifier IK in heart: Multiple state-dependent mechanisms. Clin Res 1988;36:260A.
84. Funck-Brentano C, **Roden DM**, Woosley RL: Mechanism of the decreased heart rate by d-sotalol. Clin Res 1988;36:363A.
85. Funck-Brentano C, Kroemer H, Pavlou H, Wright GM, Woosley RL, **Roden DM**: Inhibition of propafenone metabolism by low doses of quinidine in man. Clin Res 1988;36:­363A.
86. Lee JT, Funck-Brentano C, Lineberry MD, Chaffin PL, **Roden DM**, Woosley RL: Beta receptor antagonism by propafenone in man: Influence of polymorphic metabolism. Clin Res 1988;36:294A.
87. Wikswo JP Jr, Barach JP, Altemeier WA, **Roden DM**: Measurement and modeling of virtual cathode effects in cardiac muscle. Phys Med Biol 1988;33:172.
88. Balser JR, **Roden DM**, Bennett PB: Quinidine preferentially suppresses a subconductance state of the inward rectifier. Circulation 1988;78:SII-411.
89. Funck-Brentano C, Turgeon J, Woosley RL, **Roden DM**: Reversal of encainide effects due to a genetically-determined interaction with low dose quinidine. Circulation 1988;78:SII-498.
90. Funck-Brentano C, Silberstein DJ, Wood AJJ, **Roden DM**, Woosley RL: D-sotalol-induced changes in heart rate are not due to ß-adrenergic blockade. Circulation 1988;78:SII-499.
91. Lineberry MD, Lee JT, Turgeon J, Crawford DM, Horrell KD, Woosley RL, **Roden DM**, Echt DS: Encainide plus lidocaine or mexiletine in patients with sustained ventricular tachycardia. Circulation 1988;78:SII-627.
92. Lee JT, Lineberry MD, Funck-Brentano C, Chaffin PL, **Roden DM**, Woosley RL: Propafenone-induced beta-blockade in extensive and poor metabolizer subjects. Circulation 1988;78:SII-499.
93. Pavlou HN, Funck-Brentano C, Lineberry MD, Woosley RL, **Roden DM**: Pharmacokinetically-based dose-ranging evaluation of ACC-9358 in patients with ventricular arrhythmias. Circulation 1988;78:SII-500.
94. Altemeier WA, Turgeon J, Wisialowski T, Wikswo JP Jr, **Roden DM**: Contrasting effects of class I and class III antiarrhythmics on virtual cathode dimension. Circulation 1988;78:SII-414.
95. Kroemer H, Silberstein DJ, Woosley RL, Eichelbaum M, Wood AJJ, **Roden DM**: Effects of propafenone enantiomers on sodium conductance and beta-blockade. Circulation 1988;78:SII-349.
96. Hammon JW Jr, Frist WH, Stewart JR, Echt DS, Lee JT, **Roden DM**: Implantation of the automatic implantable cardioverter-defibrillator in patients undergoing direct-ablative operations for ventricular tachycardia. The American Association for Thoracic Surgery, 1988.
97. Zhou HH, Anthony LB, **Roden D**, Wood AJJ: Evaluation of cardiac response to propranolol-quinidine combination. Clin Res 1989;37:10A.
98. Zhou HH, Anthony LB, **Roden D**, Wood AJJ: Quinidine stereoselectively alters the disposition of propranolol. Clin Res 1989;37:10A.
99. Kroemer HK, Turgeon J, Gray HT, Meese CO, **Roden DM**: *In vitro* electrophysiology and *in vivo* disposition of flecainide enantiomers. Clin Pharmacol Ther 1989;45:179.
100. Kroemer HK, Turgeon J, Thomas T, **Roden DM**: Accumulation of propafenone glucuronide during chronic oral therapy in man. Clin Pharmacol Ther 1989;45:180.
101. Turgeon J, Kroemer HK, McAllister CB, Branch RA, Wilkinson GR, Woosley RL, **Roden DM**: Heterogeneity in the extensive metabolizer phenotype of encainide. Clin Pharmacol Ther 1989;45:181.
102. Funck-Brentano C, Turgeon J, Kroemer H, Woosley RL, **Roden DM**: Consequences pharmacocinetiques et pharmacodynamiques de l'interaction entre quinidine et propafenone ou encainide. Arch Mal Coeur, March, 1989.
103. Zhou HH, Anthony LB, **Roden D**, Wood AJJ: Cardiac interaction of propranolol and quinidine combination. Clin Res 1989;37:342A.
104. Zhou HH, Anthony LB, **Roden D**, Wood AJJ: Stereoselective alteration of propranolol disposition by quinidine. Clin Res 1989;37:343A.
105. Turgeon J, Funck-Brentano C, Pavlou H, Woosley RL, **Roden DM**: Differential sensitivity of P450db1 substrates to inhibition by quinidine in man. Eur J Clin Pharm 1989;36:A41.
106. Kroemer HK, Silberstein DJ, Wood AJJ, **Roden DM**: Do metabolites contribute to the beta-blocking effects of propafenone? Eur J Clin Pharm 1989;36:A62.
107. Funck-Brentano C, Light RT, Wright GM, **Roden DM**, Woosley RL: Study of the interactions of procainamide and N-acetylprocainamide in man. Eur J Clin Pharm 1989;36:A262.
108. Turgeon J, Pavlou H, Funck-Brentano C, **Roden DM**: Genetically-determined interaction of encainide and quinidine in patients with arrhythmias. Circulation 1989;80:SII-326.
109. Echt DS, Lee JT, **Roden DM**, Crawford DM, Horrell KD, Frist WH, Hammon JW: Effects of lidocaine on defibrillation energy requirements in patients. Circulation 1989;80:SII-224.
110. Turgeon J, Li P, Branch RA, **Roden DM**: Acute alteration of antiarrhythmic drug-induced QRS widening by modulation of angiotensin II. Circulation 1989;80:SII-137.
111. Wong W, Pavlou HN, **Roden DM**: Pharmacology of sematilide, a class III procainamide analog in man. Circulation 1989;80:SII-326.
112. Fish FA, **Roden DM**: *In vitro* and *in vivo* antiarrhythmic effects of K+ channel activators in altered repolarization. Circulation 1989;80:SII-138.
113. Turgeon JT, Balser JR, Bennett PB, **Roden DM**: Isoproterenol (ISO) blunts quinidine-induced inhibition of the cardiac delayed rectifier IK. Biophys J 1990;57:514a.
114. Birgersdottiir UM, Turgeon J, Wong W, **Roden DM**: Stereoselective genetically-determined interaction of flecainide and quinidine. Clin Res 1990;38:339A.
115. Wisialowski T, Wikswo JP Jr, **Roden D**: Lidocaine (LID) contracts the virtual cathode in a frequency-dependent fashion. Circulation 1990;82:SIII-99.
116. Turgeon J, Wisialowski T, Wong W, **Roden D**: Angiotensin II (AII) and isoproterenol (ISO) alter the effects of Na+ channel block *in vivo*. Circulation 1990;82:SIII-647.
117. Wong W, Birgersdottiir U, Turgeon J, **Roden D**: Steady-state pharmacokinetics and pharmacodynamics of the class III antiarrhythmic sematilide. Circulation 1990;82:SIII-198.
118. Turgeon J, Bennett PB, **Roden D**: N-acetylprocainamide (NAPA) blocks an early component of outward potassium current. Circulation 1990;82:SIII-528.
119. Bennett PB, Walbridge J, Glover D, Kroemer H, Knoth K, Pfaff S, Taylor W, **Roden D**, Tamkun M: Molecular cloning and functional expression of voltage-gated K+ channels from human ventricle. Circulation 1990;82:SIII-217.
120. Kroemer HK, Turgeon J, Prakash C, Funck-Brentano C, **Roden DM**: Determination of debrisoquine/sparteine phenotype during chronic propafenone therapy: A new approach using intact conjugates. Eur J Pharmacol 1990;183:1074.
121. Turgeon J, Wiggins S, Bennett P, **Roden D**: Time-dependent block of outward K+ current by the diuretic indapamide in guinea pig myocytes. Biophys J 1991;59:278a.
122. Turgeon J, Pavlou HN, Funck-Brentano C, **Roden DM**: Stereoselective excretion of encainide in man. Clin Pharmacol Ther 1991;49:158.
123. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, **Roden DM**: A randomized, double-blind, placebo-controlled dose-ranging study of intravenous UK-68,798 (dofetilide) in patients with inducible sustained ventricular tachyarrhythmias. Circulation 1991;84:II-714.
124. Wisialowski TA, Wong W, **Roden DM**: Premature stimuli exaggerate anisotropic conduction and latency in the dog ventricle. Circulation 1991;84:II-500.
125. Bandyopadhyay S, Fish FA, **Roden DM**: Chronic digitalis treatment prevents experimental Torsades de Pointes. Circulation 1991;84:II-500.
126. Fish F, Selby L, Bhattacharyya M, **Roden D**: Non-inactivating outward currents in rabbit ventricular myocytes. Biophys J 1992;61:A253.
127. Vorperian VR, Wisialowski TA, **Roden DM**: Hypercapnic acidemia selectively depresses transverse propagation in the canine ventricle. PACE 1992;15:522.
128. Bandyopadhyay S, Mashburn C, Tamkun M, **Roden D**: Modulation of cardiac K+ channel mRNA transcript level and electrocardiographic effect by hypertension. Circulation 1992;86:I-77.
129. Mörike K, Fish FA, Wood A, **Roden D**: Physiologic variability in sympathetic function modulates the QT-prolonging effect of quinidine. Circulation 1992;86:I-719.
130. Mörike K, **Roden D**: Quinidine-enhance beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Circulation 1992;86:I-719.
131. Gremillion ST, **Roden DM**, Lee JT, Murray KT, Borganelli M, Stewart JR, Hammon JW, Crawford DM, Echt DS: Procainamide at supratherapeutic plasma concentrations adversely affects ventricular defibrillation in patients. Circulation 1992;86:I-720.
132. Mörike K, Fish F, Mosqueda-Garcia R, Smith M, Wood A, **Roden D**: Sympathetic activity: A modulator of quinidine disposition? Clin Pharm Ther 1993;53:169.
133. Shi J, Lee JL, **Roden DM**, Kennedy HL, Singh B, Hinderling PH: Population pharmacokinetics (PK) of sematilide (S) in patients with frequent premature ventricular contractions (PVC). Clin Pharm Ther 1993;53:216.
134. Smith M, Mörike KE, Wathen MS, **Roden DM**: A K+ independent effect of epinephrine on human cardiac repolarization. PACE 1993;16:867.
135. Smith M, Mörike KE, **Roden DM**: Beta-Blockade inhibits the effects of epinephrine on repolarization. Circulation 1993;88:I-27.
136. Wathen MS, Felipe A, Knittle TJ, Yang T, Snyders DJ, Field LJ, Tamkun MM, **Roden DM**: Ion channel mRNA in atrial tumor myocytes. Circulation 1993;88:I-88.
137. Yang T, Wathen MS, Field LJ, Tamkun MM, **Roden DM**, Snyders DJ: IKr: A major repolarizing current in cultured AT1 cells. Circulation 1993;88:I-88.
138. Yang T, Snyders DJ, **Roden DM**: Ibutilide is a potent blocker of IKr in cultured atrial tumor myocytes (AT-1 cells). Biophys J 1994;66:A83.
139. Lang CC, Choy AMJ, **Roden DM**, Robertson D, Wood AJJ, Biaggioni I: Abnormal QT interval and dispersion in primary disorders of autonomic failure. Clin Res 1994;42:258A.
140. Kinirons MT, Mörike K, Shay S, **Roden DM**, Wood AJJ: Does selective inhibition of cytochrome P450s occur with aging? Clin Res 1994;42:215A.
141. Choy AMJ, Fish FA, Mörike KE, **Roden DM**: Computer-assisted evaluation of QT interval duration and morphology. PACE 1994;17:857.
142. Yang T, **Roden DM**, Prakash C, Snyders DJ: Block of a human cardiac K+ channel by terfenadine and its enantiomers, but not by terfenadine carboxylate. PACE 1994;17:777.
143. **Roden DM**: Clinical trials of new antiarrhythmic drugs: Challenges and promise. J Mol Cell Cardiol 1994;26:S34.
144. Picklo MJ, Amlicke JD, Wiley RG, Lappi DA, **Roden DM**, Robertson D: Adult and neonatal sympathectomy with anti-DBH immunotoxin. Soc Neurosci 1994;20:1367.
145. Yang T, Snyders DJ, **Roden DM**: Cardiac K+ channel blocking activity of the vesnarinone analog OPC-18790. Circulation 1994;90:I-146.
146. Yang T, **Roden DM**: Chronic protein kinase A stimulation corrects abnormal sodium current gating kinetics in cultured atrial tumor myocytes (AT-1 cells). Circulation 1994;90:I-198.
147. Selby L, Choy AM, Mörike KE, **Roden DM**: K+ channel "isoform switching" with thyroid hormone treatment, but not with hypothyroidism or amiodarone. Circulation 1994;90:I\_416.
148. Choy AM, Boyden PA, Jeck C, Mashburn C, **Roden DM**: Increased K+ channel mRNA in experimental myocardial infarction. Circulation 1994;90:I-425.
149. Amlicke JD, Picklo M, Schmidt D, Robertson D, **Roden DM**: QT prolongation in a new model of sympathetic inhibition. Circulation 1994;90:I-518.
150. Wathen MS, Tamkun MM, Quertermous T, **Roden DM**: Functioning mouse Kv1.5 promoter in neonatal ventricular cells. Circulation 1994;90:I-580.
151. Lang CC, Biaggioni I, Stein CM, **Roden DM**, Robertson D, He HB, Choy AM, Nelson R, Wood AJJ: Effects of acute and chronic sympathetic withdrawal on QT interval in humans. Circulation 1994;90:I-661.
152. Zhang L, Choy AM, Smith M, **Roden DM**, Vincent GM: Effects of adrenergic stimulation and blockade on T wave morphology in long QT syndrome patients and normals. Circulation 1994;90:I-661.
153. Yang T, **Roden DM**: Mg2+i and Ca2+i modulate drug block, but not rectification, of IKr. Biophys J 1995;68:A110.
154. Darbar D, Dell’Orto S, Mörike K, Zeng, F-D, Wilkinson GR, **Roden D**: Salt loading as a factor in quinidine bioavailability. Circulation 1995;92:I195-I196.
155. Yang T, **Roden D**: Antisense inhibition of *minK* reduces IKr in AT-1 cells. Circulation 1995;92:I-159.
156. Kupershmidt S, Kim R, **Roden D**: Tissue and species distribution of mRNA encoding *erg*, an IKr subunit. Circulation 1995;92:I-373.
157. Wu J, **Roden D**, Wikswo J: Delayed activation and retrograde propagation due to virtual electrode effects. Circulation 1995;92:I300-I301.
158. Wei J, Wathen M, Murray K, Daw R, **Roden D**, George AL Jr: Absence of HERG and SCN5A mutations in acquired long QT syndrome. Circulation 1995;92:I-275.
159. Yang T, Snyders DJ, **Roden DM**: Extracellular potassium modulates the gating, but not the rectification, of the rapidly-activating cardiac delayed rectifier IKr. Biophys J 1996;70:A276.
160. Choy AM, Fish F, **Roden D**: Potentiation of U waves by epinephrine, quinidine and rapid atrial pacing. PACE 1996;19:685.
161. Dell'Orto S, Wathen M, Choy AM, Porta A, Baselli G, Furlan R, **Roden D**: Differential sympathetic and vagal modulation of sinus and AV nodal function in human subjects. PACE 1996;19:687.
162. **Roden DM**: How do abnormalities in sodium and potassium channels prolong repolarization? Eur JCPE 1996;6:1.
163. Kupershmidt S, Yang T, **Roden DM**: Inhibition of beta-subunit expression prevents development of a mature sodium current phenotype in cultured heart cells. Circulation 1996;94:I287.
164. Darbar D, Dell'Orto S, Fromm MF, Kroemer KY, Eichelbaum M, **Roden DM**: Dietary salt as a modulator of CYP3A expression. Circulation 1996;94:I203.
165. Yang T, Snyders DJ, **Roden DM**: Mechanism of decreased activating IKr at low extracellular potassium. Circulation 1996;94:I528.
166. Choy AMJ, Darbar D, Dell'Orto S, **Roden DM**: Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. Circulation 1996;94:I202.
167. Choy AMJ, Kupershmidt S, Lang CC, Pierson RN Jr, **Roden DM**: Regional expression of HERG and KVLQT1 in heart failure. Circulation 1996;94:I164.
168. Kupershmidt S, Sutherland M, King D, Magnuson MA, **Roden DM**: Replacement by homologous recombination of the *minK* gene with *lacZ* reveals cell-specific *minK* expression. Biophys J 1997;72:A226.
169. Choy AM\*, Lang CC, Chomsky DB, Rayos GH, Wilson JR, **Roden DM**: Normalization of acquired QT prolongation by IV potassium. PACE 1997;20:1235. (\*Young Investigator Award (clinical); 18th annual Scientific Sessions, NASPE)
170. **Roden DM**: Current status of treatment for atrial fibrillation and flutter. Japanese Journal of Pharmacology 1997;73:31P.
171. Yang T, Snyders DJ, **Roden DM**: Discordance between IKr block and Torsades de Pointes. Circulation 1997;96:I554.
172. Kupershmidt S, Snyders DJ, Eck JC, **Roden DM**: Cloning and functional characterization of a C-terminal splice variant of *HERG*. Circulation 1997;96:I425.
173. Fromm MF, Kim RB, Stein CM, **Roden DM**: Role of P-glycoprotein in the quinidine-digoxin interaction. Circulation 1997;96:I292.
174. Anderson ME, Kupershmidt S, Magnuson M, **Roden DM**: QT shortening in neonatal *minK* knockout mice. Circulation 1997;96:I421.
175. Yang T, Kupershmidt S, **Roden DM**, Synders DJ: Coexpression of *minK* modifies hKv1.5 activation in mammalian cells. Biophys J 1998; 74:A346.
176. Fromm MF, Kim RB, Stein CM, **Roden DM**: Inhibition of drug transport: mechanism for the digoxin-quinidine interaction. Accepted for presentation American Society for Clinical Pharmacology and Therapeutics 1998 Annual Meeting, March 1998, New Orleans, LA. Received the "Presidential Trainee Award".
177. Kim RB, Leake B, Cvetkovic M, Wandel C, Roden MM, Fromm MF, Chaudhary AK, Belas F, **Roden DM**, Wood AJJ, Wilkinson GR: Transport of P450 (CYP) drug substrates by P-glycoprotein. American Society for Clinical Pharmacology and Therapeutics 1998 Annual Meeting, March 1998, New Orleans, LA. Clin Pharmacol Ther 1999; 99:552.
178. **Roden DM**: Use of genetically modified mice to study cardiac electrophysiology. Archives des Maladies du Coeur et des Vaisseaux1998;19(11):116-1. Cardio Tim 98.
179. Wang DW, Wei J, Alings M, **Roden DM**, George AL Jr: A mutation (E1784K) in the carboxyl terminus of the cardiac Na+ channel causes autosomal dominant congenital long QT syndrome. 1998 American Heart Association Annual Meeting. Circulation 1998;98:I-56.
180. Fromm MF, Darbar D, Dell’Orto S, Wilkinson GR, **Roden DM**: Salt loading increases quinidine’s oral clearance: underlying mechanisms. 1998 American Heart Association Annual Meeting. Circulation 1998;98:I-841.
181. Darbar D, Fromm MF, Dell’Orto S, Wilkinson GR **Roden DM**: QT prolongation by quinidine is determined by sympathetic activation. 1998 American Heart Association Annual Meeting. Circulation 1998;98:I-27.
182. Mazur A, **Roden DM**, Anderson ME: Torsades de Pointes is prevented by systemic administration of a calmodulin antagonist. 1998 American Heart Association Annual Meeting. Circulation 1998;98:I-814.
183. Wu Y, **Roden DM**, Anderson ME: The transient inward current is dependent on the multifunctional calcium/calmodulin dependent protein kinase II. 1998 American Heart Association Annual Meeting. Circulation 1998;98:I-693.
184. **Roden DM**: Ion channel clones to predict clinical drug actions. Naunyn Schmiedeberg Archives of Pharmacology 1998;358:R575 (SA 2.1).
185. Fromm MF, Leake B, **Roden DM**, Wilkinson GR, Kim RB: Molecular cloning, genomic organization, and tissue distribution of the human MRP3 transporter and its splice variants. American Society for Clinical Pharmacology and Therapeutics, 1999 Annual Meeting. Clin Pharmacol Ther 1999;65:125.
186. Yang T, **Roden DM**: Enhancement of ICa-T, but not ICa-L, in AT-1 cells by chronic exposure to phenylephrine. Biophysical Society, 1999. Biophys J 1999;76:A340.
187. Kupershmidt S, Yang I, Balser JR, **Roden DM**: Coexpression of a C-terminal HERG peptide with full-length HERG inhibits IKr. 1999 American Heart Association Annual Meeting. Circulation 1999; 100:I-632.
188. Mazur A, Anderson ME, Bonney S, **Roden DM**: Pause-dependent polymorphic VT during long-term treatment with dofetilide: a placebo-controlled, ICD-based evaluation. 1999 American Heart Association Annual Meeting. Circulation 1999;100:I-656.
189. Wei J, Yang ICH, Tapper AR, Murray KT, Viswanathan P, Rudy Y, Bennett PB, Norris K, Balser JR, **Roden DM**, George AL Jr: *KCNE1* polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium channels. 1999 American Heart Association Annual Meeting. Circulation 1999;100:I-495.
190. Wei J, Abbott GW, Sesti F, Goldstein SAN, Schwartz PJ, Saksena S, Murray KT, **Roden DM**, George AL Jr: Prevalence of *KCNE2* (Mirp1) mutations in acquired long QT syndrome. 1999 American Heart Association Annual Meeting. Circulation 1999;100:I-495.
191. Sesti F, Abbott GW, Wei J, **Roden DM**, George AL Jr, Goldstein SAN: Function of A116V-MiRP1: a missense mutation associated with acquired arrhythmia. 1999 American Heart Association Annual Meeting. Circulation 1999; 100:I-495.
192. Frias P, Zhang W, King P, Kupershmidt S, **Roden DM**: Continuous ECG monitoring in conscious unrestrained mice reveals heart rate slowing in *minK* knockouts. 1999 American Heart Association Annual Meeting. Circulation 1999; 100:I-769.
193. Schwarz UI, Choo EF, Dresser GK, Stein CM, Wood AJJ, **Roden DM**, Kim RB: Identification of a new CYP2C9 variant in African-Americans. American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharm and Ther 2000; 67:169.
194. Yang T, Kupershmidt S, Hemontolor GL, Balser JR, **Roden DM**: A single sodium channel underlies unusual pharmacologic sensitivity of INa in mouse AT-1 cells. Biophysical Society Annual Meeting, 2000. Biophys J 2000;78:89A.
195. Kupershmidt S, Sutherland M, Sugg NA, **Roden DM**: A Novel protein partner for the *minK* K+ channel Subunit. Biophysical Society Annual Meeting, 2000. Biophys J 2000;78:203A.
196. Sesti F, Abbott GW, Wei J, **Roden DM,** George AL Jr, Goldstein SA: MiRP1 mutant associated with quinidine-induced cardiac arrhythmia supports a genetic contribution to “acquired” disease. Biophys J 2000;78:204A.
197. **Roden DM**. The genetics of sudden death. Proceedings of the 5th Dead Sea Symposium. Futura Publishing Company. Europace 2000;1(Suppl A):A30.
198. Gbadebo D, Mazur A, Temple J, **Roden DM**, Anderson ME: The calmodulin inhibitor W-7 prevents initiation of Torsade de Pointes. NASPE 2000 meeting. PACE 2000;23:569.
199. Franco D, Demolombe S, Kupershmidt S, **Roden DM**, Escande D, Moorman AFM: Divergent expression domains of KvLQT1 and its regulator IsK (minK) during mouse heart development. Symposium on Heart Developmental Physiology, Prague, 2000.
200. Anderson ME, Mazur A, Yang T, **Roden DM**: Comparison of K+ current antagonist properties and proarrhythmic consequences of gatifloxacin, grepafloxacin, and sparfloxacin. 2000 European Congress on Infectious Disease.
201. Temple JD, Frias PA, Kupershmidt S, Gbadebo TD, Zhang W, King P, **Roden DM**. Spontaneous and induced atrial fibrillation in minK knockout mice. Circulation (Supplement) 2000;102:153.
202. Yang T, Balser JR, **Roden DM**. MiRP1 determines use-dependent drug block of IKr. Circulation (Supplement) 2000;102:285.
203. Yang IC, Kupershmidt S, Wei J, Petersen CI, Johns DC, George AL Jr, **Roden DM**, Balser JR. A Molecular Toggle for Drug Block of HERG Potassium Channels. Circulation (Supplement) 2000;102:260.
204. Temple J, Colbran RJ, Olson EN, Passier R, Zhang R, DasGupta J, Bass MA, **Roden DM**, Anderson ME. Increased calmodulin kinase II activity and inducible arrhythmias in calmodulin kinase IV transgenic mice. Circulation (Supplement) 2000;102:210.
205. Wang D, Makita N, Yang P, Kitabatake A, Balser JR, **Roden DM**, George AL Jr: Enhanced Na channel intermediate inactivation in idiopathic ventricular fibrillation. Biophysical Society 45th annual meeting. Biophys J 2001;80:22a.
206. Viswanathan PC, Bezzina CR, **Roden DM**, Wilde AAM, Balser JR: Gating-dependent mechanisms for flecainide intolerance in SCN5A-linked arrhythmia syndromes. Biophysical Society 45th annual meeting. Biophys J 2001;80:22a.
207. Gbadebo TD, Trimble RW, **Roden DM**, Anderson ME. A Novel Index of Ventricular Repolarization Predicts Initiation of Torsade de Pointes. J Am Coll Cardiol 2001;37:92A.
208. Sofowora G, Dishy V, **Roden DM,** Wood AJJ, Stein CM. The effect of sildenafil on QT interval in healthy men. ASCPT 2001.
209. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB, **Roden DM**. Fexofenadine bioavailability modulated by dietary salt. Clin Pharm Ther 2001; 69:P23.
210. Yang P, Wei J, Murray KT, Hohnloser S, Shimizu W, Schwartz PJ, Stanton M, Norris K, George AL Jr, **Roden DM**: Frequency of ion channel mutations and polymorphisms in a large population of patients with drug-associated Long QT Syndrome. Pacing and Clinical Electrophysiology 2001; 24(4):579.
211. Kanki H, Yang P, Xie H-G, Kim RB, George AL Jr, **Roden DM**: Polymorphisms in -adrenergic receptor genes in acquired long QT syndrome patients. Pacing and Clinical Electrophysiology 2001; 24(4):606.
212. Yang P, Nguyen VQ, Hachey D, **Roden DM**: Large scale quantitative genotyping by DNA pooling and mass spectrometry: validation with SCN5A H558R. Circulation 2001;104(17):II-310.
213. Kupershmidt S, Yang T, Chanthaphaychith S, Wang Z, Towbin JA, **Roden DM**: HERG trafficking defects linked to a C-terminal endoplasmic reticulum (ER) retention signal. Circulation 2001; 104(17):II-310.
214. Khoo MSC, Zhang W, Temple J, **Roden DM**, Olson EN, Bass M, Colbran RJ, Anderson ME: Calmodulin and calmodulin kinase inhibition suppress ventricular tachycardia in calcineurin transgenic mice with heart failure. Circulation 2001; 104(17):II-191.
215. Johnson WH, Yang P, Yang T, Lau YR, Mostella BA, Wolff DJ, **Roden DM**, Benson DW: Triple Ion Channel Mutation Causes Severe Long-QT Syndrome Phenotype. Circulation 2001; 104(17):II-746.
216. Wang Z, Yang T, Li H, Moss A, Robinson J, Bowles NE, **Roden DM**, Towbin JA: C-terminal HERG mutations in long QT syndrome: Novel mechanism of disease? Pediatric Research 2001;49:34A.
217. Kanki H, Yang T, Yang P, Gbadebo D, Murray K, Norris K, **Roden DM**: A benign KCNQ1 mutation: family and in vitro study. NASPE 2002.
218. Yang P, Yang T, Kupershmidt S, **Roden DM**: Functional consequences of a common HERG polymorphism. NASPE 2002.
219. Kanki H, Kupershmidt S, Wells S, **Roden DM**: A small domain of the KCNQ1 C-terminus mediates cell surface expression. Circulation 2002; 106(19): II-226.
220. Yang P, Kupershmidt S, Norris K, Yang T, Liu K, **Roden DM**: DNA polymorphisms in the human SCN5A promoter and regulation of transcriptional activity. Circulation 2002;106(19):II-91.
221. Jay P, Kupershmidt S, **Roden DM**, Izumo S: Congenital underdevelopment of the central conduction system in Nkx2-5 knockout mice. Circulation 2002;106(19):II-286.
222. Drolet B, Simard C, Yang P, Kim RB, **Roden DM**: A DNA polymorphism that reduces sensitivity of Kv1.5 current to drug block. Circulation 2002;106(19): II-303.
223. Yang T, Kanki H, Yang P, Liu K, Kupershmidt S, **Roden DM**: Dual targets for PKA-mediated phosphorylation of cardiac IKs. Biophysical Society 2003.
224. Kannankeril P, Norris K, **Roden DM**: Ibutilide Prolongs QT Interval and QT Hysteresis During Exercise in Normal Subjects. Pacing and Clinical Electrophysiology 2003;26(4):II-998.
225. Kannankeril P, Harris PA, Norris K, **Roden DM**: Ibutilide Prolongs QT Interval and QT Beat-to-beat QT and RR Intervals during Exercise and Recovery: Mechanisms of Drug-induced QT Hysteresis. Pacing and Clinical Electrophysiology 2003;26(4):II-1071.
226. Drolet B, Simard C, **Roden DM**: Multiple Effects of Arsenic Trioxide on Outward Currents. Pacing and Clinical Electrophysiology 2003;26(4):II-1064.
227. Kanki H, Yang T, Kupershmidt S, Wells, **Roden DM**: Channel Misprocessing in LQT1. Pacing and Clinical Electrophysiology 2003;26(4):II-956.
228. Kanki H, Kupershmidt S, Wells, **Roden DM**: A Key Structural Determinant of KCNQ1 Cell Surface Trafficking. Pacing and Clinical Electrophysiology 2003;26(4):II-957.
229. Yang P, Bezzina C, Zhou, Baldwin HS, Liu K, Kupershmidt S, **Roden DM**: Regulation of cardiac sodium channel transcription *in vitro* and *in vivo.* Circulation 2003;106(17):IV-75.
230. Drolet B, Simard C, Kanki H, Kim RB, **Roden DM**: A rare DNA polymorphism identifies a key structural determinant of Kv1.5 drug block. Circulation 2003;106(17):IV-183.
231. Yang T, Wingo T, Kanki H, Balser JR, **Roden DM**: A KCNQ1 drug binding site at the S6/C-terminus junction. Biophys J 2004;82:1(suppl.):530A.
232. Moskowitz IPG, Paytel VV, Jay PY, Pizard A, Peterson M, Bruneau BG, Kupershmidt S, **Roden DM**, Izumo S, Berul CI, Seidman CE, Seidman JG: The role of *Tbx-5* and *Nkx-2.5* in cardiac conduction system development. The American Association of Anatomists 2004 Annual Meeting.
233. Khoo MS, Kannankeril PJ, Zhang R, Litwin ST, Kupershmidt S, Zhang W, Atkinson JB, **Roden DM**, Colbran RJ, Salama G, Anderson ME: Calmodulin kinase is required for β-adrenergic increase in cardiac conduction. Heart Rhythm 2004;1:1S; S51 (157).
234. Kimbrough JT, Norris KJ, Kannankeril PJ, Anderson ME, **Roden DM**, Darbar D: QT prolongation alone does not predict torsades de pointes in patients with drug-induced LQTS. Heart Rhythm 2004;1:1S; S83 (257).
235. Kannankeril PJ,\* **Roden DM**, Norris KJ, Whalen P, George AL Jr, Murray KT: Pharmacologic challenge for genetic susceptibility to acquired long QT syndrome. Heart Rhythm 2004;1:1S;S89 (277). \*Finalist, Young investigator competition
236. Darbar D, Harris P, Hardy A, Frye-Anderson A, White B, Norris KJ, **Roden DM**: Marked steepening of QT restitution following cardioversion of atrial fibrillation. Heart Rhythm 2004;1:1S;S192.
237. Yang P, Koopmann TT, Pfeufer A, Kääb S, Wilde AA, **Roden DM**, Bezzina CR: DNA polymorphisms with variant *in vitro* function are common in the cardiac sodium channel promoter. Circulation 2004;Supplement III;110(17):III-262.
238. Crotti L, Heradien M, Goosen A, Vanoli E, Bacchini S, Corfield V, **Roden DM**, George AL Jr, Brink P, Schwartz PJ: Phenotypic Variability in a Founder Population of 23 South African LQT1 Families with the *KCNQ1*-A341V Mutation. Circulation 2004;Supplement III;110(17):III-622.
239. Pfeufer A, Bezzina CR, Jalilzadeh S, Koopmann TT, Perz S, Müller J, Hinterseer M, Huth C, Erich HE, Steinbeck G, Yang P, **Roden DM**, Wilde AA, Meitinger T, Kääb S: A common haplotype in the 5’ region of the SCN5A gene is strongly associated with ventricular conduction impairment. Circulation 2004;Supplement III;110(17):III-2293.
240. Kannankeril PJ, Chelu MG, Zhang W, **Roden DM**, Hamilton SL, Anderson ME: Inducible Ventricular Tachycardia Exacerbated by Isoproterenol in a Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation 2004;Supplement III;110(17):III-289.
241. Warsy IA, Norris KJ, **Roden DM**, Kannankeril PJ: Ibutilide-induced QT Prolongation Varies Markedly Among Individuals in a Gender and Exercise-independent Fashion. Circulation 2004; Supplement III;110(17):III-623.
242. Yang T, George AL Jr, **Roden DM**: KCNQ1 undergoes N-type fast inactivation. Biophysical Journal 2005;88:S2-452a.
243. Donahue BS, Darbar D, George AL Jr, Li C, Brown NJ, Ritchie M, **Roden DM**: Pharmacogenomics of Atrial Fibrillation. Clin Pharmacol Ther 2005;77(2):P7.
244. **Roden DM**, Pharmacogenomics of Arrhythmia Therapy (PAT) group: Genomic Screening as a starting point for Studies of Ion Channel Structure-Function. Clin Pharmacol Ther 2005;77(2):P7.
245. Kannankeril PJ, Norris KJ, Gillani N, George AL Jr, **Roden DM**: A Common Polymorphism in KCNH2 (HERG) Eliminates Gender Differences in Drug-induced QT Prolongation. Heart Rhythm 2005;2(1S);S145.
246. Kannankeril PJ, Harris PA, Warsy I, Smith PD, Norris KJ, **Roden DM**: QT Shortening With Exercise in Normals: Terminal Repolarization Does Not Shorten with Exercise. Heart Rhythm 2005;2(1S);S223.
247. Darbar D, Hardy A, Ritchie M, Gainer J, **Roden DM**: ACE I/D polymorphism modulates response to antiarrhythmic drug therapy in patients with atrial fibrillation. Heart Rhythm 2005;2(1S);S67.
248. Liu K, Yang T, **Roden DM**: Misprocessing as a mechanism for phenotypic variability in LQT3. Heart Rhythm 2005;2(1S);S7.
249. Gillis AM, Zhan S, Mathison H, **Roden DM**, Kupershmidt S, Duff H: Blunted VERP response to isoproterenol in minK (KCNE1) knockout mice. Heart Rhythm 2005;2(1S);S34.
250. Crotti L, Lundquist A, Pedrazzini M, Insolia R, Ferrandi C, DeFerrari G, Vincentini A, Yang P, Landolina M, **Roden DM**, George AL Jr, Schwartz P: Common KCNH2 polymorphism (K897T) as a genetic modifier of congenital long QT syndrome. Heart Rhythm 2005;2(1S);S111.
251. McBride BF, Yang T, Liu K, Kim RB, **Roden DM**: Potentiation of drug actions by drug uptake transporter expression in heart. Circulation 2005;112:II-494.
252. Bezzina CR, ShimizuW, Yang P, KoopmannTT, TanckMWT, MiyamotoM, KamakuraS, **RodenDM**, WildeAA: A common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 2005;112:II-95.
253. Liu K, Hipkens S, Zhang W, Magnuson MA, **Roden DM**: Application of Recombination-Mediated Cassette Exchange to rapidly and efficiently generate mice with modified sodium channels: humanizing mouse SCN5A. Circulation 2005;112:II-95.
254. Mohler PJ, EscandeD, **Roden DM**: Identification and cellular characterization of human Ank2 variants. Circulation 2005;112:II-18.
255. KaabS, Pfeufer A, HinterseerM, NabauerM, YalilzadehS, GeorgeAL Jr, NorrisKJ, WildeAA, Bezzina CR, Schulze-BahrE, HaverkampW, BerthetM, DenjoyI, GuicheneyP, WichmannHE, **Roden DM**: Common Gene Variants Associated with drug induced Long-QT Syndrome. Circulation 2005;112:II-357.
256. Yang T, Yang P, Liu K, McBride BF, Kim RB, **Roden DM**: Facilitation of drug block of the human cardiac K+ channel Kv1.5 by a human heart organic cation uptake transporter (OCTN1). Biophysical Journal 2006 (January):529a.
257. Smith AH, Bush WS, Norris KJ, Ritchie MD, **Roden DM**, Kannankeril PJ: The Common Angiotensinogen (AGT) Polymorphism T207M Protects from Drug-induced QT Prolongation. Heart Rhythm 2006;3:S119.
258. McCray R, Ritchie MD, **Roden DM**, Darbar D: Persistent Atrial Fibrillation is Associated with Reduced Risk of Torsades de Pointes in Patients with Drug-Induced Long QT Syndrome. Heart Rhythm Society, 2006. Heart Rhythm 2006;3:S114-5.
259. Chappell CH, Kucera G, Hardy A, **Roden DM**, Darbar D: Clinical Characterization of Patients with Familial Atrial Fibrillation. Heart Rhythm 2006;3:S187.
260. Watanabe H, Aizawa Y, Watanabe T, Kurashina Y, Darbar D, **Roden DM**: Metabolic Syndrome and Risk of Development of Atrial Fibrillation. Heart Rhythm 2006 3;S135-6.
261. Rhodes TE, Manderfield LJ, Lundquist AL, George AL Jr, Donahue BS, **Roden DM**, Darbar D: Gain-of-function KCNQ1 and KCNE3 Mutations Associated with Atrial Fibrillation. Circulation 2006;114:II-59.
262. Kannankeril PJ, Nguyen AT, Warsy I, Legrone A, Khuchua A, Strauss A, **Roden DM**, Exil VJ: Chronic Amiodarone Suppresses Ventricular Tachycardia in a Mouse Model of Pediatric Cardiomyopathy. Circulation 2006;114:II-505.
263. Darbar D, Hardy A, Haines JL, **Roden DM**: A Novel Locus on Chromosome 5 for Familial Atrial Fibrillation Associated with Prolonged Signal-Averaged P-wave. Circulation 2006;114:II-722.
264. Chopra N, Yang T, Hlaing T, Ettensohn K, Holinstat I, Zhang W, Pfeifer K, **Roden DM**, Knollmann BC: Cardiac Calsequestrin Deletion Causes Premature Sarcoplasmic Reticulum Calcium Release And Catecholaminergic Polymorphic Ventricular Tachycardia In Mice. Circulation 2006;114:II-267.

1. Chopra SS, Watanabe H, Smith AH, Zhong TP, **Roden DM**: Sodium Channel Beta Subunits Modulate Heart Rate, Drug Sensitivity, and Development in Zebrafish Embryos. Circulation 2006;114:II-332.
2. Chopra SS, Watanabe H, Yang T, Batts L, Qu X, Baldwin HS, Zhong TP, **Roden DM**: Expression of the Cardiac Sodium Channel Nav1.5 is Required for the Differentiation of Cardiomyocyte Progenitor Cells In Vivo. Circulation 2006;114:II-234.
3. Yang T, Kanki H, Zhang W, Yang P, **Roden DM**: Probing mechanisms for phosphorylation-dependent drug sensitivity of IKs block. Circulation 2006;114:II-203.
4. Schwarz UI, Ritchie MD, Bradford Y, Dudek SM, Kim RB, **Roden DM**, Stein CM: Genetics of the Initial Anticoagulant Response to Warfarin - a Prospective Study. Circulation 2006;114:II-488.
5. Pretorius M, Donahue BS, Yu C, Greelish JP, **Roden DM**, Brown NJ: PAI-1 as a predictor of postoperative atrial fibrillation following cardiopulmonary bypass. Circulation 2006;114:II-712.

1. Darbar D, Yang T, Yang P, Kucera G, Stubblefield T, McElroy J, **Roden DM**: KCNA5 loss-of-function mutation implicates tyrosine kinase signaling in human atrial fibrillation. Circ Res 2006;99:3. Late-breaking session AHA, 2006.

1. Pretorius M, Donahue BS, Yu C, Greelish JP, **Roden DM**, Brown NJ: Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation Following Cardiopulmonary Bypass. Council for High Blood Pressure meeting 2006.
2. Yang T, Abraham RL, Watanabe H, Holinstat IA, Knollmann BC, **Roden DM**: Biophysical Properties of Sodium Current (INa) in Mouse Atrial and Ventricular Cardiomyocytes. Biophysical Society 2007. Biophys J 2007;92: 270a.
3. Smith AH, Norris KJ, **Roden DM**, Kannankeril PJ: Autonomic tone attenuates drug-induced QT prolongation. Heart Rhythm Society, 2007. Heart Rhythm 2007;4:AB17-6.
4. Darbar D, Kucera G, Stubblefield T, Wang J, George AL Jr, **Roden DM**: Cardiac Sodium Channel (SCN5A) Variants Associated with Atrial Fibrillation. Heart Rhythm Society, 2007. Heart Rhythm 2007;4:AB28-5.
5. Watanabe H, Koopmann T, Schott J-J, Yang T, Ingram CR, Scouarnec SL, Demolombe S, Escande D, Weisfeld AC, Pfeufer A, Aizawa Y, Wilde AA, **Roden DM**, Bezzina C: Mutations in an Alternately Processed Sodium Channel Beta-1 Subunit Associated with Brugada Syndrome and Cardiac Conduction Defect. Circulation 2007;116:II-55.
6. Darbar D, Abraham R, Kucera G, Stubblefield T, Yang T, **Roden DM**: KCNQ1 gain-of-function mutation associated with familial atrial fibrillation. Circulation 2007;116:II-652.
7. Makita N, Behr E, Shimizu W, Horie M, Crotti L, Itoh H, Miyamoto K, Kamakura S, Schwartz PJ, Tsutsui H, George AL Jr, **Roden DM**: Overlap Between LQT3 and Brugada Syndrome: Clinical Features in a Common Mutation and Underlying Biophysical Mechanisms. Circulation 2007; 116:II-490.

1. Yang T, Smith JA, Meiler J, Wingo T, Kanki H, Leake BF, Sanders CR, Balser JR, **Roden DM**: An Allosteric Mechanism for Drug Block of a Cardiac Potassium Channel. Circulation 2007;116:II-187.
2. Watanabe H, Darbar D, Ingram CR, Jiramongkolchai K, Chopra S, Kucera G, Stubblefield T, Wang J, **Roden DM**: Loss of Function Mutations in Sodium Channel Beta Subunits Associated with Atrial Fibrillation and ST-segment elevation. Circulation 2007;116:II-54.
3. Bollmann A, Husser D, Stridh M, Sörnmo L, Hindricks G, **Roden DM**, Darbar D: A genotype dependent intermediate phenotype in Patients with Persistent Lone Atrial Fibrillation. Circulation 2007;116:II-477.
4. Milan DJ, Jones IL, Amsterdam AH, Rosenbaum DS, **Roden D**, MacRae CA: A Pharmacogenetic Screen for Modifiers of Drug Induced QT Prolongation Reveals 15 Novel Genes. Circulation 2007;116:II-117.
5. Watanabe H, Hwang HS, **Roden DM**, Knollman BC: Flecainide Prevents Catecholaminergic Polymorphic Ventricular Tachycardia in an Animal Model (*Casq2* Null Mice). Heart Rhythm Society, 2007. Heart Rhythm 2007;5:PO1-8.

1. Husser D, Darbar D, **RodenDM**, StridhM, Sörnmo M, Bollmann M: Connexin 40 Polymorphism in Persistent Lone Atrial Fibrillation – Relation with Intermediate ECG Phenotype and Response to Amiodarone. Heart Rhythm Society, 2007. Heart Rhythm 2007;5:PO5-52.
2. Bollmann A, Husser D, StridhM,SörnmoL, **Roden DM**, Darbar D: Association of Atrial Fibrillation Candidate Gene Variants and Atrial Fibrillatory Rate. Heart Rhythm Society, 2007. Heart Rhythm 2007;5:PO6-57.
3. Sinner MF, Pfeufer A, Akyol M, Perz S, Beckmann B, Hinterseer M, Lichtner P, Wichmann HE, Meitinger T, **Roden D**, Steinbeck G, Kääb S: A high density SNP interrogation of the association between candidate gene and ECG intervals in the population-based KORA-Study. Heart Rhythm Society, 2007. Heart Rhythm 2007;5: PO1-17.
4. Ellinor PT Darbar D, van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C, Schnabel R, Sinner F, Kannankeril PJ, Beckmann BM, Choudry S, Donahue BS, Steinbeck G, Heeringa J, Perz S, Lunetta KL, Larson MG, MacRae CA, Wichmann H, Meitinger T, Uitterlinden AG, Witteman JCM, **Roden DM**, Benjamin EJ, Kääb S: Atrial fibrillation is strongly associated with the single nucleotide polymorphism rs2200733. Heart Rhythm Society, 2007. Heart Rhythm 2007;5:AB36-3.
5. Denny JC, Ritchie MD, Crawford DC, Havens A, Weiner J, Watanabe H, Darbar D, Kannankeril PK, Pulley J, Basford M, Haines JL, Masys DR, **Roden DM**: Using a large Electronic Medical Record to validate 4q25 variants conferring risk for atrial fibrillation. Circulation 2008;118:S\_883.

1. Body SC, Collard CD, Shernan SK, Fox AA, Liu KY, Ritchie MD, Perry TE, Muehlschlegel JD, Aranki S, Seidman CE, Seidman JG, Hermann D, Lichtner P, Meitinger T, Estrada JC, Donahue BS, Pretorius M, Ellinor PT, Newton-Cheh C, Brown NJ, **Roden DM**, Darbar D: Variation in the 4q25 Chromosomal Locus Predicts New-onset Atrial Fibrillation after Cardiac Surgery. American Heart Association 2008 Scientific Sessions. Circulation Oct 2008;118:S\_882.
2. Kääb S, Sinner M, George A, Wilde AJJ, Bezzina C, Schulze-Bahr E, Guicheney P, Bishopric N, Myerburg R, Schott JJ, Pfeufer A, Hinterseer M, Beckmann BM, Steinbeck G, Perz S, Meitinger S, Wichmann HE, Ingram C, Carter S, Norris K, Crawford D, Ritchie M, **Roden DM**: High density tag SNP candidate gene analysis identifies IKs as a major modulator of genetic susceptibility to drug induced Long QT Syndrome. American Heart Association 2008 Scientific Sessions. Circulation 2008;118:S-884.

1. Watanabe H, Atack TC, Darbar D, Yang P, Ritchie MD, Ingram CR, **Roden DM**: SCN5A Promoter and Enhancer Variants associated with Atrial Fibrillation. Circulation 2008;118:S-345.
2. Mareedu R, Peterson J, Miller RA, Boyle D, Matheny M, Waitman LR, Arrieta M, **Roden DM**, Denny J: QT-Prolonging Medication Prescription Tendencies in a Cohort of Hospitalized Patients With Known Long QT Intervals. Circulation 2008;118:S-1084.
3. Chopra N, Watanabe H, Laver D, Hwang HS, **Roden DM**, Knollmann BC: Flecainide Blocks Cardiac Ryanodine Channels and Prevents Catecholaminergic Ventricular Tachycardia in Cardiac Calsequestrin Null Mice. Circulation 2008;118:S\_522-3.
4. Vaglio J, Rowan S, Kucera G, Stubblefield T, Carter S, **Roden DM**, Darbar D: Genetic and clinical predictors of response to rate control therapy in patients with atrial fibrillation. Circulation 2008;118;S-828.
5. Body SC, Collard CD, Shernan SK, Fox AA, Liu K-Y, Ritchie MD, Perry TE, Muehlschlegel JD, Donahue BS, Pretorius M, Ellinor PT, Newton-Cheh C, Seidman CE, Seidman JG, Herman DS, Lichtner P, Meitinger T, Brown NJ, **Roden DM**, Darbar D: Variation in the 4q25 Chromosomal Locus Predicts New-onset Atrial Fibrillation after Cardiac Surgery. American Society for Human Genetics, accepted for presentation, 2008.
6. Crawford DC, Ritchie MD, Denny JC, Havens A, Weiner J, Pulley J, Basford M, Masys DR, **Roden DM**, Haines JL: Electronic Medical Records Linked to DNA: A Valuable Resource for Large-Scale Genetic Association Studies. American Society for Human Genetics, accepted for presentation, 2008.
7. Wolf WA, Chisholm RL, Chute CG, Jarvik G, Larson E, Masys DR, McCarty CA, **Roden DM**, Struewing JP: The eMERGE Network: A national consortium of electronic health record-linked biobanks furthering large-scale genetic research. American Society for Human Genetics, accepted for presentation, 2008.
8. Watanabe H, Yang T, Chopra N, Atack TC, Hwang HS, Leake B, Agochukwu NB, Kannankeril PJ, Kupershmidt S, Knollmann BC, **Roden DM**: SCN5A D1275N causes dilated cardiomyopathy and arrhythmia: mechanisms revealed in mice but absent by heterologous expression. Accepted for presentation, American Heart Association 2008 Late-Breaking Scientific Sessions.
9. Atack TC, Lowe JS, Watanabe H, Yang P, Abraham RL, **Roden DM**: An SCN5A regulatory region that modulates channel expression and function in vivo. Heart Rhythm Society 2009. Heart Rhythm 2009;6:PO01-4.
10. WatanabeH, ChopraS, AtackT, Yang T, ZhongT, **Roden DM**: Novel molecular mechanism for Tetrodotoxin-resistance in voltage-gated sodium channel. Heart Rhythm Society 2009. Heart Rhythm 2009;6:PO06-73.
11. Watanabe H, Yang T, Atack T, Hasdemir C, Crawford J, Skinner J, **Roden DM**: Divergent Biophysical Effects of Cardiac Sodium Channel Mutations in the N-terminus. Heart Rhythm Society 2009. Heart Rhythm 2009;6:PO05-73.
12. Watanabe H, Atack TC, Yang T, Knollmann BC, **Roden DM**: The L1825P *SCN5A* mutation slows conduction and causes drug-induced arrhythmias in mice. Heart Rhythm Society 2009. Heart Rhythm 2009;6:PO02-92.
13. Rowan S, Estrada JC, Kucera G, Stubblefield T, Carter S, **Roden DM**, Darbar D: A single nucleotide polymorphism at 4q25associated with atrial fibrillation modulates symptomatic response to antiarrhythmic drug therapy. Heart Rhythm Society 2009. Heart Rhythm 2009;6:PO04-7.
14. Abraham RL, Yang T, Blair M, George AL Jr, **Roden DM**, Darbar D: Mechanisms underlying familial atrial fibrillation in an ANP gain-of-function mutation. Heart Rhythm Society 2009. Heart Rhythm 2009;6:AB22-3.
15. Holm H, Gudbjartsson, Arnar DO, Gretarsdottir S, Thorleifsson G, Walters BG, Thorgeirsson G, **Roden DM**, Carter S, Kucera G, Stubblefield T, Mathiesen EB, Njølstad I, Nyrnes A, Wilsgaard T, Mathiesen Hald E, Hveem K, Stoltenberg F, Gulcher J, Løchen M-L, Darbar D, Kong A, Thorsteinsdottir U, Stefansson K: A Genome-Wide Association Study in Icelanders Identifies a Novel Sequence Variant on Chromosome 16q22 that Associates with Common Atrial Fibrillation. Heart Rhythm Society 2009. Heart Rhythm 2009;6:AB22-1.
16. Gulcher J, Holm H, Gudbjartsson, Arnar DO, Gretarsdottir S, Thorleifsson G, Walters BG, Thorgeirsson G, **Roden DM**, Carter S, Kucera G, Stubblefield T, Mathiesen EB, Njølstad I, Nyrnes A, Wilsgaard T, Mathiesen Hald E, Hveem K, Stoltenberg F, Gulcher J, Løchen M-L, Darbar D, Kong A, Thorsteinsdottir U, Stefansson K: A Genome-Wide Association Study in Icelanders Identifies a Novel Sequence Variant on Chromosome 16q22 that is additive to 4q25 variants for atrial fibrillation risk. 2009 AHA Scientific sessions; Circulation 2009;120:S578.
17. Lowe JS, Yang T, Atack T, Watanabe H, Leake B, **Roden DM**: Rescue of a misprocessed LQT3 mutation in the mouse heart. 2009 AHA Scientific sessions; Circulation 2009;120:S614.
18. Havens A, Schildcrout J, Masys D, Weiner J, Pulley J, Basford M, Ritchie MD, Crawford DC, Haines JL, **Roden DM**, Denny JC: Modulators of normal ECG Intervals identified in a large Electronic Medical Record. 2009 AHA Scientific sessions; Circulation 2009;120:S679.
19. Kääb S, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK,. Sinner MF, Darbar D, van Noord C, Smith AV, Gudnason V, **Roden DM**, Witteman JCM, Barnard J, Arking DE, Benjamin EJ, Heckbert SR, Ellinor PT: Common Variants in KCNN3 are Associated with Early-Onset Atrial Fibrillation. 2009 AHA Scientific sessions; Circulation 2009;120:S578-79.
20. Kääb S, Ritchie MD, Crawford DC, Sinner M, Kannankeril P, Wilde A, Bezzina C, Schulze-Bahr E, Guicheney P, Bishopric N, Myerburg R, Schott JJ, Pfeufer A,. Nakamura Y, Tanaka T, Ingram CR, Carter S, Bradford Y, George AL Jr, **Roden DM**: Genome-wide association study identifies novel genomic regions associated with drug-induced Long QT Syndrome. 2009 AHA Scientific sessions; Circulation 2009;120:S580.
21. Gyi L, McCarty C, Chute C, Jarvik G, Kullo I, Larson E, Masys D, **Roden D**, Li R, Chisholm R: The eMERGE Network: Challenges and Lessons Learned. Society of Epidemiologic Research, 2010.
22. Wang DW, Gillani N, **Roden DM**, Darbar D, George AL Jr: Sodium Channel Variants Associated with Atrial Fibrillation Exhibit Abnormal Fast and Slow Inactivation. Biophysical Society, 2010.
23. Bezzina CR, Pazoki R, Bardai A, Marsman RF, de Jong JSSG, Blom MT, Scicluna BP, Jukema WJ, Bindraba NR, Lichtner P, Pfeufer A, Bishopric N, **Roden DM**, Meitinger T, Chugh SS, Myerburg RJ, Jouven X, Kääb S, Dekker LRC, Tan HL, Tanck MW, Wilde AAM: Genome-Wide Association Study Identifies a Region at Chr 21q21 as a Susceptibility Locus for Ventricular Fibrillation in Acute Myocardial Infarction. Circulation 2010;122:A19099.
24. Vaglio J, Rowan S, Kucera G, Stubblefield T, Carter S, **Roden DM**, Darbar D: A Common Single Nucleotide Polymorphism Associated With Atrial Fibrillation Modulates Symptomatic Response To Antiarrhythmic Drug Therapy. Circulation 2010;122:A17900
25. Ramirez AH, Shaffer C, Sexton DP, Levy S, George AL Jr, **Roden DM**: Targeted Next Generation Exomic Sequencing of Cardiac Electrophysiology Genes in Cases of Drug-Induced Torsades de Pointes. Circulation 2010;122:A12560.
26. Kannankeril PJ, Yang T, Atack TC, Ramirez AH, Young AL, Levy S, **Roden DM**: Next-generation-based Mutation Screening Identifies A Dysfunctional Calcium Channel β-subunit Mutation In Short QT Syndrome. Circulation 2010;122:A15725.
27. Ramirez AH, Xu H, Oetjens M, Jeff JM, Zuvich R, Basford MA, Bowton E, Pulley JM, Cowan JD, Ritchie MD, Crawford DC, Masys DR, **Roden DM**, Denny JC: Identifying Genotype-Phenotype Relations in Electronic Medical Record Systems: Application to Warfarin Pharmacogenomics. Circulation 2010;122:A19509.
28. Dias EC, Menon UN, **Roden DM**, Brown NJ, Caprioli RM: Development of a semi-quantitative, high-throughput method for simultaneous detection of commonly prescribed cardiovascular drugs in hospitalized patients. ASMS Abstract Acceptance. 2011
29. Muhammad R, Parvez B, Kucera G, Stubblefield T, Richardson R, Blair M, Carter S, Ellis C, Saavedra P, Whalen SP, **Roden D**, and Darbar D: Differential Response to Ablation Therapy in Patients with Familial Atrial Fibrillation. 2011 Heart Rhythm Society. Heart Rhythm 2011;8:AB14-2.
30. Parvez B, Wasserman B, Carter S, Kucera G, Stubblefield T, Clair W, Whalen PS, Saavedra P, Rottman J, Abraham RL, Murray KT, Ellis C, Lee J, Raj S, **Roden DM**, and Darbar D: Evolving Therapy for Atrial Fibrillation: Insights from the Vanderbilt Atrial Fibrillation Registry. 2011 Heart Rhythm Society. 2011 Heart Rhythm Society. Heart Rhythm 2011;8:AB37-1.
31. Stroud DM, Atack T, Leake B, Lowe JS, Ramirez AH, Kupershmidt S, **Roden DM**: Junctophilin2 is Part of the Cardiac Sodium Channel Macromolecular Complex. 2011 Heart Rhythm Society. Heart Rhythm 2011;8:PO1-5.
32. Parvez B, Abraham RL, Muhammad R, Richardson R, **Roden D**, Dawood Darbar: Automated Rate Independent Method Of Assessing QT Interval In Atrial Fibrillation And Following Cardioversion. 2011 Heart Rhythm Society. Heart Rhythm 2011;8:PO2-58.
33. Lowe JS, Yang T, Atack TC, Myers Stroud D, **Roden DM**: Increased Late Sodium Current Contributes To Long QT-Related Arrhythmia Susceptibility In Female Mice. 2011 Heart Rhythm Society. Heart Rhythm 2011;8:PO2-90.
34. Delaney J, Myers Stroud D, Venkataraman R, Baudenbacher F, **Roden D**: Abnormal Conduction Velocities In D1275N SCN5A Transgenic Mice. Heart Rhythm 2011;8:PO-116.
35. Schildcrout J, Denny J, Bowton E, Gregg W, Pulley J, Basford M, Cowan J, Xu H, Ramirez A, Crawford D, Ritchie M, Peterson J, Masys D, Wilke R, **Roden D**: Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Presented at ASHG 2011.
36. Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Zink R, Cowan J, Pulley JM, Ritchie MD, Peterson JF, Masys DR, **Roden DM**, Crawford DC, Denny JC: Predicting warfarin dosage in European and African Americans using DNA samples linked to an electronic health record. Presented at ASHG 2011
37. Crawford DC, Denny JC, Ritchie MD, Basford MA, Bradford Y, Chai HS, Zuvich RL, Bastarache L, Peissig P, Carrell D, Pathak J, Wilke RA, Rasmussen L, Wang X, Pacheco JA, Kho A, Weston N, Matsumoto M, Newton KM, Li R, Kullo IJ, Chute C, Chisholm RL, Larson EB, McCarty CA, Masys DR, **Roden DM**, Bielinski SJ, de Andrade M: Genome-wide study of autoimmune hypothyroidism using existing genomic data and electronic medical records. Presented at ASHG 2011
38. Muhammad R, Delaney JT, Yang T, Atack T, Savio-Galimberti E, Denny JC, Ritchie M, Haines JL, Basford MA, Parvez B, Kucera G, Stubblefield T, Blair M, Ansari S, Kor K, **Roden DM**, Darbar D: Common and Rare Variants in SCN10A Associated with Atrial Fibrillation. Circulation 2011;124:A13007.
39. Muhammad R, Parvez B, Ritchie MD, Kubo M, Kamatani N, Tanaka T, **Roden DM**, Darbar D:A Genome-Wide Association Analysis to Identify Genomic Modulators of Rate Control Therapy in Patients with Atrial Fibrillation. Circulation 2011;124:A12933.
40. Yang T, Atack TC, Abraham RL, Darbar D, **Roden DM**: Striking Electrophysiologic Differences Between Cardiac Sodium Channel Isoforms SCN10A and SCN5A. Circulation 2011;124:A16237.
41. Lynch D, Delaney J, Kasasbeh E, **Roden D**, Cleator J: Evaluation of the association of the F2R IVS-14A/T PAR-1 polymorphism with stent thrombosis and subsequent cardiovascular events in a cohort of coronary artery disease patients. ACC 2012;59;E1399.
42. Muhammad R, Parvez B, Blair M, Short L, Shoemaker B, Kucera G, Stubblefield T, **Roden D**, Darbar D: Candidate gene approach to identifying novel genetic variants associated with atrial fibrillation. Heart Rhythm Society. Heart Rhythm 2012;9:S-120.
43. Parvez B, Muhammad R, Estrada JC, Richardson R, Shoemaker B, Abraham RL, **Roden D**, Darbar D: Neurohormonal and inflammatory modulation of QT interval during atrial fibrillation. Heart Rhythm Society. Heart Rhythm 2012;9:S-322.
44. Delaney J, Stroud DM, Harder R, Venkataraman R, Baudenbacher FJ, **Roden DM**: Disproportionate conduction slowing in the rvot of D1275N SCN5A mice. Heart Rhythm Society. Heart Rhythm 2012;9:S-326.
45. Knollmann BC, Savio-Galimberti E, Faggioni M, Yang T, **Roden D**, Darbar D: SCN5A and CASQ2 mutations increase susceptibility to atrial fibrillation in mice by different cellular mechanisms that predict response to targeted drug therapy. Heart Rhythm Society. Heart Rhythm 2012;9:S-327.
46. Husser D, Ueberhan L, Hindricks G, Arya A, Ingram C, Darbar D, Adams V, **Roden DM**, Bollmann A: Cardiac sodium channel mutations and outcome of catheter ablation for atrial fibrillation. Heart Rhythm Society. Heart Rhythm 2012;9:S-346.
47. Parvez B, Muhammad R, Estrada JC, Richardson R, Shoemaker B, Jiang L, Blair M, **Roden D**, Darbar D: Common genetic polymorphism at 4q25 predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm Society. Heart Rhythm 2012;9:S-395.
48. Parvez B, Muhammad R, Shoemaker B, Blair M, Stubblefield T, Kucera G, Denny J, **Roden D**, Darbar D: An ECG endophenotype for a common genetic variant associated with atrial fibrillation. Heart Rhythm Society. Heart Rhythm 2012;9:S-396.
49. Shoemaker B, Ahmad F, Muhammad R, Parvez B, Song Y, Kucera G, Stubblefield T, Blair M, Whalen SP, Ellis C, Saavedra P, Bradham W, Lawson M, **Roden D**, Darbar D: Chromosome 4q25 atrial fibrillation susceptibility alleles do not correlate with pulmonary vein or left atrial size. Heart Rhythm Society. Heart Rhythm 2012;9:S-396.
50. Yang T, Atack TC, Stroud DM, Zhang W, Hall L, **Roden DM**: Blocking SCN10A channels in heart reduces late sodium current and is antiarrhythmic. American Heart Association 2012. Circulation 2012;126:A14423.

1. Shoemaker MB, Muhammad R, Parvez B, White BW, Streur M, Song Y, Stubblefield T, Kucera G, Blair M, Rytlewski J, Parvathaneni S, Nagarakanti R, Saavedra P, Ellis C, Whalen SP, **Roden DM**: Common Atrial Fibrillation Risk Alleles at 4q25 and 1q21 Predict AF Recurrence after Catheter-based AF Ablation. AHA 2012 Scientific Sessions. Circulation 2012;126:A17002.
2. Shoemaker MB, Muhammad R, Parvez B, White BW, Streur M, Song Y, Stubblefield T, Kucera G, Blair M, Saavedra P, Ellis C, Whalen SP, **Roden DM**, Darbar D: A Common Variant at the 16q22 Atrial Fibrillation Risk Locus is Unexpectedly Associated with Reduced Left Atrial Size. AHA 2012 Scientific Sessions. Circulation 2012;126:A16519.
3. Shoemaker MB, Muhammad R, Parvez B, White BW, Streur M, Stubblefield T, Rytlewski J, Parvathaneni S, Nagarakanti R, **Roden DM**, Saavedra P, Ellis C, Whalen SP, Darbar D: Morbid Obesity Increases the Risk of Procedural Complications in Patients Undergoing Atrial Fibrillation Ablation. AHA 2012 Scientific Sessions. Circulation 2012;126:A16470.
4. Weeke P, Delaney J, Mosley JD, Kannankeril PJ, Well Q , Van Driest S, Norris K, Kucera G, Stubblefield T, Tanaka T, Nakamura Y, Crawford D, **Roden DM**: Genetic Variants Associated with QT Prolongation in Patients Exposed to Sotalol: A Genome Wide Association Study. AHA 2012 Scientific Sessions. Circulation 2012;126:A18723.
5. Delaney JT, Weeke P, Van Driest SL, Mosley J, Bowton E, Zink R, Denny JC, **Roden DM**: A Genome Wide Association Study (GWAS) of the early repolarization phenotype in BioVU implicates variants at 12q22. AHA 2012 Scientific Sessions. Circulation 2012;126:A12067.
6. Parvez B, Muhammad R, Shoemaker MB, Blair M, Kor KC, Brown N, **Roden D**, Bush W, Darbar D: Common Atrial Fibrillation Susceptibility Alleles Enhance Clinical Risk Prediction Model for Postoperative Atrial Fibrillation. AHA 2012 Scientific Sessions. Circulation 2012;126: A18516.
7. Wells, Q, Becker, J, Mosley J, Weeke P, Su YR, Naftilan AJ, Exil V, Pfotenhauer J, **Roden D**, Hong CC: Exome sequencing identifies Rbm20 as a cause of DCM in a large pedigree as well as Hdac7: A potential genetic modifier. AHA 2012 Scientific Sessions. Circulation 2012;126:A11966.
8. Yagihara N, Watanabe H, Atack TC, Ohno S, Shimizu W, Chatel S, Koopmann TT, Yang P, Ritchie MD, Turner S, Hasegawa K, Wakasugi M, Onodera O, Kuwano R, Duboscq-Bidot L, Redon R, Horie M, Schott JJ, Takayama M, Nakano Y, Bezzina CR, Wilde AA, Momotsu T, Endo N, Darbar D, **Roden DM**, Makita N: Arrhythmia-associated Variants in the SCN5A Promoter and Regulatory Regions. AHA 2012 Scientific Sessions. Circulation 2012;126:A12219.
9. Parvez B, Shah A, Muhammad R, Shoemaker MB, Graves AJ, Heckbert SR, Xu H, Ellinor PT, Benjamin EJ, Alonso A, Shintani AK, **Roden D**, Darbar D: Replication of a Risk Prediction Model for Ambulatory Incident Atrial Fibrillation Using Electronic Medical Record. AHA 2012 Scientific Sessions. Circulation 2012;126:A18578.
10. Van Driest SL, McGregor TL, Lu Z, Vear S, Creech CB, Kannankeril PJ, Brothers KB, Potts A, Bowton E, Delaney JT, Bradford Y, Wilson S, Olson L, Crawford DC, Saville B, **Roden DM**, Denny JC: Genome-wide association study of vancomycin pharmacokinetics using a de-identified biorepository. Presented at American Society for Human Genetics 2012 Scientific sessions.
11. Bennett J, Stroud D, **Roden D**: Voltage-gated sodium channels are required for proliferation of embryonic myocardium in zebrafish. American Society for Human Genetics, 2012 Scientific sessions, accepted
12. Jeff JM, Ritchie M, Denny J, Dilks HH, Sutcliffe C, Basford MA, **Roden DM**, Crawford DC: Fine Mapping the SCN10A Gene Region Identifies Novel Associations with Atrioventricular Conduction in African Americans: Using Electronic Medical Records as a Tool for Genome Science. Presented at American Society for Human Genetics 2012 Scientific sessions.
13. Oetjens M, Feng Q, Ramirez AH, Bowton E, Shaffer C, Clark T, **Roden DM**, Crawford D, Wilke RA: Survey of Rare Variants in Pharmacogenes for Patients with Statin Myopathy. American Society for Human Genetics, 2012 Scientific sessions, accepted
14. Mosley JD, **Roden DM**, Denny JD: Low frequency SNPs are associated with congenital and severe clinical phenotypes in an Electronic Medical Record. Presented at American Society for Human Genetics 2012 Scientific sessions.
15. Denny J, Bastarache L, Bhave G, McCall S , Sample M, Carroll R, Peissig P, Kho A, McCarty CA, Brilliant M, Chisholm RL, Larson EB, Jarvi GP, Chute CG, Kullo IJ, **Roden DM**, Hudson BG: Phenome-wide association study of common PXDN variants demonstrates association with aortic aneurysms. Presented at American Society for Human Genetics 2012 Scientific sessions.
16. Dumitrescu L, Ritchie MD, Denny JC, Bielinski SJ, Peissig P, Pacheco JA, Kho AN, Hayes MG, Jarvik GJ, Li R, Kullo IJ, Chute CG, Chisholm RL, Larson EB, McCarty CA, **Roden DM**, de Andrade M, Crawford DC on behalf of the eMERGE network: Genome-wide study of resistant hypertension using existing genomic data and electronic medical records. Presented at American Society for Human Genetics 2012 Scientific sessions.
17. Barrett TW, Abraham RL, Storrow AB, Jenkins CA, Harrell FE, Miller KF, Moser KM, Russ S, **Roden DM**, Darbar D: Incidence Of 5 And 30 Day Adverse Events In Emergency Department Patients With Symptomatic Atrial Fibrillation And Atrial Flutter. Acad Emerg Med, 2013, accepted.
18. Yang Z, Chopra N, Knollmann BC, George Jr. AL, Campbell CM, **Roden DM**, Murray KT: Electrophysiologic Effects of Azithromycin in Cardiomyocytes. Biophysical Society 57th Annual Meeting 2013, accepted.
19. Marpuri I, Bottinger EP, Brilliant MH, Carey D, Chisholm RL, Chute CG, Haines JL, Hakonarson H, Harley J, Jarvik GP, Kohane I, Kullo I, Larson EB, McCarty C, **Roden DM**, Smith M, Williams MS, Rongling L: Electronic medical records and genomics network – from GWAS to implementation. Society for Epidemiological Research 2013, accepted.
20. Husser D, Ueberham L, Hindricks G, Ingram C, Darbar D, Weeke P, Adams V, **Roden D**, Bollmann A: Mutations of genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation for atrial fibrillation. Presented at American College of Cardiology and German Cardiac Society, 2013.
21. Weeke P, Parvez B, Blair M, Short L, Shaffer C, Ingram C, Kucera G, Stubblefield T, **Roden DM**, Darbar D: Candidate Gene Approach To Identifying Rare Genetic Variants Associated with Lone Atrial Fibrillation. Heart Rhythm 2013;10;5S:S8.
22. Barrett TW, Abraham RL, Jenkins CA, Storrow AB, Harrell Jr. FE, Miller KF, Moser KM, Russ S, **Roden D**, Darbar D: Incidence Of 5 And 30 Day Adverse Events In Emergency Department Patients With Symptomatic Atrial Fibrillation And Atrial Flutter. Heart Rhythm 2013;10;5S:S308.
23. Husser D, Kootz V, Hindricks G, Darbar D, **Roden DM**, Bollmann A: Experience With Diagnostic And Research Driven Genetic Analysis In A High Volume Cardiogenetics Clinic. Heart Rhythm 2013;10;5S:S324.
24. Postema PG, Kolder I, Tanck MW, Barc JG, Zumhagen S, Husemann A, Sinner M, Koopmann T, Hofman N, Pfeufer A, Lichtner P, Meitinger T, Myerburg RJ, Bishopric NH, **Roden DM**, Kaab S, Wilde A, Schott JJ, Schulze-Bahr E, Bezzina CR: Genetic Modifiers in Long QT syndrome type 2. Heart Rhythm 2013;10;5S:S54.
25. Vijayakumar R, Silva JNA, Desouza KA, Abraham RL, Van Hare GF, **Roden DM**, Rudy Y: Electrophysiologic Substrate in Patients with Long QT Syndrome (LQTS): Noninvasive Mapping with ECGI. Heart Rhythm 2013;10;5S:S54.
26. Weeke P, Muhammad R, Delaney J, Shaffer C, Mosley J, Blair M, Short L, Stubblefield T, **Roden DM**, Darbar D: Whole Exome Sequencing Implicates Abnormal Calcium Signaling in Familial Atrial Fibrillation. Heart Rhythm 2013;10;5S:S55.
27. Stroud DM, Yang T, Atack TC, Short L, Delaney JT, Hall L, **Roden DM**: HCN1 Overexpression And Ivabradine Sensitive If In D1275N Mice. Heart Rhythm 2013;10:5S;S438.
28. Savio Galimberti E, Vanoye CG, George Jr AL, Kor KC, Yang T, **Roden DM**, Darbar D: Enhanced Peak and Late Sodium Currents Evoked by a Rare Double SCN10A Variant Increase the Risk for Atrial Fibrillation. Heart Rhythm 2013;10;5S:S437.
29. Rasmussen-Torvik LJ, Stallings S, Denny J, Williams M, Keating B, Brautbar A, Prows C, Manzi S, Bielinski S, Scott S, Ralston J, Gordon A, **Roden D**, Volpi S: The PGx project: design and implementation. Presented at International Genetic Epidemiology Society, 2013.
30. Weeke PE, Mosley JD, Hanna D, Shaffer C, Delaney JT, Wells QS, Van Driest S, Karnes J, Ingram C, Guo Y, Shyr Y, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis E, Nickerson DA, George Jr A, **Roden D:** Exome Sequencing Implicates the Burden of Rare Potassium Channel Variants in the Risk of Drug Induced Long QT Syndrome. Circulation 2013;128:A520.
31. Savio-Galimberti E, Weeke P, Vanoye CG, Yang T, Kor KC, Atack T, George Jr L, **Roden DM**, Darbar D: Rare SCN10A Variants Associated With Lone Atrial Fibrillation Modulate Peak and Late Sodium Currents. Circulation 2013;128:A18645.
32. Wells QS, Mosley JD, Van Driest SL, Weeke P, Karnes JH, Shaffer CM, Bowton E, Denny JC, **Roden DM**: Genomewide-Association Identifies a Novel Locus for Anthracycline Cardiotoxicity. Circulation 2013;128:A15509.
33. Barc J, Bezzina C, Mizusawa Y, Remme C, Gourraud JB, Verkerk A, Schwartz P, Guicheney P, Antzelevitch C, Schulze-Bahr E, Behr E, Tfelt-Hanson J, Kaab S, Watanabe H, Horie M, Makita N, Shimizu W, Froguel P, **Roden D**, Christoffels V, Gessler M, Wilde A, Probst V, Schott JJ, Dina C, Redon R: Genome-Wide Association Analysis Identifies 3 Common Variants Predisposing to Brugada Syndrome, a Rare Disease With High Risk of Sudden Cardiac Death Circulation 2013;128:A14459.
34. Yang T, Chun YW, Stroud DM, Knollmann BC, Hong CC, **Roden DM**: Screening for Acute Ikr Block is Insufficient to Detect Torsades Liability: Role of Late Sodium Current. Circulation 2013;128:A14816.
35. Yang T, **Roden DM**: Late Sodium Current-Mediated Arrhythmias Are Inhibited in Scn10a Knockout Mouse Myocytes. Circulation 2013;128:A14942.
36. Kolek MJ, Muehlschlegel JD, Parvez B, Bush WS, Murray KT, Stein CM, Shoemaker BM, Blair MA, Kor KC, **Roden DM**, Fox AA, Shernan SK, Collard DC, Body SC, Darbar D: A Combined Clinical and Genetic Risk Model for Predicting Postoperative Atrial Fibrillation. Circulation 2013;128:A15918.
37. Week PE, Hanna JD, Shaffer C, Delaney JT, Wells QS, Van Driest S, Karnes J, Ingram C, Guo Y, Shyr Y, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis E, Nickerson DA, George Jr A, **Roden D**: Exome Sequencing Implicates the Burden of Rare Potassium Channel Variants in the Risk of Drug Induced Long QT Syndrome. Presented at AHA Scientific Sessions. Circulation. 2013;128:A11082
38. Mosley JD, Van Driest SL, Larkin EK, Weeke PE, Witte JS, Wells QS, Karnes JH, Bastarache L, Olson LM, McCarty CA, Pacheco JA, Jarvik GP, Larson EB, Crosslin DR, Kullo IJ, Tromp G, Kuivaniemi H, Carey DJ, Ritchie MD, Li R, Denny JC, **Roden DM**: Mechanistic Phenotypes: An aggregative phenotyping strategy to identify disease mechanisms using GWAS data. ASHG 2013 Scientific Sessions.
39. Oetjens MT, Denny JC, Gillani NB, Herrera M, Olson L, Dilks HH, Richardson DM, Bowton E, **Roden DM**, Crawford DC: A Phenome-Wide Association Study of ADME Core Variants in an EMR-linked Biobank. ASHG 2013 Scientific Sessions.
40. Iverson CC, Xu H, Chen Q, Shah A, Dai Q, Warner J, Peterson NB, Olson L, Crawford DC, **Roden DM**, Denny JC, Aldrich MC: Personalized Genomics of Metformin Therapy for Improved Cancer Survival. ASHG 2013 Scientific Sessions.
41. Wei WQ, Feng QP, Jiang L, Waitara MS, Iwuchukwu OF, **Roden** DM, M Jiang, Xu H, Krauss RM, Rotter JI, Nickerson DA, Davis RL, Berg RL, Peissig PL, McCarty CA, Wilke RA, Denny JC: Characterization of Statin Dose-response within Electronic Medical Records. ASHG 2013 Scientific Sessions.
42. Dina C, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, Schwartz PJ, Crotti L, Guicheney P, Leenhardt A, Antzelevitch C, Schulze-Bahr E, Behr ER, Tfelt-Hansen J, Kaab S, Watanabe H, HorieM, Makita N, Shimizu W, Froguel P, Balkau B, Gessler M, **Roden D**, Christoffels VM, Le Marec H, Wilde AA, Probst V, Schott JJ, Redon R, Bezzina CR: Genetic association of common variants with a rare cardiac disease, the Brugada Syndrome, in a multi-centric study. ASHG 2013 Scientific Sessions.
43. Iwuchukwu OF, Jiang L, Feng Q, Wei-Qi W, **Roden DM**, Stein CM, Wilke RA: UGT1A Polymorphisms and Simvastatin Efficacy in Routine Clinical Care. Accepted for presentation American Society for Clinical Pharmacology and Therapeutics, 2014.
44. McGregor TL, Kannankeril P, Smith A, **Roden D**: MTRNR1 Aminoglycoside Variants in a Pediatric Population. Accepted for presentation, American College of Medical Genetics 2014
45. Kolek MJ, Graves AJ, Bian A, Teixeira PL, Shoemaker BM, Parvez B, Xu H, Heckbert SR, Ellinor PT, Benjamin EJ, Alonso A, Denny JC, Moons KGM, Shintani AK, **Roden DM**, Darbar D: External Validation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. AHA 2014 Scientific Session, Circulation 2014;130:A17956
46. Savio-Galimberti E, Yang T, **Roden D**, Behr ER, Kor KC, Jamshidi Y, Petropoulou E, Guicheney P, Tfelt-Hansen J, Wilde AAM, Bezzina CR, Olesen MS, Holst AG, Ackerman MJ, Schwartz PJ, Crotti L, Probst V, Redon R: Both Common and Rare SCN10A Variants Associated with Brugada Syndrome Displayed an Increase in Late Nav1.8 Sodium Currents in ND 7/23 cells. AHA 2014 Scientific Sessions, Circulation 2014;130:A17782
47. Karnes JH, Denny JC, Cronin RM, Shaffer CM, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, **Roden DM**: Influence of Exonic Variation on Heparin-Induced Thrombocytopenia. AHA 2014 Scientific Sessions. Circulation 2014;130:A11449
48. Weeke P, Denny JC, Basterache L, Shaffer C, Bowton E, Ingram C, Darbar D, **Roden DM**: Examining Rare and Low-Frequency Genetic Variants Previously Associated With Lone or Familial Forms of Atrial Fibrillation in an Electronic Medical Record System: A Cautionary Note. AHA 2014 Scientific Sessions. Circulation. 2014;130:A11864
49. Abraham RL, Savio-Galimberti E, Yang T, **Roden DM**, Darbar D: Modeling of a Rare SCN10A Variant (A1886V) Linked with Early-Onset Atrial Fibrillation Shortens Atrial Action Potential Duration. AHA 2014 Scientific Sessions. Circulation 2014;130:A18012
50. Stroud DM, Hall L, Hwang HS, Baudenbacher F, Knollmann B, **Roden DM**: Cellular and Functional Defects Contributing to Dilated Cardiomyopathy in SCN5A D1275N Mice. AHA 2014 Scientific Sessions. Circulation 2014;130:A17778
51. Kolek MJ, Parvez B, Song Y, Abraham RL, **Roden DM**, Darbar D: Comprehensive Evaluation of QT Interval During Abrupt Changes in Heart Rate and Associated Neurohormonal and Inflammatory Markers. AHA 2014 Scientific Sessions. Circulation. 2014;130:A17726
52. Barrett TW, Storrow AB, Jenkins CA, Abraham RA, Liu D, Miller KF, Moser K, Russ S, **Roden DM**, Harrell Jr. FE, Darbar D: A Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events. AHA 2014 Scientific Sessions. Circulation. 2014;130:A12515
53. Yee S, Wen C, Mefford JA, Chua K, Mosley JD, Goswami S, Takahashi D, Kubo M, Maeda S, Simpson MD, Davis RL, **Roden DM**, Giacomini KM: Transporterome-wide analysis of genetic variatns in SLC transporters and their effects on metformin response. Accepted for presentation, Clinical Pharmacology and Therapeutics Scientific Sessions 2014.
54. Goswami S, Yee S, Stocker SL, Mosley JD, M Kubo, Maeda S, Simpson MD, Davis RL, **Roden DM**, Savic R, Giacomini KM: Genetic variants in transcription factors are linked to the pharmacokinetics and pharmacodynamics of metformin. Accepted for presentation, Clinical Pharmacology and Therapeutics Scientific Sessions 2014.
55. Kullo IJ, Bielinski SJ, Carrell DS, Stallings S, Pathak J, Gordon A, Rasmussen-Torvik L, Dohney KF, Volpi S, Ritchie MD, Denny JC, Chute CG, **Roden DM**, Nickerson DA, Jarvik GP, Crosslin DR: Association of rare variants in LDLR, HMGCR, NAT2, ABCA1, and APOA1 with plasma lipid levels; initial results from the eMERGE PGx project. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions.
56. Van Driest SL, Stallings S, Bush WS, Gordon A, Crosslin DR, Jarvik GP, Carrell DS, Bielinski SJ, Olson JE, Ye Z,Kullo IJ, Abul-Husn NS, Scott SA, Castillo BA, Connolly J, Hakonarson H, Rasmussen-Torvik LJ, Persell S, Smith M, Kitchner T, Wallace JR, Doheny KF, Li R, Manolio TA, Callis TE, Macaya D, Ackerman MJ, Ritchie MD, Denny JC, **Roden DM**: Rare potentially pathogenic variants in the congenital arrhythmia syndrome disease genes SCN5A and KCNH2 are detected frequently but rarely associated with arrhythmia phenotypes in electronic health records. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions
57. Mosley JD, Shaffer CM, Van Driest SL, Weeke PE, Wells QS, Karnes JH, Velez-Edwards DR, Wei W, Teixeira PL, Bastarache L, Crawford DC, Pacheco JA, Manolio TA, Bottinger EP, McCarty CA, Linneman J, Thompson W, Chisholm RL, Jarvik GP, Crosslin DR, Carrell DS, Larson EB, Jouni H, Kullo IJ, Tromp G, Borthwick KM, Kuivaniemi H, Ritchie MD, Denny JC, **Roden DM**: A genome-wide association study identified variants in KCNIP4 associated with ACE inhibitor induced cough. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions
58. McGeachie MJ, Wu AC, Tse SM, Clemmer GL, Sordillo J, Weeke P, Shaffer C, Denny J, **DM Roden**, Raby BA,Weiss ST, Tantisira KG: CTNNA3 and SEMA3D: Promising loci for asthma exacerbation identified through multiple cohorts. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions
59. Mo H, Braggs N, Bastarache L, Carroll RJ, **Roden D**, Raychaudhuri S, Karlson EW, Denny JC: A genome-wide association study of hepatic toxicity of methotrexate therapy for rheumatoid arthritis. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions
60. Peterson JF, Field JR, Shi Y, Schildcrout JS, Denny J, McGregor T, Van Driest S, Pulley J, Lubin I, Laposata M, **Roden DM**, Clayton EW: Clinician Views about Implementation of Pharmacogenomics into Practice. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions
61. The International Clopidogrel Pharmacogenomics Consortium: International Clopidogrel Pharmacogenomics Consortium Genome Wide Association Study Identifies Novel Variants for Clopidogrel Response. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions
62. Bastarache L, Bochenek J, Edwards T, Xu Y, Pulley J, Bowton E, Mo H, Wei W, Wiley L, **Roden D**, Denny J: Investigation of synthetic association in GWAS using pheWAS and exome sequencing. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions
63. Joshi AD, Andersson C, Buch S, Gala M, Noordam R, Teumer A, Stender S, Nordestgaard BG, Weng L, Folsom AR, Lutsey PL, Ellinghaus D, Lieb W, Shafmayer C, Boehm B, Tybjærg-Hansen A, Völker U, Völzke H, Rose L, Weeke PE, **Roden DM**, Denny JC, Tang W, Stricker BH, Hampe J, Chasman DI, Johnson AD, Chan AT: GWAS meta-analysis of ten studies identifies five novel loci associated with gallstone disease in European ancestry individuals. Accepted for presentation, American Society for Human Genetics 2014 Scientific Sessions.
64. Savio-Galimberti E, Kannankeril PJ, Hall L, **Roden DM**, Darbar: SCN10A knockout mice exhibit increased susceptibility to atrial fibrillation without atrial structural remodeling. Heart Rhythm Society 2014. Heart Rhythm 2014;11;5S:S7.
65. Shoemaker BM, Bollmann A, Lubitz SA, Ueberham L, Saini R, Montgomery J, Edsawrs T, Delaney JT, Goyal S, Saavedra PJ, Kanagasundram AN, Whalen PS, **Roden DM**, Hindricks G, Ellis CR, Husser D: A meta-analysis of atrial fibrillation susceptibility alleles at 4Q25, 1Q21, and 16Q22 and response to catheter ablation of atrial fibrillation. Heart Rhythm Society 2014. Heart Rhythm 2014;11;5S:S551.
66. Karnes JH, Denny JC, Bowton EA, Shaffer CM, Mosley JD, VanDriest S, Weeke PE, Wells QS, **Roden DM**: Genome-wide association study of platelet factor 4/heparin antibody formation. ASCPT 2015. Clinical Pharmacology and Therapeutics 2015;97;PI-022;S27.
67. Goswami S, Yee S, Mosley J, Hedderson M, Kabu M, Maeda S, **Roden DM**, Simpson MD, Giacomini KM, Savic RM: A pharmacogenomics approach combined with various genetic analyses uncovers genes linked to the dynamics of HBA1C. ASCPT 2015. Clinical Pharmacology and Therapeutics 2015;97;PI-030;S29.
68. Yoneda Z, Montgomery J, Lugo R, Aznaurov S, Parvez B, Adkins K, Whalen SP, **Roden D**, Estrada JC, Kanagasundram A, Saavedra P, Ellis C, Darbar D. Shoemaker MB: 4q25 Atrial Fibrillation Susceptibility Alleles Predict Typical Atrial Flutter in Patients Undergoing Ablation for Atrial Fibrillation. Heart Rhythm Society, 2015. Heart Rhythm 2015;12;5S:S113.
69. Montgomery J, Yoneda Z, Lugo R, Aznaurov S, Parvez B, Adkins K, Whalen SP, **Roden D**, Estrada JC, Kanagasundram A, Saavedra P, Ellis C, Darbar D, Shoemaker MB: Cavotricuspid Isthmus Ablation and Reduction of Atypical Atrial Tachycardia and Flutter Following Catheter-based Ablation for Atrial Fibrillation. Accepted for presentation, Heart Rhythm Society, 2015. Heart Rhythm 2015;12;5S:S447.
70. Yang T, Hong CC, **Roden DM**: Inhibition of the α-subunit of PI3 kinase increases late sodium current (INa-L) and generates arrhythmias. Heart Rhythm 2015;12;5S:S150.
71. Hall MA, Wallace JR, Verma SS, Bradford Y, Pendergrass S, Brantley M, Brilliant, Chen L, Denny J, Frost R, Hayes MR, Kitchner T, McCarty C, Muller-Myhsok B, Peissig P, **Roden DM**, Van Steen K, Moore JH, Ritchie MD: Data-Driven Genetic Encoding: A robust approach for detecting diverse action in main effect models and genetic interactions. ASHG 2015 Scientific Sessions.
72. Galarneau G, Nadkarni GN, Ellis SB, Nadukuru R, Scott SA, Manolio TA, Li R, Rasmussen-Torvik LJ, Kho AN, Hayes MG, Pacheco JA, Chisholm RL, **Roden DM**, Denny JC, Kenny EE, Bottinger EP: APOL1 risk allele is associated with early diagnosis of hypertension and a 2-3 mmHg increase in systolic blood pressure in young African American adults. ASHG 2015 Scientific Sessions
73. Mosley JD, Witte JS, Hebbring JS, Larkin EK, Bastarache L, Shaffer CM, Karnes JH, Stein CM, Denny JC, **Roden DM**: Identifying genetically-driven clinical phenotypes using linear mixed models. ASHG 2015 Scientific Sessions.
74. Edwards TL, Bray MJ, Tsosie MS, Hartmann KE, Denny JC, Jeff J, Kenny E, Peissig PL, McCarty CA, Williams MS, Gogoi RP, Kuivaniemi HS, Tromp GS, Kho A, Pacheco, Jackson JL, Kullo IJ, Pathak J, Stewart EA, **Roden DM**, Velez Edwards DR: A genome-wide association study of uterine fibroids confirmed by imaging in eMERGE. ASHG 2015 Scientific Sessions
75. Yang T, Moslehi J, **Roden DM**: Proarrhythmic effects of ibrutinib, a clinically approved inhibitor of Bruton’s tyrosine kinase (BTK) used in cancer therapy. Presented at American Heart Association. Circulation. 2015;132:A14587
76. Karnes JG, Denny JC, Cronin RM, Shaffer CM, Mosley JD, Mallal SA, Phillips EJ, **Roden DM**: Association of HLA-DRB3\*01:01 With Heparin-Induced Thrombocytopenia. Presented at AHA Scientific Sessions. Circulation. 2015;132:A13476
77. Bersell K, Hong C, Behr E, Petropoulou E, Jamshidi Y, Wells Q, Kannankeril P, **Roden D**: Function Consequences of a Rare TBX5 Variant in Familial Brugada Syndrome. Presented at American Heart Association. Circulation Research. 2015;117:A96

1. Daniel L, Yang T, **Roden D**: Potassium-dependence of Arrhythmias due to the SCN5A Variant R222Q. Presented at AHA Scientific Session. Circulation. 2016;134:A12604
2. Cadar AG, Feaster TK, Bersell KR, Wang L, **Roden DM**, Knollmann BC, Hong CC, Lim CC: Real-Time Visualization of Endogenous Titin Dynamics in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Presented at AHA Scientific Sessions. Circulation. 2016;134:A19317
3. Stroud DM, Bersell KR, DelaneyJ, Hall L, Agullo-Pascual E, Hwang HS, Yang T, Knollmann B, Delmar M, Baudenbacher F, **Roden DM**: Abnormal Conduction and Arrhythmias Precede the Development of Dilated Cardiomyopathy in D1275n Mutant Mice. Presented at AHA Scientific Sessions. Circulation. 2016;134:A18898
4. Lubitz S, Lin H, Weng LC, Lunetta K, Roselli C, Gupta N, Gabriel C, Abecasis G, MacArthur D, Albert C, Alonso A, Arking A, Chasman D, Ramachandran V, **Roden D**, Shoemaker MB, HeckbertS, Darbar D, Benjamin E, Ellinor P: Feasibility of Whole Genome Sequencing for Atrial Fibrillation. Presented at AHA Scientific Sessions. Circulation. 2016;134:A1405.
5. Kannankeril PK, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro P, Batra AS, Kaufman ES, Fairbrother EL, Saarel EV, Etherdige SP, Kanter RJ, Carboni MP, Dzurik MV, Fountain D, Chen D, Ely EW, **Roden DM**, Knollmann BC: A Prospective Randomized Placebo-Controlled Crossover Trial of Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia. Presented at AHA Scientific Sessions. Circulation. 2016;134:A12009
6. Bersell K, Yang T, Hong CC, Petropolulou E, Jamshidi Y, Wells QS, Kannankeril PJ, **Roden DM**: Genomic editing in iPSCs establishes that a rare TBX5 variant causes Brugada syndrome. Selected as a student platform presentation at the 2016 ASCI-AAP annual meeting.
7. Bersell K, Yang T, Hong CC, Petropolulou E, Jamshidi Y, Wells QS, Kannankeril PJ, **Roden DM**: Genomic editing in IPSCs establishes that a rare TBX5 variant casues Brugada syndrome. Heart Rhytm 2016;13;5s:AB04-02.
8. Barc J, Mizusawa Y, Dina C, Gourraud JB, Simonet F, Behr ER, Schulze-Bahr E, Nuyens D, Saenen J, Lambiase PD, Guicheney P, Borggrefe MM, Antzelevitch C, Kaab S, Tfelt-Hansen J, **Roden DM**, Brugada R, Priori SG, Schwartz PJ, Giustetto C, Schott JJ, Probst V, Wilde AA, Redon R, Bezzina CR: Extended GWAS In Brugada Syndrome Uncovers Additional Risk Alleles At The SCN5A/SCN10A Locus With Marked Cumulative Effects On Risk For The Disorder. Heart Rhythm 2016;13;5s:AB04-03.
9. Yang T, Daniel LL, **Roden DM**: Mice with the common SCN5Avariant S1103Y are highly susceptible to arrhythmias on provocation. Heart Rhythm 2016;13;5s:PO02-66.
10. Iwuchukwu OF, Andrea R, Shi Y, Bowton EA, Kawai VK, Schildcrout J, Denny JC, **Roden DM**, Stein MC: Genetic variants influencing INR variability in warfarin treated patients after the dose-titration phase. Clinical Pharmacology and Therapeutics 2016 Scientific Sessions.
11. Redon R, Mizusawa Y, Dina C, Gourraud JB, Simonet F, Behr ER, Schultze-Bahr E, Robyns T, Saenen J, Lambiase JD, Guicheney P, Mabo P, Haissaguerre M, Borggrefe MM, Antzelevitch C, Kaab S, Tfelt-Hansen J, **Roden DM**, Brugada R, Sarquella-Brugada G, Brugada J, Priori SG, Schwartz PJ, Giustetto C, Schott JJ, Probst V, Wilde AA, Barc J, Bezzina CR: The predominant effect of common variation at the SCN5A-SCN10A locus on susceptibility to Brugada Syndrome. ASHG 2016 Scientific Sessions.
12. JD Mosley, SL Van Driest, QS Wells, CM Shaffer, TL Edwards, L Bastarache, CA McCarty, W Thompson, CG Chute, GP Jarvik, DR Crosslin, EB Larson, IJ Kullo, JA Pacheco, PL Peissig, MH Brilliant, JG Linneman, JC Denny, **DM Roden**: Defining updated risk profiles by linking contemporary cohorts with historical cohorts based on shared genetics. ASHG 2016 Scientific Sessions.
13. L Bastarache, JH Karnes, CM Shaffer, S Gaudieri, AM Glazer, H Steiner, JD Mosley, S Mallal, JC Denny, EJ Phillips, **DM Roden**: Comparison of HLA allelic imputation programs. ASHG 2016 Scientific Sessions.
14. Yang BQ, Yoneda ZT, Montgomery JA, Farrell M, Gayle KA, Crawford DM, Xu M, Kolek MJ, Lugo RM, Richardson TD, Metawee ML, **Roden DM**, Darbar D, Abraham RL, Estrada JC, Saavedra PA, Shen ST, Crossley GT, Kanagasundram AN, Whalen SP, Soliman EZ, Ellis C, Shoemaker B: Long-term Changes in P-wave Morphology Following Atrial Fibrillation Ablation and the Association with Arrhythmia Recurrence. Heart Rhythm Society 2017 Scientific Sessions
15. Kolek M, Kucera G, Blair M, Kor K, Wang L, Shoemaker MB, Murray K, Stein CM, **Roden DM**, Darbar D: Effect a Common Variant in the Adrenoceptor Beta-1 Gene on Ventricular Rate Response in Permanent Atrial Fibrillation. Heart Rhythm Society 2017 Scientific Sessions
16. Lahrouchi N, Tadros R, Mizusawa Y, Postema PG, Yoshinaga M, Behr ER, Rydberg A, Van Den Berg MP, Robyns T, **Roden DM**, Brugada J, Olesen MS, Tfelt-Hansen J, Skinner JM, Antzelevitch C, Odening KE, Borggrefe MM, Loeys B, Lubitz SA, Brugada GS, Veldink J, Al-Chalabi A, Andersen P, Müller-Nurasyid M, Cusi D, Galan P, Werge T, Ribasés M, Lichtner P, Meitinger T, Brugada R, Makita N, Shimizu W, Priori SG, Guicheney P, Kaab S, Schulze-Bahr E, Schwartz PJ, Probst V, Ohno S, Wilde AA, Tanck M, Bezzina CR: Multinational genome-wide association study in long QT syndrome identifies a role for common genetic variation in disease susceptibility and points to a polygenic architecture in mutation-negative cases. Heart Rhythm Society 2017 Scientific Sessions
17. Safarova MS, Fan X, Jarvik GO, Leppig KA, Rasmussen-Torvik LJ, Pendergrass S, Sturm A, Namjou B, Shah A, Carroll R, Chung WK, Wei WQ, Stein M, Williams MS, **Roden DM**, Denny JC, Kullo IJ: Abstract 20688: A Phenome-Wide Association Study to Assess Pleiotropic Effects of LPA. AHA presentation 2017. Circulation. 2017;136:A20688
18. Levinson RT, Farber-Eger E, Shaffer CM, Mosley JD, **Roden DM**, Wells QS: Genome Wide Association Studies of Heart Failure With Reduced and Preserved Ejection Fraction Point to Different Genetic Architectures. AHA 2017. Circulation. 2017;136:A19353
19. Wei WQ, Li X, Feng Q, Mosley J, Kullo I, Shaffer C, Bland S, Peissig P, Cox N, Stein CM, Rotter JI, Edwards T, Kubo M, Maeda S, Horikoshi M, Crosslin D, Momozawa Y, Wilke R, Larson EA, Cronkite D, Karlson E, Jarvik G, Hripcsak G, Shang N, Pacheco J, Rasmussen-Torvik L, Ta Lee M, Ritchie M, Williams M, Larson EB, **Roden DM**, Krauss R, Denny J: Lpa Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins Abstract. AHA 2017 Circulation. 2017;136:A15433
20. Bersell KR, Yang T, Mosley JD, Glazer AM, Brown JD, Campbell C, Hong CC, Wells QS, Johnson AN, Short L, Blair MA, Behr ER, Petropoulou E, Jamshidi Y, Gerszten R, Benson MD, Vasan RS, Yang Q, Jarvik GP, Namjou B, Shaffer CM, Parikh S, Sheng Q, Kannankeril PJ, Wang TJ, Knollmann BC, **Roden D**: Integrating Patient-Specific Cardiomyocyte Function With Population Multi-omics Identifies a Novel Arrhythmia Pathway. AHA 2017. Circulation. 2017;136:A14477
21. Goldstein JA, Bastarache LA, Speltz P, Gifford A, **Roden DM**, Denny JC: LabWAS: A catalog of real-world associations between genetic variants and lab values. ASHG Scientific Sessions 2017
22. Glazer A, Kroncke B, Matreyek K, Yang T, Fowler D, **Roden D**: High-throughput discovery of deleterious cardiac sodium channel variants. ASHG Scientific Sessions 2017
23. Choi SH, Weng LC, Shoemaker MB, Barnard J, Arking DE, Chasman DI, Albert CM, Smith JD, Gabriel S, Boerwinkle E, Silverman EK, Redline S, Vasan RS, Weiss ST, Burchard EG, Jaquish CE, Papanicolaou GJ, Sotoodehnia N, Van Wagoner DR, Psaty BM, Darbar D, Alonso A, Heckbert SR, Chung MK, **Roden DM**, Benjamin EJ, Lunetta KL\*, Lubitz SA\*, Ellinor PT\*, on behalf of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium: Large-Scale Whole Genome Sequencing in Atrial Fibrillation. ASHG Scientific Sessions 2017
24. Feng Q, Wei WQ, Chung CP, Levinson RT, Sundermann AC, Bastarache L, Ferguson JF, Cox NJ, **Roden DM**, Denny JC, Linton MF, Edwards DRV, Stein CM: Low LDL cholesterol concentrations are associated with increased risk of type 2 diabetes. ASHG Scientific Sessions 2017
25. Salem JE, Waintraub X, Courtillot C, Shaffer C, Gandjbakhch E, Maupain C, Moslehi J, Badilini F, Gougis P, Fressart V, Glazer A, Hidden Lucet F, Touraine P, Lebrun-Vignes B, **Roden DM**, Bachelot A, Funck-Brentano C: Hypogonadism as a reversible cause of Torsade de Pointes in men. Accepted Printemps de la Cardiologie, 2018